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PREFACE 
 
 
The contents of this PhD thesis are focussed on a grave form of heart failure in women that occurs 
most commonly within the first two months after delivery, leaving many young mothers who survive 
the initial episode morbidly ill for the rest of their lives. This condition is called peripartum 
cardiomyopathy (PPCM). Whilst studying the disease (PPCM), it was often necessary to make 
comparisons to its closest simulant, non-ischaemic dilated cardiomyopathy, with a special focus on 
the clinical, biochemical and genetic risk factors, which were used to inform a small trial of a new 
treatment modality for this condition.  
This PhD in Cardiovascular Medicine was done as a 50% collaboration between the University of 
Cape Town and the University of the Witwatersrand. 
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ABSTRACT 
Introduction: Peripartum cardiomyopathy (PPCM) is a form of unexplained heart failure associated 
with pregnancy that leads to considerable morbidity and mortality. Most patients present with acute 
postpartum heart failure that otherwise resembles dilated cardiomyopathy (DCM). Little is 
understood about the aetiopathogenesis of PPCM, including the genetic contribution; or its 
treatment. I hereby report on a comprehensive collection of studies that begins with a study of 
familial DCM in PPCM, which incorporated genetic screening for mutations in the Lamin-A gene 
(LMNA), known for their virulence in familial DCM, to assess their role in the development of PPCM. I 
then proceeded to identify risk factors and prognostic indicators for PPCM, including those 
identifiable through the electrocardiogram (ECG). Finally, given the shortage of evidence for a 
treatment modality specific to PPCM, a trial of the use of Bromocriptine in the treatment of PPCM 
was conducted. 
Methods: Consenting prevalent and incident PPCM patients seen at two tertiary hospitals across 
South Africa, were recruited, and systematic analyses done of their full clinical profiles. A small 
subset of patients recruited immediately post-partum underwent a trial of Bromocriptine therapy.  
Another subset of PPCM patients had their respective first degree relatives undergo full clinical 
screening for DCM. 
Results and Conclusion: Our findings support the notion that over a third of PPCM cases may form 
part of the spectrum of familial DCM. Routine family screening may be as much merited in PPCM as 
it is in DCM. The ECG appears to be a useful adjunctive tool in both screening and prognostication in 
resource-poor settings. Further assessment of the prognostication of PPCM suggests that increased 
LVESD, lower BMI and lower serum cholesterol at baseline may be independent predictors of poor 
outcome in patients with PPCM, while older age and smaller LVESD at baseline appear to be 
independently associated with a higher chance of LV recovery. In the trial reported herein, the 
addition of Bromocriptine to standard heart failure therapy appeared to improve left ventricular 
ejection fraction and a composite clinical outcome in women with acute severe PPCM. 
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1.1. Literature Review 
 
1.1.1 Cardiovascular disease in Africa 
Historically, sub-Saharan African societies have fought a long and difficult battle against 
malnourishment and infectious disease, as the major cause of morbidity and mortality (Bradshaw et 
al, 2003; Steyn et al, 2006). The impact of globalisation and growing economies has had the 
additional influence of Westernising at least parts of the health profiles of these African countries 
(Tibazarwa et al, 2008). However, despite sporadic observations of a rise in the burden of non-
communicable disease in these societies, there remains a paucity of data to describe the emergence 
and impact of cardiovascular disease (CVD) in low to middle-income countries. 
A recent report on the largest township in South Africa (Soweto) helped to address this gap by 
providing novel and systematic data on the cardiovascular profiles of its population. The report 
highlights how, despite a sustained epidemic of HIV/AIDS epidemic (responsible for 41% and 64% of 
deaths for men and women aged 15 - 44 years, respectively),  coronary artery disease, hypertensive 
heart disease and stroke already account for more than a third of deaths in those aged above 65 
years (Sliwa et al, 2008a). 
Apart from patients with a primary diagnosis of hypertension, most cases represented late clinical 
presentation, with established heart disease with more than one cause. Overall, the four most 
common diagnoses were: hypertension, heart failure, valvular heart disease and coronary artery 
disease. Overall, rheumatic valvular heart disease, the cardiomyopathies and tuberculous pericardial 
effusion combined, accounted for 40% of these newly diagnosed cases. On presentation, most 
patients had evidence of advanced and complex disease (Sliwa et al, 2008a). In all diagnostic groups, 
the rate of common risk factors for cardiovascular disease was very high; overall, only 13% had no 
risk factors, whereas 59% had several risk factors (Sliwa et al, 2008a). 
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The study provides preliminary evidence to show the effect of epidemiological transition in this 
population, which face many threats to their present and future cardiac health, including a 
combination of infectious and non-communicable forms of heart disease and late clinical 
presentations. This mirrors the findings of its sister-study, a large-scale community-based survey and 
awareness campaign that showed that, contrary to popular belief, common risk factors for 
atherosclerotic heart disease are highly prevalent in the urban Black African population of Soweto 
and resemble the proportions seen in Western societies, where all forms of CVD (and most 
particularly, coronary heart disease) has reached epidemic proportions (Tibazarwa et al, 2008). 
 
1.1.2 Heart Failure in Africa: A South African study representative of Africa 
Historically, heart failure in tropical African countries has been attributed to infective aetiologies of 
the poor, including: rheumatic heart disease, endocardial myofibrosis, tuberculous pericarditis, 
cardiomyopathy (Abengowe, 1979; Antony, 2000; Mayosi, 2007,) and anaemia-induced heart failure 
in areas where malaria and tuberculosis are endemic (Brown et al, 1975; Korner, 1980). The last few 
decades, however, have shown hypertension rise to take the lead in causing heart failure in Sub-
Saharan Africa (Amoah et al, 2000, Sliwa et al, 2005, Mayosi, 2007). Still, heart failure and CVD from 
the region remains grossly under-reported, with only two countries (Nigeria and South Africa) 
accounting for the majority of Medline publications from the region.  
Being the first systematic study to describe the epidemiological profile of cardiovascular disease in 
sub-Saharan Africa in such great clinical detail, the Heart of Soweto Study might be considered 
representative of many other African nations (Sliwa et al, 2008). Its strengths include it  being the 
largest such study to have attempted to do so in a predominantly disadvantaged society that 
nevertheless has access to the commercial aspects of industrialisation. In this study, the most 
frequent primary diagnosis was heart failure. In comparison to men, proportionately fewer women 
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were diagnosed with heart failure [OR 0·89, 0·79–0·99]. In absolute terms, however, 112 more 
women than men were diagnosed with heart failure. Of the cases of heart failure seen in this 
Soweto study: a quarter had a mixed underlying aetiology; over a third had developed valvular 
dysfunction; 8% had a primary diagnosis of valve disease.   The three most common forms of heart 
failure were the dilated cardiomyopathies (35%), which included: peripartum cardiomyopathy; heart 
failure second to hypertensive heart disease (33%); and right heart failure (27%), which was 
commonly associated with underlying cor pulmonale. Overall, half the patients with heart failure had 
moderate to severe systolic dysfunction and just over a quarter had impaired diastolic function. 
Mean left ventricular ejection fraction was: 34% in those with idiopathic dilated cardiomyopathy; 
and 39% in those with ischaemic cardiomyopathy. Patients with heart failure related to underlying 
hypertensive heart disease and valvular disease were most likely to have impaired diastolic function. 
Almost all ECGs in patients diagnosed with heart failure had some form of abnormality, with 16% 
patients having ECG evidence of left ventricular hypertrophy. 
 
1.1.3 A focus on dilated cardiomyopathy 
Having been characterised historically as a group of various forms of heart failure of “no apparent 
cause”, the cardiomyopathies pose the greatest challenge of all the cardiovascular diseases in Africa, 
because of: their greater prevalence in impoverished communities; the difficulty in diagnosis, which 
often requires specialised cardiological investigation that is lacking in resource-poor environments; 
the lack of access to effective interventions, such as heart transplantation; and the high mortality 
associated with these often irreversible disorders of heart muscle (Sliwa et al, 2005). Nowadays, 
cardiomyopathies are defined as diseases of the myocardium associated with cardiac dysfunction 
(Richardson et al, 1996). They are classified into: dilated cardiomyopathy (DCM); hypertrophic 
cardiomyopathy (HCM); restrictive cardiomyopathy; arrhythmogenic right ventricular 
cardiomyopathy (ARVC); and unclassified cardiomyopathies (Sliwa et al, 2005).  
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Idiopathic DCM (IDCM) is one form of DCM, comprising a clinical syndrome of heart failure 
characterised by impaired systolic function and left ventricular dilatation in the absence of an 
identifiable cause (Akinkugbe et al, 1991). IDCM occurs at any age (but remains more common in the 
third and fourth decades of life) and men are affected twice as commonly as women (Sliwa et al, 
2005). In South Africa and Uganda, DCM accounts: for up to 17% of all cardiac conditions 
encountered at autopsy; and in many parts of Africa, for 17% to 48% of patients who are 
hospitalised for heart failure (Sliwa et al, 2005). In the West, up to one-fifth of IDCM patients will 
have familial DCM (FDCM), whereby, i.e. 15-25% of first degree relatives demonstrate IDCM at some 
time in their life (McKenna et al, 1997). 
Table 1. Profile of cardiovascular disease in Soweto 
 
[Extracted from Sliwa et al, 2008a] 
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1.1.4 Peripartum Cardiomyopathy 
Peripartum cardiomyopathy (PPCM) has previously been considered a variant of DCM, although 
current criteria do not mandate the presence of a dilated left ventricle (Sliwa et al, 2010). PPCM is 
defined as per Lampert and Lang’s (1995) modification of Demakis et al’s definition (1971), i.e.: the 
development of new heart failure in the last month of pregnancy or within the first five months 
post-partum, in the absence of any other determinable cause for cardiac failure and in the absence 
of demonstrable heart disease prior to the last month of pregnancy; and bearing echo-
cardiographical evidence of left ventricular systolic dysfunction (Ladwig et al, 1997). Restriction to 
this particular puerperal period serves to exclude pre-existing causes of cardiomyopathy that may be 
exacerbated by pregnancy, rather than arise as a result of pregnancy (Ladwig et al, 1997; Pearson et 
al, 2000). The vast majority of cases present within the first four months post-partum (Ladwig et al, 
1997; Fett et al, 2003; Sliwa et al, 2006a), with only 10% presenting in the last month ante-partum 
(Ladwig et al, 1997; Sliwa et al, 2006a). 
 
1.1.4.1 The epidemiology of Peripartum Cardiomyopathy 
The incidence reportedly varies from 1 in 3000 - 4000 deliveries in Western societies (Satpathy et al, 
2008) to 1 in 1000 in developing societies (Sliwa et al, 2006b), with the highest incidence of 1 in 300 
live births being reported in Haiti (Fett et al, 2005). The apparent rise in incidence across all 
geographical borders is most likely due to improved awareness and diagnostic measures (Satpathy 
et al, 2008). In a large African centre, PPCM was seen in 1.5% of all patients with heart failure 
attending the centre during one year (Stewart et al, 2008). While studies in the USA show PPCM to 
occur more in women of African descent and those aged above 30 years (Ventura, 1991), PPCM has 
been reported across the world and across all ages and parities (Ladwig et al, 1997; Fett et al, 2003). 
The younger age of PPCM patients in developing nations (Fett et al, 2003; Sliwa et al, 2006b) may 
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reflect the younger age of the bulk of reproductive activity in developing nations. Multiple gestation 
within the index pregnancy has been implicated in causing PPCM in 7-10% of women (Veille et al, 
1984), while multi-parity is a more widely documented predisposing factor to the development of 
PPCM (Sliwa et al, 2006b; Satpathy et al, 2008). However, recent studies have suggested that the 
effect of multi-parity is far less significant in the development of PPCM (Fett et al, 2005). PPCM also 
appears to occur more commonly in women who breastfeed for longer (Watkins et al, 2005). 
PPCM is an important cause of mortality and chronic, debilitating morbidity that affects relatively 
young women in the reproductive age group. It is the second most-common aetiology of 
cardiomyopathy-related cardiac transplant in women in the United States (Habli et al, 1994); hence 
it poses a considerable burden on the health, economic and other social sectors of society. 
 
1.1.4.2 The diagnosis of PPCM 
The diagnosis of apparently unexplained heart failure is based on symptoms and clinical findings in 
combination with appropriate investigations, such as electro-cardiography, chest radiograph, 
biomarkers and echocardiography. PPCM is a diagnosis of exclusion. However, there is no agreement 
on the exclusion of pre-eclampsia. Unfortunately, the inclusion of patients with varying degrees of 
gestational hypertension, in the index as well as prior pregnancies, has contributed greatly to the 
discrepancy in reported characteristics of PPCM. This may also form the basis for the difference in 
the puerperal time of presentation. Studies comprising greater proportions of patients with pre-
eclampsia, and of greater severity, tend to have far greater concentrations of PPCM cases presenting 
in the last month of pregnancy (Sliwa et al, 2006a; Duran et al, 2008; Sliwa et al, 2011). In contrast, 
studies that have attempted to minimize the inclusion of patients with pre-eclampsia to milder 
forms show a clear post-partum peak in the presentation of PPCM, with reported onset of symptoms 
most commonly being 2-62 days post-partum (Satpathy et al, 2008; Fett et al, 2005). 
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Symptoms of PPCM 
PPCM often presents with acute onset of heart failure. The presentation, with reduced cardiac 
output, tissue hypo-perfusion, increase in the pulmonary capillary wedge pressure and tissue 
congestion, is often life-threatening and requires urgent treatment. Most patients report severe 
shortness of breath of the order NYHA-FC III – IV (Sliwa et al, 2008a), presenting with: lower limb 
swelling; some with right upper quadrant pain; as well as other symptoms of acute heart failure.  
Signs of PPCM 
Most patients will manifest grade III – IV functional class by being overtly tachypnoeic in the clinic or 
hospital room. Systematic clinical assessment of the peripheral circulation, venous filling and 
peripheral temperature are important. Most patients (Lee, 1991) have a mild resting tachycardia 
(Tibazarwa et al, 2010). Blood pressure averages are usually normal, with larger prospective studies 
reporting mean systolic and diastolic blood pressure of 113±19mmHg and 75±12mmHg, respectively 
(Sliwa et al, 2011). Bedside examination often suggests a dilated cardiomyopathy in the lateral 
and/or downward displacement of the apex, with dyskinetic apex and sometimes palpable gallop 
rhythm (Talley et al, 2006). Arterial blood gas and pulse oximetry are important in a first assessment 
of the severity of respiratory insufficiency. 
Complications of PPCM 
Thromboembolic complications are common (Lee, 1991; Liakakos et al, 2009; Dresang et al, 2008). 
Often these will manifest in the form of pulmonary embolism and stroke, usually resulting from 
embolised mural thrombi in the dilated myopathic chambers of the heart. Rarely, this has 
culminated in embolic retinal artery occlusion that caused acute onset of unilateral blindness in the 
patient with PPCM (Liakakos et al, 2009). Bearing in mind that pregnancy itself potentiates a state of 
hyper-coagulability (Dresang et al, 2008), the added risk in PPCM is a major concern. Although  anti-
coagulation has been recommended in PPCM patients with left ventricular ejection fractions of less 
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than 35% (Lata et al, 2009), there remains no systematic data to support this practice for PPCM or 
for other forms of left ventricular dysfunction in sinus rhythm (Hirsh et al, 2003). As with other forms 
of cardiomyopathy, arrhythmias are a common complication of PPCM and are further described 
below. 
Routine biochemical tests 
The full blood count is usually normal (given that significant anaemia has been excluded as a 
separate potential cause of heart failure), with normal electrolytes and bio-markers of renal 
function.   In advanced cases, congestive cardiac failure will cause renal insufficiency and a pre-renal 
biochemical profile.  Most patients have normal liver function tests. In PPCM patients with abnormal   
liver function tests, this often represents the acutely congested liver; and manifests as raised 
canalicular enzymes, with only slightly raised transaminases. While older studies suggested micro-
nutrient deficiency could play a role in the development of PPCM (Ventura, 1991), many of these 
were smaller descriptive studies. Since then, a comparative study on a larger series of PPCM patients 
has shown micro-nutrient deficiencies not to differ significantly between cases and controls (Fett et 
al, 2003). The micro-nutrients included selenium, vitamins A-, B12-, C-, and E-, as well as beta-
carotene (Fett et al, 2003).  Hence these tests are no longer considered necessary in the diagnostic 
work-up of patients with PPCM.  
To date, many centres in developing countries have considered HIV serology to be an important 
baseline investigation, as HIV-positivity formed an exclusion criteria for clinical studies in the face of 
HIV-associated cardiomyopathy bearing clinical resemblance to PPCM. However, novel data report 
that patterns of left ventricular function and mortality were similar between PPCM patients with and 
without HIV co-infection (Sliwa et al, 2011). 
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Urine samples need to be assessed for albumin and other proteinuria, as an essential means of 
excluding pre-eclampsia. While a proteinuria presence helps to confirm the diagnosis of pre-
eclampsia, its absence does not exclude it. 
The electrocardiogram in PPCM 
The vast majority of patients present in sinus rhythm (Elkayam et al, 2001), although little else has 
been reported on the occurrence of other common electrocardiographic abnormalities in PPCM. 
Arrhythmias in PPCM occur as with cardiomyopathies and heart failure in general (Tibazarwa et al, 
2009) and include: atrial fibrillation, frequent premature ventricular systoles, ventricular tachy-
arrhythmias, and bundle branch block (Lamparter et al, 2007) - the latter occurring more frequently 
among chronic cases (Duran et al, 2008). While ventricular arrhythmias have been reported in up-to 
one-fifth of patients thought to have PPCM (Diao et al, 2004), one of the few comparative studies 
showed the more life-threatening complex ventricular arrhythmias to occur almost as often in PPCM 
(60%) as in its closest variant, idiopathic dilated cardiomyopathy (76% of patients) (O’Connell et al, 
1986). Another study suggests that subsequent pregnancy in PPCM patients might result in 
deterioration of ventricular arrhythmias through various mechanisms, including triggering 
premature ventricular extra systoles as the cardiomyopathy worsens in subsequent pregnancy 
(Yamada et al, 2009). This arrhythmic deterioration is thought to either precede (and hence 
facilitate) further decompensation of heart failure, or else to be triggered by already worsening left 
ventricular dysfunction in asymptomatic patients (Yamada et al, 2009). Furthermore, they suggest 
that ventricular arrhythmias occurring in the acute phase of PPCM are likely to improve with left 
ventricular recovery, whereas those in patients not recovering will more likely require intervention 
(Yamada et al, 2009). 
Radiological findings in PPCM 
Chest Roentgenogram 
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Typically, the chest x-ray will show cardiomegaly, pulmonary congestion (including upper lobe 
diversion and Kerley-B lines) and, occasionally, right-sided pleural effusion, in keeping with more 
severe congestive cardiac failure.    
Echocardiography 
Echocardiography has become the mainstay for definitive diagnosis of PPCM. Diagnosis requires 
echocardiographic evidence of left ventricular systolic dysfunction (ejection fraction < 45%) (Sliwa et 
al, 2008b). Echocardiography allows for visual estimations of global and regional cardiac chamber 
function to assess systolic and diastolic function, thrombotic complications of PPCM, as well as to 
exclude other organic heart disease. While most reports document elevated left ventricular end-
diastolic diameters (LVEDD) in PPCM (averaging 6cm in most studies), not all patients will present 
with dilated left ventricles. Hence the current definition of PPCM does not mandate the presence of 
left ventricular dilatation.  
Magnetic Resonance Imaging (MRI) 
Over the last few years, MRI has received increasingly favourable attention in the evaluation of 
patients with PPCM. This is due to the ability to elicit the presence of myocardial fibrosis using late 
enhancement imaging in cardiac MRI with a marker of the persistence of left ventricular dysfunction 
(32). Given the poor understanding of the pathophysiology of PPCM and the conflicting data on 
myocarditis as the causative process, there has been hope that cardiac MRI would also help to clarify 
pathogenetic mechanisms. Further attributes of cardiac MRI are its ability to assess myocardial 
kinesia and ejection fraction, and view the shapes, size and contents of the cardiac chambers 
through the use of cine cardiac MRI (Marmursztejn et al, 2009). One study of over 1000 consecutive 
patients with heart failure assessed eight women considered to have PPCM, yet found: no specific 
pattern of PPCM on cardiac MRI; no late enhancement; and no difference in MRI features between 
patients recovering within the first two years and those who failed to recover systolic function 
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(Mouquet et al, 2008).  However, the PPCM sample size was small, making more research 
mandatory.  
Cardiac Catheterisation 
As with other forms of heart failure, in patients with PPCM cardiac catheterisation and angiography 
remains the gold standard for the determination of systolic function.  Yet few systematic reports of 
PPCM have conducted haemodynamic studies; those existing having shown decreased cardiac 
output and high filling pressure, but normal coronary arteriograms (Ventura, 1991). 
 
1.1.4.3 The immunology of PPCM 
Increasingly, studies have suggested myocarditis to be a key pathogenetic process in the 
development of PPCM (O’Connell et al, 1986; Melvin et al, 1982; Midei et al, 1990; Sanderson et al, 
1979). Endomyocardial biopsies have strongly supported this theory (O’Connell et al, 1986), as has 
the demonstrable clinical and histological improvement of PPCM patients on immuno-suppressive 
therapy (O’Connell et al, 1986), such as prednisone and azathioprine (Melvin et al, 1982). The 
specific aetiology of the underlying myocarditis remains to be confirmed. For many years, the 
enhanced suppressor cell activity during pregnancy was thought to predispose pregnant women 
exposed to cardiotropic viruses to more severe forms of viral myocarditis (O’Connell et al, 1986). 
Common pathogens implicated include Coxsackie and encephalo-myelocarditis viruses (O’Connell et 
al, 1986), as well as Parvovirus B 19 (Kuhl et al, 2005). Adenovirus, HSV-6, EBV, and CMV DNA have 
been isolated in endomyocardial biopsies of PPCM patients (Ramaraj et al, 2009). However, 
myocarditis could simply reflect the immune response from any other form of myocardial damage.  
In essence, the molecular components of the inflammatory process in PPCM have been found to be 
very similar to that of idiopathic dilated cardiomyopathy, with elevated tumour necrosis factor alpha 
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(TNF-) and C-reactive protein (CRP) and (in particular) persistently raised leukocyte cytokines despite 
treatment (Watkins et al, 2009).  
The above-mentioned aetiology is not restricted to PPCM, but may form the basis of a variety of 
dilated cardiomyopathies. First, the prevalence of myocardial inflammation in PPCM appears to be 
similar to that of age-matched patients with idiopathic dilated cardiomyopathy (Rizeq et al, 1994) 
and has thus far failed to predict outcome in PPCM (Felker et al, 2000). Secondly, viral clearing has 
been associated with clinical improvement in both PPCM and idiopathic dilated cardiomyopathy 
(Sliwa et al, 2006b). Unique to PPCM, however, are certain immune activation processes, such as the 
finding of elevated levels of the apoptotic marker Fas/Apo-1, which predicts mortality (Sliwa et al, 
2006a) and is considered causative (Sliwa et al, 2006b). Class G3 immunoglobulins (Lamparter et al, 
2007; Wairraich et al, 2005), which act against cardiac myosin (Sliwa et al, 2006b), bear the sub-class 
IgG3. This IgG3s sub-class has pro-inflammatory characteristics and may be associated with higher 
NYHA-FC at presentation (Wairraich et al, 2005). While idiopathic dilated cardiomyopathy 
demonstrates highly selective up-regulation of the IgG3s sub-class of G3 immunoglobulins, the 
humoral response in PPCM is not sub-class-restricted, with class G and all sub-class immunoglobulins 
being raised in PPCM (Wairraich et al, 2005). Sliwa et al identified increased plasma levels of the 
inflammatory cytokine tumour necrosis factor (TNF) α, C-reactive protein and a plasma marker of 
apoptosis, Fas/Apo-1 in a large population of newly diagnosed patients with PPCM (2006a and 
2006b).  Furthermore, C-reactive protein levels on presentation demonstrate linear correlations with 
left ventricular end-diastolic, end-systolic diameters and, inversely, with left ventricular ejection 
fraction (Sliwa et al, 2006a). Given the ethnic variations in serum levels of C-reactive protein, it was 
therefore proposed that an increase in the intensity of an inflammatory response could be one of 
the many factors contributing to the development of PPCM (Sliwa et al, 2006b). 
Ground-breaking data on the pathogenesis of PPCM emerged in recent reports of enhanced 
oxidative stress in a mouse model for PPCM (i.e. mice with a cardiac-specific deletion for signal 
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transducer and activator of transcription-3 [STAT 3]) being the trigger for activation of cathepsin D. 
Cathepsin D is a ubiquitous lysosomal-enzyme that subsequently cleaves serum prolactin into its 
anti-angiogenic and pro-apoptotic 16-kDa form(Hilfiker-Kleiner et al, 2007a).The presence of this 
shorter aberrant form of prolactin was associated with endothelial inflammation, impaired 
cardiomyocyte metabolism, reduced myocardial contraction and increased apoptosis. This suggested 
that oxidative stress, inflammation and prolactin maybe inter-connected and responsible for 
initiating PPCM. Similar evidence of increased oxidative stress, enhanced cathepsin D activity and 
increased prolactin cleavage has been shown in patients with acute PPCM (Hilfiker-Kleiner et al, 
2007a), who had higher levels of circulating serum 16-kDa prolactin. This led this research group to 
consider new treatment options in PPCM by using Bromocriptine to block prolactin further 
upstream.  
 
1.1.4.4 The genetics of PPCM 
Only a few studies have assessed the genetics of peripartum cardiomyopathy (Ventura, 1991; Pierce 
et al, 1963), with the occurrence of PPCM in twins having been reported by Constanzo-Nordin et al 
(Constanzo-Nordin et al, 1989). Most recently, two studies conducted in Western societies 
demonstrated familial disease and went further to suggest that: a sub-set of PPCM patients may in 
fact be familial IDCM (FDCM) presenting in pregnancy (Van Spaendonck et al, 2010; Morales et al, 
2010); while a smaller sub-set may be due to  sporadic mutations (Morales et al, 2010). This was 
after their demonstration of genetic mutations similar to those found in FDCM among their recruited 
PPCM patients. Specifically, mutations found in patients with familial disease: were on TNNC1 of the 
troponin C gene (Van Spaendonck et al, 2010), as well as MYH7, SCN5A and PSEN2 (Morales et al, 
2010); while MYH6 and TNNT2 mutations were found in patients with sporadic disease (Morales et 
al, 2010). Interestingly, the Lamin A/C mutation (considered the most virulent among patients with 
FDCM, due its phenotype of aggressive heart failure, arrhythmia and high mortality (Taylor et al, 
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2003), was not found in either of these PPCM studies. However, the small sample sizes and 
retrospective nature of identifying PPCM patients may have limited the spectrum of PPCM patients 
recruited for genetic studies - one study recruited patients from known families with FDCM. For 
example, PPCM patients bearing the LMNA/C mutation may have died before the onset of their 
study period. 
Polymerase chain reaction testing has been recommended in assessing the role of cardiotropic 
viruses in inflammatory cardiomyopathies such as PPCM; and not just in endomyocardial biopsy 
tissue, but possibly also in the study of peripheral blood samples, particularly for IgM detection 
during the viraemic phase (Fett et al, 2008a).  
Persistent microchimerism has been implicated in the aetiopathogenesis of PPCM (Ansari et al, 
2002). This is the presence of foetal cells in maternal circulation, which can be investigated through 
the demonstration of foetal male chromosomal DNA in maternal plasma within a narrow period 
from term pregnancy to a few days post-partum (Fett et al, 2003). This test remains to be validated 
in the evaluation of PPCM. However, high levels of foetal microchimerism in mono-nuclear cells has 
been found in PPCM patients bearing high titres of auto antibodies; these levels of foetal 
microchimerism being significantly higher than in control non-PPCM mothers during the third 
trimester of pregnancy, at term, and in the first week post-partum (Ansari et al). Most of these auto-
antibodies happen to target human cardiac tissue proteins of 37kD, 35KD and 25kD (Ramaraj et al, 
2009; Lamparter et al, 2007), leading to auto-immune myocarditis (Sliwa et al, 2006b; Lamparter et 
al, 2007). This emphasises the need to facilitate detection tools for foetal microchimerism. 
The pro-apoptotic gene Nix or Bnip3 has been considered a possible precipitant of apoptosis in 
PPCM and heart failure in vitro (Hilfiker-Kleiner et al, 2008). Up-regulation of Bnip3: was also 
observed in postpartum ventricular tissue of mice with a cardiomyocyte-specific deletion of the 
signal transducer and activator of transcriptin-3 (STAT3, STAT3-KO mice); and was associated with a 
high degree of myocardial apoptosis (Hilfiker-Kleiner et al, 2007a). 
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1.1.4.5 Prognosis 
Local data (Johannesburg) 
Our research unit studied a large cohort of PPCM patients and described a pro-inflammatory 
response in PPCM patients with: elevated plasma levels of TNF-alpha, Fas-Apo-1, Interleukin-6 (IL-6) 
(Sliwa et al, 2002); and a positive correlation between C-reactive protein (CRP) levels, left ventricular 
(LV) end-diastolic and end-systolic diameters at the time of diagnosis (Sliwa et al, 2006a). A potential 
causative effect of a cascade involving enhanced oxidative stress, subsequent activation of cathepsin 
D and cleavage of serum prolactin in an anti-antigenic, pro-apoptotic and pro-inflammatory 16-kDa 
form on the development of PPCM was later postulated by members of the collaborative research 
group (Hilfiker-Kleiner et al, 2007a; Tabruyn et al, 2007). Moreover, they recently reported a positive 
correlation of this cascade in PPCM patients who failed to recover within a six-month follow-up 
(Forster et al, 2008), suggesting that oxidative stress, inflammation and prolactin may all be inter-
connected in a vicious cycle of events responsible for initiating and progressing PPCM. 
The first prospective report of the long-term outcome of a large series of PPCM patients in Africa 
was also conducted by the same research team; it provided much needed data on the “natural 
history” of PPCM patients who received only standard heart failure treatment. At baseline, this 
cohort had a mean age of 30±7 years; with one-third being primigravid women and a similar 
proportion being co-infected with HIV. Almost 90% of patients presented with: NYHA functional class 
III-IV; the mean left ventricular ejection fraction (LVEF) was 30±9%. The two-year mortality rate was 
28%. Contrary to what most other Western studies have reported, only a minority of these (10%) 
died by six months. Interestingly, the novel finding of this study was not only the continuous high 
mortality of PPCM patients occurring beyond six months independent of HIV infection and 
subsequent pregnancy, but also the high number of patients who delayed or failed to recover their 
ejection fractions, with the earliest evidence of recovery being at 18 months. Of patients still 
enrolled at 6 months, 20% died over the remaining 18-month period, despite functional recovery. 
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Mean LVEF of surviving patients was: 44±11% at six-months, 46±13% at 12-month follow-up and 
50±14% at 24-month follow-up [see Figure 1]. This finding strongly encourages the need for long-
term clinical follow-up and management of women with PPCM. 
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1.1.4.6 Summary of global data on prognosis of PPCM 
Recovery from PPCM has often been limited to achievement of left ventricular ejection fraction 
above 50% (Fett et al, 2005 and 2009a), while the term “full recovery” in PPCM has been considered 
to be achievement of both NYHA-FC I and left ventricular ejection fraction above 50% (Fett et al, 
2005; Duran et al, 2008).  
Historically, most studies have suggested that full recovery of left ventricular function occurs in up-
to 50% of patients (Pearson et al, 2000; Elkayam et al, 2001; O’Connell et al, 1986; Forster et al, 
2008). Larger and more recent prospective studies of patients from lower and middle-income 
cohorts suggest; only a quarter will fully recover by the end of the first six months (Fett et al, 2005; 
Duran et al, 2008); while 10-15% will die by six months (Sliwa et al, 2006a and 2009). Long-term 
prospective outcome studies have shown overall recovery in a quarter of all PPCM patients, the vast 
Figure 1: Trend in %LVEF with time in PPCM; 
 
By point in time of death. 
 
This graph of mortality among the 11 HIV-
negative PPCM patients illustrates that even 
among patients who recovered their ejection 
fraction within six months, the risk of 
mortality persists well beyond six months of 
follow-up. From this graph, it appears neither 
baseline EF, six-month EF, nor the degree of 
change in EF within the first six months can 
predict the point in time of death. 
 
 
[Extracted with permission from Sliwa et al, 
Int J Cardiol. 2011 Mar 3;147(2):202-8] 
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majority of these being achieved only 18 - 24 months after diagnosis (Sliwa et al, 2011; Forster et al, 
2008). Long-term overall mortality rates in Haiti, Turkey and South Africa are estimated at 15% (Fett 
et al, 2005) to 30% (Duran et al, 2008; Sliwa et al, 2009a), with average death occurring: at 54±41 
months in one study (Duran et al, 2008); but within the first couple of months in another study (Fett 
et al, 2005). This is markedly higher than the mortality rates of 0 - 6% (Lamparter et al, 2007; Brar et 
al, 2007; Mielniczuk et al, 2006; Felker et al, 2000) and 9% (Elkayam et al, 2001) reported in the 
United States. Interestingly, two of these United States studies demonstrate low mortality rates of 
0% (Lamparter et al, 2007) and 6% (Felker et al, 2000), despite the high prevalence of myocarditis 
within their PPCM cohorts (of 50% (Felker et al, 2000) and 29% (Lamparter et al, 2007), respectively). 
Felker et al’s cohort from the United States further showed PPCM to have a far better prognosis 
than all other forms of cardiomyopathy (2000).  
Earlier studies consistently showed a greater chance of survival in patients with higher ejection 
fractions and smaller left ventricular end-diastolic diameters at baseline (Sliwa et al, 2006a; 
O’Connell et al, 1986). The suggested cut-off values for left ventricular dimensions that predict a 
favourable outcome at six months after first presentation are: >27% for the ejection fraction; and 
≤5.5cm for the end-diastolic diameter (Duran et al, 2008). Strikingly, recent data imply that the 
impact of baseline and six-month left ventricular dimensions and function in predicting outcome falls 
away among chronic PPCM patients, i.e. those who failed to recover fully by six months (Fett et al, 
2005 and 2009a). These long-term outcome studies present a consistent message that the natural 
history of PPCM goes far beyond what the six-month prognoses were suggesting in earlier years. 
They show that while a minority of only 25% of PPCM patients will recover, the vast majority of 
these will only do so from 18 to 24 months onwards.  
Perhaps inclusion criteria that strictly excludes pre-existing cardiovascular disease (such as pre-
eclampsia) applied in some of the more recent prospective studies of PPCM has facilitated this 
revelation, which further strengthens the theory that the higher rates of rapid recovery in earlier 
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studies could possibly be attributed to reversible effects of gestational hypertension. However, it 
may remain true that inherent differences in socio-genetic predisposition of PPCM patients in the 
United States (Elkayam et al, 2001; Felker et al, 2000) and in less developed societies (Sliwa et al, 
2009a; Fett et al, 2005; Duran et al, 2008) account for the better prognosis in the former group. 
Consistent among studies of PPCM is the high risk of relapse with subsequent pregnancy (Elkayam et 
al, 2001; Sliwa et al, 2004), with remarkable levels of mortality post-partum, alongside a strong 
association between TNF-α and deteriorating left ventricular function (Sliwa et al, 2004). A recent 
publication by Forster at al (2008) in an African cohort showed that a significantly higher baseline 
NT-proBNP and failure to decrease oxLDL, IFN-gamma and prolactin were all associated with poor 
outcome in patients with newly diagnosed PPCM; this suggests a potential role of these factors in 
the pathophysiology of PPCM and allows for further exploration of target substances for monitoring 
and treatment programmes. 
 
1.1.4.7 Therapy in PPCM 
So far, medical management and therapy of patients with PPCM has been similar to other forms of 
heart failure, with detailed reviews having been attempted (Sliwa et al, 2008b). 
Administration of diuretics is indicated in the presence of symptoms secondary to fluid retention, 
whereas ionotropic agents are recommended in the presence of peripheral hypo-perfusion 
(particularly hypotension and decreased renal function). Temporary mechanical circulatory 
assistance should be used in patients with acute heart failure who are not responding to 
conventional therapy. Generally favourable outcomes have been attributed to the young age of 
recipients and to the relatively short duration of heart failure, resulting in minimal end-organ 
damage. Conventional pharmacological therapy with angiotensin-converting enzyme inhibitors or 
angiotensin receptor blockers (and, if haemo-dynamically stable, beta-adrenergic blockers) are 
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effective in the treatment of PPCM. Because of the potential hazardous effects on the foetus, 
hydralazine (with or without additional nitrates) should replace ACE-inhibitor use during pregnancy. 
Digitalis, an inotropic agent, is also safe during pregnancy and may help to maximize contractility 
and rate control. However, its use requires close monitoring of the patient, which may prove difficult 
in low-resource environments.    
Cardiac transplantation has been performed successfully in PPCM patients. Given the potentially 
inflammatory nature of PPCM with up-regulated inflammatory cytokines, such as TNF-alpha, IL6 and 
Fas-Apo-1, there may be a role for immuno-modulatory therapy. A prospective study of 59 
consecutive women reporting with PPCM reported a significant reduction in TNF-alpha and 
improved outcome in patients receiving the immuno-modulating agent pentoxifylline in addition to 
conventional therapy (that included ACE-inhibitors and beta-blockers) (Sliwa et al, 2002). 
However, further research into the pathogenetic mechanisms of PPCM by Hilfiker-Kleiner et al 
(2007a) revealed the co-existence of systemic oxidative stress and significantly higher prolactin levels 
in patients with PPCM; this supports the notion of the previously published concept that oxidative 
stress-mediated prolactin cleavage into its detrimental 16kDa form is crucial for the initiation of 
PPCM and subsequently for the release of inflammatory cytokines.  This suggests that inhibition of 
prolactin with Bromocriptine may prevent a prolonged inflammatory response via activation and 
perpetuation of the inflammatory cascade.  A recent pilot study in newly diagnosed PPCM patients 
suggested that this process can be ameliorated or even abolished by administering the prolactin 
inhibitor Bromocriptine (Sliwa et al, 2009b). 
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Figure 2: Development of peripartum cardiomyopathy in the mouse model: The STAT3-oxidative stress-cathepsin D-16 kDa cascade. 
By knocking out STAT 3 in the cardiomyocyte, the expression of the oxygen radical scavenger manganese sodium dismutase (MnSOD) is 
attenuated. As a consequence, reactive oxygen species (ROS) accumulate and promote the release of matrix metalloproteinases (MMPs) 
and the production of active cathepsin-D (CD) from the cardiomyocyte. Prolactin is produced by the pituitary gland and cardiac fibroblasts. 
CD and MMPs cleave this 23kDa full-length form into its 16kDa form. In cardiomyocytes, this leads to affected function and endothelial 
cells react with vaso-constriction, apoptosis, inflammation and dissociation of capillary structures, which display peripartum 
cardiomyopathy. The blockage of systemic and local prolactin release by Bromocriptine prevents the generation of 16 kDa prolactin, 
thereby preventing this fragment’s detrimental effects on endothelial cells and cardiomyocytes. 
[Extracted with author’s permission from Selle et al, 2009.] 
 
1.1.4.8 Challenges to improving the diagnosis and prognosis of PPCM in Africa 
The lack of uniformity in case definitions of PPCM may result from clinicians differing in opinion 
about what constitutes an alternative cause of heart failure in patients evaluated for the diagnosis of 
PPCM; and it is also fuelled by the shortage of large studies for this rare disease.  Confounding the 
issue are studies comparing PPCM patients with various levels of gestational hypertension to those 
who are hypertension naïve.  
In an attempt to address this deficit, the American College of Cardiology (ACC) guidelines now 
classifies PPCM as an entity on its own (Maron et al, 2006), while the European Society of Cardiology 
(ESC) has taken active measures towards this process (Sliwa et al, 2010). To benefit from the success 
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in recognizing PPCM as a disease on its own, awareness of PPCM must be raised amongst clinicians 
and across societies, as this has been shown to contribute significantly to delayed diagnosis and 
under-reporting of PPCM (Sliwa et al, 2008b; Deneux-Tharaux, 2005). This will have a great impact in 
developing societies, where levels of awareness of cardiovascular disease are disproportionately 
lower than the actual prevalence of cardiovascular disease (Sliwa et al, 2008a) and particularly so in 
Africa (Tibazarwa et al, 2008) - and more so in the case of PPCM. 
The plight of poverty-related infectious disease has over-ridden many African countries’ ability to 
pay sufficient attention to heart failure. Despite the greatest burden of heart failure in Africa caused 
by two infectious disease, rheumatic heart disease and tuberculous pericarditis (Sliwa et al, 2005), 
inequitable access to facilities permitting the definitive diagnosis and management of these patients 
has contributed to the paucity of research data on the epidemiology of the many various forms of 
heart failure in sub-Saharan Africa. To date, no population-based epidemiological studies on PPCM in 
Africa have been published (Mayosi, 2007). Like idiopathic dilated cardiomyopathy, PPCM is a 
diagnosis of exclusion. To confirm that the case fits the definition, Lampert et al (2005) mandate the 
use of sophisticated echocardiography. The exhaustive requirements for serological tests, imaging 
and, in more mature women, cardiac catheterization to exclude coronary artery disease, falls 
beyond the capacity of most tertiary health centres in sub-Saharan Africa. Patients in rural areas 
continue to suffer grossly inequitable access to health facilities capable of even the most basic of 
these investigations. Recently, however, joint efforts to increase global awareness of the burden of 
cardiac disease in Africa has, to some extent, facilitated access to practical solutions, such as 
partially-subsidized portable echocardiography equipment and regional sharing of laboratory 
services for the rarer disease tests.  
Across the world, a major challenge to clinicians remains the gross overlap between clinical features 
of PPCM and the dyspnoea, fatigue and pedal oedema of normal pregnancy (Tibazarwa et al, 2010; 
Sliwa et al, 2008b; Lata et al, 2009; Abboud et al, 2007). In this regard, recent studies have suggested 
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adoption of the ECG as a simple screening tool for PPCM (or at least for heart failure) in women 
presenting peripartum with symptoms and signs resembling those of PPCM, particularly shortness of 
breath and fatigue. 
Globally, the gap in available data on PPCM remains vast and the shortage of long-term outcome 
studies is also evident. We are only aware of seven long-term outcome studies (Fett et al, 2005; 
Habli et al, 2008; Duran et al, 2008; Sliwa et al, 2009a; Elkayam et al, 2001; Amos et al, 2006; Fett et 
al, 2009), two of which were retrospective in nature (Habli et al, 2008; Amos et al, 2006). Much of 
the gaps in the literature should be overcome with new research into the aetiology of PPCM and also 
by the creation and use of registries (Damasceno et al, 2007). 
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Peripartum cardiomyopathy (PPCM) is a form of heart 
failure that occurs in women within 1 month of pre-
delivery and 5 months postdelivery. Echocardiography 
demonstrates features of cardiomyopathy with impaired 
ejection fraction; global dilatation and thinned-out 
walls are sometimes present. The symptoms and signs 
of PPCM are similar to those in patients with idiopathic 
dilated cardiomyopathy. The acute form of PPCM is a 
clinical syndrome, with reduced cardiac output, tissue 
hypoperfusion, and increase in the pulmonary capil-
lary wedge pressure. Monitoring of the patient with 
the acute form of PPCM should be initiated as soon as 
possible. The types and levels of monitoring required 
for an individual patient vary widely depending on the 
severity of the cardiac decompensation and response 
to initial therapy. The syndrome carries a high morbid-
ity and mortality, and diagnosis is often delayed. This 
review summarizes recent data charting the incidence, 
recent advances in the understanding of the patho-
physiology of PPCM, and outlines the current treatment 
options available.
Introduction
Peripartum cardiomyopathy (PPCM) is defi ned as a dis-
order of unknown pathogenesis, in which left ventricular 
dysfunction and symptoms of heart failure are present 
and occur between the last month of pregnancy and the 
fi rst 5 months postpartum. By defi nition, PPCM occurs 
in the absence of an identifi able cause of heart failure 
and in the absence of recognizable heart disease prior 
to the last month of pregnancy [1,2•]. Some authors 
go beyond this defi ned time frame to include patients 
diagnosed with heart failure as early as 3 months of 
pregnancy [3•]. Diagnosis requires echocardiographic 
evidence of left ventricular systolic dysfunction (ejec-
tion fraction < 45%) [4]. Heart failure that occurs in 
earlier pregnancy may be caused by previously unsus-
pected familial or other forms of cardiomyopathy that 
(unmasked by the hemodynamic and hormonal stress of 
pregnancy) forms a different entity. Diagnosis of PPCM 
should be established by ruling out other causes of 
perinatal heart failure, such as infectious diseases, met-
abolic disorders, and ischemic or valvular heart disease. 
Complications of late pregnancy that may have similar 
symptoms and signs to PPCM include pre-eclampsia, 
amniotic or pulmonary embolism, hemolysis, elevated 
liver enzymes, and low platelets [5]. 
The American College of Cardiology (ACC) guide-
lines classify PPCM as an entity of its own [6]. However, 
in the recently published European Society of Cardiol-
ogy classifi cation [7], PPCM is not listed as a specifi c 
disease and is placed under the category of “unclassifi ed 
cardiomyopathies.” The more recently described cardio-
myopathies, such as left ventricular noncompaction 
and Takotsubo cardiomyopathy, for which little of their 
pathogenesis is known, have been listed as “unclassifi ed 
cardiomyopathies” [7], which promote ongoing interest 
and research into these conditions. Because gynecolo-
gists, physicians, and cardiologists have little awareness 
of PPCM, the condition is not diagnosed quickly and 
often leads to unnecessary morbidity and mortality. A 
recent publication by Deneux-Tharaux et al. [8] high-
lights the underreporting of pregnancy-related mortality 
in the United States and Europe. The study clearly shows 
the limitations of maternal mortality statistics based 
on the International Classifi cation of Diseases cause of 
death codes. 
Epidemiology of PPCM
PPCM is most common in women of African descent 
[2•,9], but it has been reported in all major ethnic popu-
lations. The incidence varies from 1:100 to 1:10,000 
between geographic regions. Due to diagnostic limita-
tions, including limited access to echocardiography, the 
incidence in some areas may be overestimated. 
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Etiology and Pathogenesis 
There is considerable controversy regarding the etiology of 
human PPCM, but a number of recent publications have 
contributed to better understanding of its pathogenesis 
[10,11•,12,13]. A number of mechanisms have been pro-
posed in the development of PPCM, including nutritional 
defi ciencies, genetic disorders, viral or autoimmune eti-
ologies, hormonal imbalances, volume overload, alcohol, 
physiologic stress of pregnancy (Fig. 1), and unmasking of 
latent idiopathic dilated cardiomyopathy (DCMO) [2•]. 
However, none of these mechanisms have been confi rmed 
in detailed investigations or prospective studies [14]. The 
rare incidence of PPCM and the paucity of relevant animal 
models have limited guided research and understanding 
of the pathogenic mechanisms involved. Several authors 
have suggested that multiparity may be a risk factor for 
PPCM. However, a study by Elkayam et al. [3•] does 
not support this theory within their cohort in the United 
States because almost 40% of the cases occurred in asso-
ciation with a fi rst pregnancy and more than 50% within 
the fi rst two pregnancies. 
Clinical Presentation and Diagnosis
Features of a normal pregnancy include an expansion of 
blood volume, an increase in metabolic demands, relative 
anemia, and changes in vascular resistance that are asso-
ciated with mild ventricular dilatation and an increase 
in cardiac output. These physiologic changes are due to 
an increase in preload and heart rate accompanied by a 
Figure 1. Proposed mechanism that possibly 
contributes to pathogenesis of peripartum 
cardiomyopathy (PPCM).
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decrease in afterload. Decompensation of patients with 
subclinical valvular, ischemic, or myopathic heart dis-
ease usually occurs during the second or third trimester 
of pregnancy. The onset of PPCM can be easily missed 
because many symptoms and signs of pregnancy and post-
pregnancy stages are similar to those of early congestive 
heart failure (CHF) (eg, dyspnea, abdominal discomfort, 
and fatigue) [15]. Elkayam et al. [3•] reported that 7% of 
their patients in the United States were diagnosed within 
1 month before delivery, whereas 75% were diagnosed 
during the fi rst month postpartum, the remainder hav-
ing fulfi lled criteria for PPCM before the last 1 month 
of pregnancy. In contrast, patients in South Africa and 
Haiti developed symptoms almost exclusively within the 
postpartum period [16,17]. The symptoms and signs are 
similar to those in patients with idiopathic DCMO. Echo-
cardiography usually demonstrates features of DCMO 
with impaired ejection fraction, often global dilatation, 
and sometimes thinned-out walls. 
PPCM often presents with acute onset of heart failure 
(AHF). The presentation, with reduced cardiac output, 
tissue hypoperfusion, increase in the pulmonary capillary 
wedge pressure, and tissue congestion, is often life threat-
ening and requires urgent treatment. The diagnosis of AHF 
is based on symptoms and clinical fi ndings in combination 
with appropriate investigations, such as electrocardiogra-
phy, chest radiograph, biomarkers, and echocardiography. 
Systematic clinical assessment of the peripheral circulation, 
venous fi lling, and peripheral temperature are important. 
Right ventricular fi lling in decompensated heart failure may 
be evaluated from the central jugular venous pressure. Cau-
tion is necessary in the interpretation of raised measures 
of central jugular venous pressure in AHF, as it may be a 
refl ection of decreased venous compliance together with 
decreased right ventricular compliance [18]. Left-sided car-
diac fi lling pressure is assessed by chest auscultation, with 
the presence of wet rales in the lung fi elds usually indica-
tive of raised pressure. The confi rmation, classifi cation of 
severity, and clinical follow-up of pulmonary congestion 
and pleural effusions should be done using chest radio-
graph. Cardiac palpation and auscultation for ventricular 
and atrial gallop rhythms (S3, S4) and an electrocardiogram 
should be performed. 
Chest radiograph and other imaging modalities should 
be conducted early for all patients with AHF to evalu-
ate pre-existing chest or cardiac conditions and to assess 
pulmonary congestion. They are used for confi rmation of 
the diagnosis and monitoring response to therapy. Chest 
radiograph allows the differential diagnosis of left-sided 
heart failure from infl ammatory or infectious lung disease. 
A chest CT scan with or without contrast angiography and 
scintigraphy may be used to clarify pulmonary pathology 
and diagnose major pulmonary embolism [18]. 
A number of laboratory tests should be used in all 
patients with PPCM presenting with AHF: full blood count, 
urea and electrolytes, C-reactive protein (CRP), blood glu-
cose, D-dimer, creatine kinase-MB (CKMB), and cardiac 
troponin T (cTnT). In severe heart failure, international 
normalized ratio (INR) and arterial blood gas should also 
be performed. Transaminases, urinalysis, and plasma B-
type natriuretic peptide (BNP) or N-terminal pro–B-type 
natriuretic peptide (NTproBNP) can be considered. Arterial 
blood gas analysis allows assessment of oxygenation (pO2), 
respiratory adequacy (pCO2), acid base balance (pH), and 
base defi cit, and should be performed in all patients with 
severe heart failure. Noninvasive measurement with pulse 
oximetry and end-tidal carbon dioxide (ETCO2) can often 
replace arterial blood gas analysis, but not in very low output 
vasoconstricted shock states [19]. BNP is released from the 
cardiac ventricles in response to increased wall stretch and 
volume overload and has been used to exclude or identify 
CHF in patients. NTproBNP has been found to be elevated 
in patients with PPCM presenting with AHF [12].
Echocardiography is an essential tool for evaluat-
ing the functional and structural changes underlying or 
associated with AHF. The most important measurement 
of ventricular function is the left ventricular ejection 
fraction for distinguishing patients with cardiac systolic 
dysfunction from those with preserved systolic function. 
Echocardiography with Doppler imaging should be used 
to evaluate and monitor regional and global left and right 
ventricular function, valvular structure and function, pos-
sible pericardial pathology, and mechanical complications. 
We have observed that patients with severe functional 
mitral regurgitation at presentation have a lower chance 
of full recovery of LV function (Sliwa, unpublished data). 
Appropriate echocardiographic Doppler study can also 
estimate pulmonary artery pressures and may help to 
detect the presence of pulmonary embolus. 
Monitoring of Patients With Newly 
Diagnosed PPCM
Monitoring of the patient presenting with AHF should 
be initiated as soon as possible. The extent and means in 
which to monitor for an individual patient vary widely 
depending on the severity of the cardiac decompensation 
and the response to initial therapy. However, we observed 
that because of their young age our patients often appear 
relatively well at fi rst glance despite low cardiac output and 
marked tachycardia. Many women request inappropriate 
early discharge due to social pressures, including caring 
for their newborn, which may lead to rapid readmission or 
possible death (Sliwa, unpublished data). 
Current Theories on the Pathogenetic 
Mechanisms in PPCM
Over the past decade, accumulating evidence has suggested 
distinct pathogenetic mechanisms for PPCM, which may 
differ from those of other forms of DCMO. Apoptotic 
events—systemically and in the myocardium—appear to 
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be causally associated with PPCM. In this regard, trans-
genic mice with cardiac-restricted over-expression of Gαq 
exhibit a lethal PPCM accompanied by strongly enhanced 
apoptosis [10]. Reduction in cardiac apoptosis by caspase 
inhibition through administration of the polycaspase 
inhibitor IDN-1965 improved left ventricular function 
and survival in pregnant Gαq mice, suggesting that car-
diac apoptosis plays a causal role in the pathogenesis of 
cardiomyopathy [10].
The apoptosis signaling surface receptor Fas/Apo-1 
is known to trigger cell death in a variety of cell types. 
Patients with PPCM had signifi cantly higher plasma levels 
of Fas/Apo-1 compared with healthy volunteers [16]. Ele-
vated plasma levels of tumor necrosis factor (TNF)-α have 
also been found in a cohort of 100 patients with PPCM. 
Elevated TNF-α has also been implicated in the pathogen-
esis of idiopathic DCMO [20•].
There is evidence suggesting the role of viral illness 
or an autoimmune etiology in the development of PPCM 
[21–24], with histologic samples of myocardial tissue 
having shown infl ammatory infi ltrates similar to that of 
myocarditis. Biopsies from PPCM patients often do not 
show infl ammatory infi ltrates (Fig. 2). Furthermore, a high 
prevalence of viral genomes were detected in endomyocar-
dial biopsy (EMB) specimens of PPCM patients in 8 of 26 
PPCM patients, and in 10 of 33 control subjects (30.3%) 
[21]. Viruses identifi ed (parvovirus B19 [PVB19], human 
herpesvirus 6 [HHV-6], human herpesvirus 5 [HCMV], 
and EMBs) have been related to infl ammatory cardio-
myopathy, but also exist at high prevalence in healthy 
populations [21]. Similar results were presented by Rizeq 
et al. [24], whose retrospective review of EMB specimens 
from 34 PPCM patients showed a comparable incidence of 
myocarditis (8.8%) to that found in age- and sex-matched 
patients undergoing transplantation for idiopathic DCMO 
(idiopathic cardiomyopathy: 9.1%). Thus, the role of EMB 
remains controversial and is likely to be clinically useful 
only if performed early in the course of the disease. 
Recently, we discovered increased serum levels of 
oxidized low-density lipoprotein (oxLDL), indicative of 
enhanced systemic oxidative stress together with signifi -
cantly higher prolactin levels and increased activation of 
the prolactin-cleaving protease cathepsin D [11•,12] among 
PPCM patients compared with healthy nursing- and preg-
nancy-matched control women. Moreover, we detected 
substantial amounts of cleaved 16-kDa prolactin in some 
PPCM patients, but not in healthy nursing mothers [11•].
In a mouse model for PPCM that lacked the signal 
transducer and activator of transcription 3 (STAT3) in car-
diac myocytes, we were able to demonstrate that increased 
oxidative stress is responsible for the activation of cathep-
sin D and the subsequent cleaving of prolactin in a 16-kDa 
fragment. Furthermore, we showed that the 16-kDa pro-
lactin has detrimental effects on the maternal heart by 
impairing the cardiac microvasculature and the cardiac 
myocyte metabolism, all of which appear to be largely 
responsible for the development of PPCM in mice [11•]. 
Bromocriptine is a dopamine D
2 receptor antagonist that is 
known to effi ciently block prolactin release from pituitary 
glands in humans [25] and mice [26] and is widely used in 
stopping lactation in women who cannot or do not want to 
nurse. Bromocriptine prevented PPCM in mice [11•]. This 
observation supports a crucial role of prolactin, namely its 
16-kDa form in prolactin for PPCM, and supports previ-
ous studies viewing prolactin as a potential factor in the 
pathogenesis of PPCM [27]. 
In a recent study, the kinetics of a set of biomarkers asso-
ciated with cardiac function, oxidative stress, apoptosis, 
infl ammation, remodeling, and pregnancy were monitored 
at 6-month follow-up of PPCM patients, comparing bio-
markers between patients who improved clinically versus 
those who did not [12]. This study revealed that among 
all markers analyzed, only the kinetics of NTproBNP, 
oxLDL, and interferon-γ (IFN-γ) correlated signifi cantly 
with nonimprovement in there being a positive correlation. 
Moreover, NTproBNP correlated positively with oxLDL, 
IFN-γ, and prolactin. Thus, the kinetics of NTproBNP in 
correlation with the kinetics of more disease-specifi c mark-
ers (oxLDL, IFN-γ, and prolactin) may serve to distinguish 
patients with poor prognosis from those who may recover 
[12]. However, the role of each of these factors in disease 
progression is still unclear and needs further clinical and 
experimental analysis. 
Current Therapeutic Approaches Towards 
Heart Failure in PPCM
Treatment is directed toward symptomatic relief and 
improvement of cardiac function, similar to other forms of 
heart failure treatment. The maintenance of blood oxygen 
saturation within the normal range (95%–98%) is impor-
tant to maximize oxygen delivery to the tissues and tissue 
Figure 2. Left ventricular biopsy from a patient with acute peri-
partum cardiomyopathy. Formalin and paraffi n-embedded tissue 
was stained with hematoxylin and eosin (H&E). No signifi cant 
infi ltrations are visible.
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oxygenation, thus helping to prevent end-organ dysfunc-
tion and multiple organ failure. This is best achieved by 
fi rst ensuring that there is a patent airway and then admin-
istering an increase in fraction of inspired oxygen (FiO2). 
Endotracheal intubation is indicated if these measures 
fail to improve tissue oxygenation. The use of continuous 
positive airway pressure (CPAP) and noninvasive positive 
pressure ventilation (NIPPV) in acute cardiogenic pulmo-
nary edema is associated with a signifi cant reduction in 
the need for tracheal intubation and mechanical ventila-
tion [28]. Respiratory muscle fatigue is the most frequent 
reason for endotracheal intubation and mechanical ventila-
tion in AHF. It may be diagnosed by decreasing respiratory 
rate associated with hypercapnia and a confused state of 
mind. Invasive mechanical ventilation should only be used 
if acute respiratory failure does not respond to vasodila-
tors, oxygen therapy, and/or CPAP or NIPPV [18,29]. 
Administration of diuretics is indicated in the pres-
ence of symptoms secondary to fl uid retention. Ionotropic 
agents are indicated in the presence of peripheral hypo-
perfusion (hypotension, decreased renal function) with 
or without congestion or pulmonary edema refractory to 
diuretics and vasodilators. 
Temporary mechanical circulatory assistance may be 
indicated in patients with AHF who are not responding to 
conventional therapy and where there is reasonable potential 
for myocardial recovery, for use as a bridge to heart trans-
plantation, or interventions that may result in signifi cant 
recovery of heart function. These include an intra-aortic 
balloon pump and a left ventricular assist device [19]. 
Cardiac transplantation has been successfully performed 
in PPCM patients. Favorable outcomes have been attributed 
to the young age of the recipients and to the relatively short 
duration of heart failure, resulting in minimal end-organ 
damage. However, there are reports of increased transplant 
rejection [30]. In view of the success of transplantation in 
these young and otherwise healthy mothers, aggressive 
temporary life support measures, such as cardiopulmonary 
bypass or a left ventricular assist device, have been encour-
aged until a transplant becomes available [31]. 
Coexistence of systemic oxidative stress and signifi -
cantly higher prolactin levels in patients with acute PPCM 
supports the notion of our previously published concept 
that oxidative stress-mediated prolactin cleavage into its 
detrimental 16-kDa form is crucial for the initiation of 
PPCM. A recent pilot study suggests that this process can 
be ameliorated or even abolished by bromocriptine, an 
inhibitor of the detrimental prolactin [11•,32]. In this light, 
trials assessing the therapeutic effects of prolactin block-
ade with bromocriptine have begun in PPCM patients. A 
few case reports suggest that the addition of bromocrip-
tine to standard therapy of heart failure may be benefi cial 
in patients with acute onset of PPCM [11•,32].
In patients with stable heart failure, β-blockers and 
angiotensin-converting enzyme (ACE) inhibitors should 
be initiated when the patient has stabilized after the acute 
episode (usually after 4 days). ACE inhibitors should 
be titrated up to dosages shown to be effective in the 
large controlled trials of heart failure and not towards 
symptomatic improvement alone. ACE inhibitors are 
contraindicated during pregnancy because of teratogenic-
ity, but should be considered a mainstay of treatment for 
PPCM after delivery.
β-blockers, preferably carvedilol, should be consid-
ered for treatment of all patients with heart failure, unless 
there is a contraindication. β-blocker therapy reduces 
hospitalization, improves the New York Heart Assoc-
iation (NYHA) functional class, and leads to smaller 
proportions of patients whose heart failure worsens [29]. 
The initial dose should be small and increased slowly 
and progressively to the target dose used in the large 
clinical trials. Aldosterone receptor antagonists are rec-
ommended in addition to ACE inhibitors, β-blockers, and 
diuretics in advanced heart failure (NYHA III–IV) with 
systolic dysfunction to improve survival and morbidity. 
Angiotensin II receptor blockers (ARBs) can be used as 
an alternative to ACE inhibition in symptomatic patients 
who are intolerant to ACE inhibitors to improve morbid-
ity and mortality. Digoxin therapy is associated with an 
increased risk of death from any cause among women, but 
not men, with heart failure and depressed left ventricular 
systolic function [33]. Retro spective analysis of data from 
the Digitalis Investigation Group (DIG) trial indicates a 
benefi cial effect of digoxin on morbidity and no excess 
mortality in women at serum concentrations from 0.5 to 
0.9 ng/mL, whereas serum concentrations of 1.2 ng/mL 
or greater appear harmful [34]. 
Thromboembolic phenomena have been reported 
frequently in PPCM patients. Pregnant patients are at 
increased risk of thromboembolic complications due to the 
hypercoagulable state of late pregnancy that may persist 
for up to 6 weeks postpartum. Left ventricular systolic dys-
function resulting in blood stasis additionally predisposes 
to formation of left ventricular, pulmonary, and cerebral 
thromboemboli. During the last weeks of pregnancy, low-
molecular weight heparin is the agent of choice, whereas 
warfarin is preferred postpartum in patients with low ejec-
tion fraction (< 30 %) [18]. 
Appropriate birth control measures are recommended 
for patients with enlarged hearts. Oral contraceptives 
should be avoided because of the risk of increasing the 
incidence of thromboembolism.
Prognosis and Subsequent Pregnancy
Echocardiography is an important diagnostic tool in PPCM 
and may provide signifi cant prognostic information with 
regard to recovery of cardiac function [35•]. A fractional 
shortening value of less than 20% and a left ventricular 
end-diastolic dimension of more than 6 cm at the time of 
diagnosis are associated with a threefold or higher risk for 
persistent left ventricular dysfunction [4]. 
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In a cohort of 100 patients from South Africa, a mor-
tality of 15% within a 6-month period was reported. 
Baseline plasma levels of Fas/Apo-1 and NYHA func-
tional class were identifi ed as independent predictors of 
death [2•]. Compared with other forms of cardiomyopa-
thy (n = 1230), patients with PPCM (n = 51) demonstrate 
better survival [36]. In a study from Haiti, the ratio of 
PPCM deaths for the 5-year period was 47.1 per 100,000 
births, and the mortality rate was 15.3% during a mean 
follow-up period of 2.2 years. Only 28% of patients who 
were observed for at least 6 months regained  normal left 
ventricular function [37]. 
One of the most common issues for women surviving 
an episode of PPCM is whether it is safe to become preg-
nant again. If a subsequent pregnancy occurs, it should be 
managed in close collaboration between the obstetrician 
and attending physician or cardiologist. Most authors 
agree that PPCM patients with persistent left ventricular 
dilatation and dysfunction are at high risk for complica-
tions and death should they become pregnant again [38].
In contrast, the issue of whether patients with PPCM 
and recovered left ventricular function can safely undergo 
a subsequent pregnancy remains controversial. Elkayam 
et al. [39] conducted a record review among members of 
the ACC in the United States and one hospital in South 
Africa and described the outcome of 60 subsequent preg-
nancies in 44 women with a history of PPCM. Among the 
fi rst subsequent pregnancies in the 44 women, 28 occurred 
among women in whom left ventricular function had 
returned to normal (group 1) and 16 occurred in women 
with persistent left ventricular dysfunction (group 2). The 
pregnancies were associated with a reduction in mean left 
ventricular ejection fraction in each group; 19% of PPCM 
patients with sustained impaired systolic function, who 
then conceived their fi rst subsequent pregnancy, eventually 
died [39]. Although the likelihood of maternal death seems 
to be very low in women who recovered their left ventricu-
lar function before a subsequent pregnancy, a reduction in 
left ventricular ejection fraction and symptomatic heart 
failure will occur in the majority of PPCM patients in sub-
sequent pregnancies.
However, pilot data of bromocriptine trials are 
promising. Twelve patients who suffered from PPCM in 
a previous pregnancy presented with a subsequent preg-
nancy and therefore had a high risk for developing the 
disease again [11•]. Six patients obtained bromocriptine 
immediately after delivery, in addition to standard ther-
apy for heart failure, and all of them had an uneventful 
postpregnancy follow-up. In contrast, all patients (n = 6) 
in the group who obtained only standard therapy suffered 
from recurrence of PPCM, three of whom subsequently 
died. Since this pilot, another four patients have had simi-
lar positive outcome on bromocriptine, and further efforts 
to clarify its effi cacy in preventing recurrence of PPCM 
continue to be encouraging (Sliwa, unpublished data). 
Conclusions
PPCM is a common disorder in some geographic regions 
and possibly goes unrecognized in others. Defi ning this 
disorder as an entity of its own may be justifi able given 
the recent discovery of an oxidative stress cathepsin D 
16-kDa prolactin cascade in experimental and human 
PPCM serving as a specifi c pathophysiologic mechanism 
that may provide the rationale for a specifi c therapeutic 
intervention. Bromocriptine, a drug blocking the release 
of prolactin systemically and locally, has been used for 
many years in women to stop lactation, and now needs 
to be tested in randomized trials to treat women with 
PPCM. Systematic prospective data collection is required 
as well as international cardiac registries to study the 
etiology and different pathogenic mechanisms of PPCM, 
including potential genetic and lifestyle aspects. Further-
more, attempts to establish specifi c biomarker profi les 
and diagnostic tests are warranted for risk stratifi cation 
and prevention of PPCM.
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1.3 Problem Statement and Rationale 
 
Peripartum cardiomyopathy (PPCM) is a severe form of heart failure affecting women of child-
bearing age. In a single centre study offering optimal PPCM management, as many as 15% of 
patients died and only 23% achieved full recovery (Sliwa et al, 2006a). While the loss of maternal life 
or functionality bears the most obvious consequences for both the individual and society, the 
repercussions on the young infant remain as a deepening scar over a broader period of time. This 
indicates that PPCM is a disease of public health concern, with the majority of survivors requiring 
prolonged and often repeated inpatient care for heart failure.  
 
1.3.1 PPCM: A diagnostic dilemma – the need for a rapid screening tool 
Despite recent efforts to increase recognition of PPCM, it often remains undetected – particularly in 
resource-poor environments. Definitive diagnosis and subsequent management requires a high 
index of suspicion and, usually, referral to a tertiary centre with the capacity to perform echo-
cardiographic studies alongside specialist cardiologic and neo-natal care services. Anecdotal 
evidence suggests that many women who initially present with signs and symptoms of heart failure 
indicative of PPCM are concluded to suffer non-specific symptoms of the puerperal period and are 
not adequately investigated, which leads to their deterioration. This clearly represents a preventable 
component of PPCM-related morbidity and mortality. 
Patients who have experienced an episode of PPCM are at a very high risk of relapse in further 
pregnancies (Elkayam et al, 2001; Sliwa et al, 2004), even those patients who recovered left 
ventricular function after the first pregnancy (Sliwa et al, 2008b). Therefore, early diagnosis of PPCM 
is important to limit the high risk of morbidity and mortality induced by subsequent pregnancy.  
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Until specific aetiologies can be identified and tested for, PPCM remains a diagnosis of exclusion. 
Women in their peripartum period suspected of having PPCM are thus required to undergo rigorous 
investigation; a task that is costly and laborious for the patient and health care provider. For this 
reason, prompt use of simpler screening tools for this form of heart failure could help limit the 
number of women eligible to undergo the full series of expensive investigations. The challenge in 
resource-poor environments is to provide relatively easy, cheap and reliable investigative tools for 
potentially fatal but rare conditions not easily diagnosed (Stewart et al, 2009; Tibazarwa et al, 2010). 
In the case of PPCM, it is unlikely, for example that every pregnancy in sub-Saharan Africa will trigger 
an echo-cardiograph (even if confined to those with advanced symptoms of heart failure).  Although 
screening with (point-of-care derived) brain natriuretic peptide levels may offer a means for 
detecting elevated atrial pressures secondary to systolic dysfunction (particularly given the age of 
those affected [Sliwa et al, 2008b; Cardarelli et al, 2003; Martin-Du Pan et al, 2003), there are 
technical issues and the cost remains prohibitive. It is within this context that we regard the electro-
cardiogram (ECG) to be a relatively cheap and effective tool for diagnosis and treatment of many 
forms of heart disease, including heart failure. In a resource-poor environment, the cost-
effectiveness of ECG screening, automated software for detecting abnormalities and portability of 
findings for evaluation at a central point makes ECG an attractive option for detecting PPCM. 
 To date, in the literature, the nature, frequency and evolution of ECG abnormalities in PPCM is not 
well defined and limited to small studies. There is also a lack of data on ECG characteristics of PPCM 
patients in Africa, as well as data on what characterises a normal ECG in African societies. Should 
ECG abnormalities prove to be common in women with PPCM, this would provide a strong basis for 
further studies examining the utility of ECG screening in a larger cohort of pregnant women in the 
sub-Saharan Africa context. 
 
 
37 
 
1.3.2 Shortage of data on the natural history of PPCM 
Across the world, there is a dire shortage of data on the natural history of PPCM.  Short-term studies 
have yielded conflicting data on the pattern of recovery in PPCM within the first six months of 
diagnosis, while long-term studies of PPCM remain few in number. Less than ten accessible 
Anglophonic publications on the long-term outcome of PPCM have been identified. Of these, three 
were of relatively compromised quality by being retrospective in nature and no studies reported the 
long-term outcome of PPCM in Africa. Amidst these studies on the short and long-term outcome of 
PPCM, there is considerable variation in baseline clinical entry criteria for patients recruited. This has 
further weakened the ability to come to consensus on some of the clinical patterns that have been 
observed. The study of PPCM in an African setting is further complicated by the high prevalence of 
communicable disease, for which the concomitant presence of some infections (no matter how 
subtle their clinical manifestation) may confound the diagnosis of PPCM. This could occur, for 
example, through the overlapping symptomatology with that of PPCM, or through objective 
demonstration of reduced systolic function in persons with systemic infections that might lead to the 
mis-classification of PPCM. No other disease could pose a greater threat to such confounding than 
infection with the HIV virus, where the virus itself, the persistent inflammatory state that it places 
the body in and the plethora of opportunistic infections that it invites through the state of 
immunodeficiency of AIDS has meant that HIV co-infected persons have been excluded from being 
diagnosed with PPCM. As yet, however, there is no systematic data on the impact of HIV infection on 
PPCM. 
 
1.3.3 No clinical trials published on the medical management of PPCM 
With the exception of Pentoxyfillene, which has only been studied in a small series of patients (Sliwa 
et al, 2002; Batchelder et al, 2005), no clinical trials on the pharmacological management of PPCM 
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have been published. This is almost entirely attributed to a lack of insight into the aetiopathogenetic 
mechanisms leading to the development of PPCM. However, recent reports show that enhanced 
oxidative stress in a mouse model for PPCM (mice with a cardiac specific deletion for signal 
transducer and activator of transcription-3, STAT3-KO) triggers the activation of cathepsin D, a 
ubiquitous lysosomal enzyme that subsequently cleaves serum prolactin into its anti-angiogenic and 
pro-apoptotic 16-kDa form (Hilfiker-Kleiner et al, 2007a). The subsequent co-existence of the triad of 
oxidative stress, endothelial inflammation and prolactin seen in these mice was also documented in 
patients with acute PPCM (Brar et al, 2007); thereby strengthening suggestions that they may be 
inter-connected and responsible for initiating PPCM. 
Blockage of prolactin with the dopamine-2D agonist Bromocriptine prevented onset of PPCM in mice 
and in 12 women at high risk of this condition identified through documented PPCM in a previous 
pregnancy (Hilfiker-Kleiner et al, 2007a).  A number of case reports further describe seemingly 
beneficial effects from the addition of Bromocriptine to standard heart failure therapy in patients 
with acute PPCM (Forster et al, 2008; Hilfiker-Kleiner, 2007b; Jahns et al, 2008). While these 
preliminary results for the beneficial effects of Bromocriptine treatment in patients with acute PPCM 
are promising, concerns have been raised regarding the risk of thrombotic complications. These 
include cerebral vascular incident and myocardial infarction related to Bromocriptine therapy (Hopp 
et al, 1996; Loewe et al, 1998; Dutt et al, 1998; Fett, 2008b) and the consequences for the children of 
these patients, as the mothers are unable to breast-feed (Fett et al, 2008b). This presented an urgent 
need for the systematic evaluation of the effectiveness of Bromocriptine as a medical therapy in the 
treatment of patients with PPCM. 
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1.3.4 No systematic study of familial component to PPCM 
Non-systematic studies have revealed siblings of PCM patients demonstrating left ventricular 
dilatation and left ventricular dysfunction. Even more striking, however, is that PCM appears to 
share similar predisposing factors and clinical features with non-ischaemic idiopathic dilated 
cardiomyopathy (IDCM); hence our partial concern that they may be different manifestations of the 
same disease. If this were true, the prevalence of FDCM in families of PPCM patients might even 
resemble that of FDCM (this being as high as 30% - 48% when screening of asymptomatic relatives is 
included (Ghosh et al, 2011; Mahon et al al, 2005). 
In this doctoral report, the researcher addressed this question by first investigating whether there is 
evidence of increased familial occurrence of DCM in patients with PCM. Thereafter, the researchers 
proceeded to evaluate the presence of one of the most virulent genetic mutations known to FDCM 
amongst PPCM patients in the study, namely the Lamin A/C gene. 
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1.4 Objectives 
 
The objectives of this doctoral thesis are as follows: 
 
[1] To determine the role of genetics in the aetio-pathogenesis of PPCM.  
Specifically: 
a. To measure the prevalence of DCM, left ventricular enlargement and depressed fractional 
shortening among first degree relatives of patients with PPCM. 
b. To determine if the prevalence of DCM among first degree relatives of PPCM patients is 
independent of the socio-environmental conditions within families screened. 
c. To determine the prevalence of potentially pathogenic mutations along the Lamin A/C gene 
in patients with PPCM. 
 
[2] To provide the first systematic descriptive study of ECG characteristics in PPCM, and thereby 
determine any characteristics typical to PPCM (to inform us of the electro-physiological 
causes and/or consequences of PPCM) and their possible application in clinical detection 
and monitoring.  
Specifically: 
a. To assess the prevalence of 12-lead ECG abnormalities in newly diagnosed South African 
women with PPCM at baseline and at six-months follow-up. 
b. For PPCM patients who had six-month follow-up data, to identify any association between 
12-lead ECG characteristics at baseline and at six-months with echocardiographic LV systolic 
dysfunction. 
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[3] To conduct the first randomised control trial of Bromocriptine therapy in humans; this is the 
first drug thought to be uniquely beneficial to PPCM of all the dilated cardiomyopathies. 
Specifically: 
a. To assess the efficacy of Bromocriptine on recovery of LV function, symptom status and 
other clinical measures in PPCM patients presenting within the first month post-partum with 
new onset symptomatic PPCM and a left ventricular ejection fraction (LVEF) less than 35%.  
b. To assess the clinical safety of Bromocriptine on young infants of patients with PPCM over 
the six-month follow-up period. 
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2. METHODOLOGY 
 
 
2.1 GENERAL METHODS 
 
 
2.2 METHODS SPECIFIC TO SUB-STUDY ON THE GENETICS OF PPCM 
          2.2.1 SUB-STUDY ON FAMILIAL AGGREGATION OF IDCM IN PCM 
          2.2.2 SUB-STUDY ON THE PREVALENCE OF POTENTIALLY PATHOGENIC MUTATIONS ON THE  
                    LAMIN A/C GENE AMONG PPCM PATIENTS 
 
 
2.3 METHODS SPECIFIC TO SUB-STUDY OF ECG CHARACTERISTICS IN PPCM 
 
 
2.4 METHODS SPECIFIC TO SUB-STUDY OF BROMOCRIPTINE THERAPY IN PPCM 
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2.1 General Methodology 
Prior to commencement of this study, ethical approval was obtained from the Human Research 
Ethics Committee (HREC) of the University of the Witwatersrand, Johannesburg, South Africa (PRC 
990409) as well as the Research Ethics Committee (REC) of the University of Cape Town (REC.REF: 
309/2006). The study complies with the Declaration of Helsinki. All patients and controls gave 
written informed consent before being enrolled into the study.  
Study Period 
The study was conducted over a two-year period between 2006 and 2007. All PPCM cases (prevalent 
and incident) were recruited during this study period. However, some components of the family 
screening exercise had to continue well into 2008 and 2010. 
Study Site 
The study was conducted at two tertiary health care institutions in South Africa, namely Chris Hani 
Baragwaneth Hospital in Soweto, Johannesburg (a teaching hospital of the University of the 
Witwatersrand) and Groote Schuur Hospital in Cape Town (a teaching hospital of the University of 
Cape Town). 
Despite Chris Hani Baragwaneth Hospital being the sole accessible tertiary medical facility for the 
vast community of Soweto, the apparent under-detection of PPCM necessitated me to take active 
measures to raise awareness about PPCM and the call to refer patients suspected of having PPCM at 
both study sites. Therefore, patients were referred from local clinics, secondary hospitals, private 
GPs and from within the Departments of Medicine and Obstetrics at Chris Hani Baragwaneth 
Hospital. 
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PPCM patients 
Consenting patients with a provisional diagnosis of PPCM underwent thorough medical interview 
and examination and were investigated to confirm the diagnosis. Thus, all patients had routine blood 
tests, as per the requirements to confirm the diagnosis, as well as a 12-lead ECG and 
echocardiography. Patients requiring additional investigation to exclude potential differential 
diagnoses had these done (as indicated) for that specific case. 
Any history of pre-eclampsia and mode of delivery were obtained from the patient and confirmed by 
examining the obstetric card carried by each patient. The history of the onset of symptoms and signs 
were recorded at first presentation at the Cardiac Clinic at Chris Hani Baragwaneth Hospital 
(baseline) and after a follow-up period of 6-months (6-month visit), patients enrolled in the long-
term outcome sub-study were assessed again at 12-months (12-month visit) and 24 months (24-
month visit). Clinical assessment, echocardiography, and, where relevant for that sub-study in 
question, blood analyses were performed at baseline and at each of those visits.   
It must be noted that although all new patients presenting within the study period were approached 
for consent to join each sub-study, the ECG and familial screening study also targeted prevalent 
PPCM cases, including those that had been discharged from the clinic’s care.  
A physician, who was provided with the clinical data, but blinded to the study protocol and unaware 
of the results of the laboratory tests, evaluated the New York Heart Association Functional Class 
(NYHA FC) of each patient during baseline and follow-up visits.  
Heart rate and systolic and diastolic blood pressure were measured non-invasively with a Critikon 
Dinamap Vital Signs Monitor 1846 and calculated as mean values from five serial readings. 
Measurements were made after a 30-minute resting period in a seated position with two-minute 
intervals between successive measurements. 
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ECG data 
At baseline, a simultaneous 12-lead electro-cardiogram (ECG) was recorded at a paper speed of 25 
mm/s and an amplitude of 10mV/mm on a digital ECG recorder (Philips). The ECGs were analysed by 
one of the investigators (KT) and validated by another (KS) using standard methods of ECG reading 
and interpretation [see Figure 3.] QRS duration was calculated using the standard leads from start to 
end of the QRS complex, and the longest QRS was considered (Iacoviello et al, 2007; Baye’s et al, 
1993). The QT interval and the QT interval corrected for heart rate using Bazett’s formula (known 
asQTc) were calculated in all chest leads (V1 to V6) from the onset of the QRS complex to the end of 
the T-wave (Suwaricz, 1995) ( at the point at which it returned to the iso-electric line) (Iacoviello et 
al, 2007; Statters et al, 1994). Prolonged QRS was defined as a QRS width of 110 milliseconds (ms) 
and prolonged QTc as a QTc interval of greater than 470ms; prolonged PR was defined as a PR 
interval greater than 220ms. For the sub-study on the ECG characteristics of PPCM, an additional 
analysis of ECGs was done using the Minnesota Code [see Section 2.3 below]. 
Echocardiographic studies, assessment of New York Heart Association (NYHA) functional class and 
non-invasive blood pressure measurements 
Echocardiographic examinations were taped on video and a portable hard-drive device and stored at 
the respective research unit for that study site; the purpose for storage was for further reference, 
audit purposes and to enable repeat blinded analysis by a single operator. All studies were 
performed and interpreted by the same operators who were blinded to the protocol (AY1 and AB2 at 
Chris Hani Baragwaneth hospital; the resident echo-cardiographer at Groote Schuur Hospital). For 
purposes of standardisation and research storage, all echoes were reviewed by two of the 
investigators (KT3 and KS4), the latter of whom was first blinded to the results of the diagnostic  
 
                                                          
1AY: Dr Anthony Yip  
2AB: Dr Anthony Becker 
3KT; Dr. Kemi Tibazarwa  
4KS; Prof. Karen Sliwa 
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echoes above. There was a high level of concordance between the echocardiographic card reports at 
the two phases described above. Standard methods of 2D-doppler transthoracic echocardiography 
were adopted according to the American Society of Echocardiography (ASE) guidelines (Sahn et al, 
1978). LV systolic dysfunction was defined by echocardiographic documentation of left ventricular 
ejection fraction (LVEF) of ≤45%. Two-dimensional targeted M-mode echocardiography with Doppler 
colour flow mapping was performed using an echocardiography machine attached to a 2.5 or 3.5 
MHz transducer. 
At Chris Hani Baragwaneth Hospital, either a Hewlett Packard Sonos 5500 (Philips, Bothell, 
Washington) or a VIVID-e (General Electric Company, Fairfield, Connecticut, USA) echo machine was 
used. At Groote Schuur Hospital a General Electric Vivid-3 machine was used. All measurements, 
including systolic and diastolic left ventricular dimensions, valve dimensions and Doppler parameters 
were measured according to the ASE guideline (Sahn et al, 1978). Measurements of left ventricular 
dimensions and function were determined using an average of ≥ 3 beats. [See Figure 4.] 
Having followed the processes described above on first presentation, the following inclusion and 
exclusion criteria were applied to each patient before finalising recruitment: 
Inclusion criteria 
1) Symptoms of congestive heart failure that developed in the last month of pregnancy or 
during the first five months post-partum. 
2) No other identifiable cause for heart failure, such as: current or past severe hypertension, 
current or past ischaemic heart disease (IHD), rheumatic valvular disease, mitral valve 
prolapse, significant aortic valve disease, congenital heart disease, metabolic disorders 
(including diabetes mellitus), severe anaemia, or HIV infection. 
3) LVEF <45% by transthoracic echocardiography.  
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Figure 4. Examples of echocardiographic images obtained from a patient with PPCM 
 
 
 
 
 
 
 
 
 
 
Final inclusion and exclusion criteria 
 
Exclusion criteria 
1) Systolic blood pressure >160 mmHg or <95 mmHg or diastolic >105 mmHg. 
2) Clinical conditions other than cardiomyopathy that could increase plasma levels of 
inflammatory markers, such as: sepsis, autoimmune disease or being HIV positive. 
3) Significant liver disease (defined as liver transaminase levels greater than two times the 
upper limit of normal).  
4) History of psychiatric disorders. 
b. Severely reduced fractional shortening on repeated measures. a. Dilated LV & LA, hypokinetic septum, no organic MV 
disease. 
d. Functional TR with mild PHT (after adding patient’s JVP reading). c. 4-Chamber view; Dilated LV, LA and RA. Normal MV inflow. 
  
  
LVL Left ventricle | LA: Left atrium | RA: Right atrium | MVL Mitral valve |TR: Tricuspid regurgitation; PHT: Pulmonary hypertension; JVP: Jugular Venous Pressure 
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5) Impaired renal function (defined as urea and/or serum creatinine greater than 1.5 times the 
upper limit of normal). 
6) Rapid atrial fibrillation at the time of first diagnosis of PPCM. 
7) Any clinical condition that, according to the investigators, precluded inclusion in the study 
(such as malignancy). 
The key inclusion and exclusion criteria have been summarised in Table 2 below. 
 
 
Table 2. Summary of key inclusion and exclusion criteria 
Inclusion Criteria Exclusion Criteria 
Age > 16 and < 40 years Significant organic valvular heart disease 
Symptomatic CHF* Systolic BP>160mmHg and/or diastolic BP>100mmHg 
No other identifiable cause for heart failure Severe anaemia  (haemoglobin concentration <9gm/dL) 
Left ventricular EF<45% by trans-thoracic 
echocardiography 
Other clinical conditions accounting for raised 
inflammatory markers# 
 Rapid atrial fibrillation at the time of first diagnosis 
 
 
 
Medical management of PPCM patients 
Following the initial screening and baseline visits, monthly out-patient visits were scheduled for 
clinical assessment and evaluation of medication compliance. All patients received treatment with 
the diuretic Furosemide and the angiotensin-converting enzyme (ACE) inhibitor Enalapril. Patients 
with an LVEF <25% or LV thrombus received anti-coagulation therapy using Warfarin for six months. 
Carvedilol was added after resolution of acute heart failure. Enalapril and Carvedilol doses were 
*Symptoms of congestive heart failure (CHF) that developed in the last month of pregnancy or during the first five months post-partum   
 BP: Blood pressure.                          #NB: For purposes of this study, this meant HIV-seropositivity was considered an exclusion factor. 
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titrated upward, as tolerated, during the first four weeks after diagnosis (as long as systolic blood 
pressure was ≥ 100 mmHg or symptoms, such as dizziness, did not occur) and then remained 
unchanged throughout the remainder of the six month study period. For patients who stabilized 
quickly on treatment, Furosemide doses were gradually decreased, as indicated, according to clinical 
assessment during the six-month study period.  
Statistical analysis  
The primary data collection instrument was the proposed Cardiomyopathy Registry for Sub-Saharan 
Africa (SSA), as developed by Mayosi et al from the University of Cape Town (unpublished). Data 
from hard copies of the Cardiomyopathy Registry were captured on its identical electronic registry 
database in Access format (using Microsoft Office Access 2007). Preliminary data analysis was begun 
by exporting encoded data from the Access database into Excel for reference purposes. Final 
cleaning and statistical analysis was done using Version 8 of the STATA software (STATA Corp., 2003), 
while ECG data were analysed using the SAS Version 9.1 statistical program (SAS, Cary, NC, USA). 
Descriptive summary results were expressed as “mean (standard deviation)” or “median *inter-
quartile range+”. Wilcoxon Scores (Rank Sums) were used for comparison between patients for 
continuous measurement. When data were non-normally distributed, log transformation was 
performed of all variables at baseline across the comparison groups for that sub-study. Comparison 
between groups and within groups of categorical variables were analysed using the Chi-square test 
and McNemar test or Mantel-Haenszel Test for repeated measurements.  Subsequently multivariate 
analysis of variance (MANOVA) within groups (for time) and between groups was performed. 
Significance was assumed at a two-tailed value of p < 0.05.  
Finally, a pre-specified combined end-point of poor outcome was created in an attempt to improve 
the chances of detecting associations of smaller effect. This end-point variable was defined as:  
death; NYHA functional class III/IV; or LVEF <35% at six months.  
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2.2 Methods Specific to Sub-Study on the Genetics of PPCM 
The study design for this sub-study was cross-sectional in nature. During the study period, all 
prevalent PPCM patients known to the two hospitals were sought out and requested to participate 
in the study. In addition, all patients newly diagnosed with PPCM during the study period were 
requested to participate in the study.   
 
2.2.1 Methods specific to sub-study on familial aggregation of DCM in PPCM 
Only first degree relatives (aged 17 years or above) of consenting patients were approached 
telephonically or through the index case for enrolment into the study. In the event of positive 
findings amongst screened adult relatives, the screening exercise was expanded to include younger 
relatives and, where necessary, more distant relatives. Consenting relatives underwent the same 
clinical procedure of interview, examination, 12-lead ECG and echocardiography.  
All family members were: assessed and their echocardiography done by KT; and reviewed by 
another expert echo-cardiographer blinded to the study protocol (A.B. in Soweto and J.S. in Cape 
Town). All relatives found to have any abnormality on initial screening were then requested to 
undergo blood tests for baseline screening of common cardiovascular risk factors, as per the 
recommendations of Fatkin et al (Fatkin et al, 2006). Relatives with any abnormality found during 
the assessment were referred as appropriate for correct management and treatment. 
While patient and relative data were uploaded onto the main database described above (unique 
codes being applied to identify members of the same family and to separate patients from relatives 
screened), qualitative and more descriptive details of the family trees were uploaded onto Cyrillic 
software [Version 2.1].  
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2.2.2 Methods specific to sub-study on the prevalence of potentially pathogenic mutations on the  
          Lamin A/C gene among PPCM patients 
Overview 
Genetic screening for mutation on the Lamin A/C gene (LMNA) was successfully conducted in 38 
PPCM patients, alongside two separate pairs of controls matched for sex and ethnicity. These 
controls were randomly selected from a pool of apparently healthy controls, who had been recruited 
for such purposes by the Cardio-Genetics Laboratory of the University of Cape Town. Mutations 
were detected by genomic DNA screening assay; variants were confirmed by direct sequencing.  
Standardisation of DNA 
During the study period, peripheral venous blood samples were obtained using conventional 
methods. From these, DNA was extracted and purified using the GentraPuregene Blood Kit (Quiagen 
Catalogue No. 158422). While this DNA was stored, any remaining buffy coat and whole blood 
samples were also stored, in case more DNA would need to be extracted in the future. However, 
given that most of the blood samples and stored DNA were at least 3 years old by the time of this 
analysis, it was important to re-assess the concentrations of all DNA samples stored. This was done 
using the Qubit5dsDNA Broad Range (BR) Assay Kit and its respective protocol (Invitrogen, 2006). 
[See Figure 5]. DNA concentrations yielded from this process were used to calculate appropriate 
volumes of distilled water needed for standardised working samples, each containing 50ng of DNA. 
 
Figure 5 The Qubit Fluorometer and its reagents 
 
                                                          
5
The various Qubit Assay kits were previously known as “Quanti-iTTM” Assay kits. 
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PCR primer design 
Twelve exons were identified for the LMNA gene, each complete with the appropriate flanking 
regions. Larger exons were broken into two sub-components (e.g. exon 7 was broken into exons 7.1 
and 7.2), bringing the total number of exon components to 18. To locate these exons on the 
samples, 18 primers needed to be developed. These were designed as follows: 
1. The LMNA gene sequence was obtained from Ensembl and NCBI genome browsers. 
2. Primers were chosen with reference to annotated sequences, then analysed with web-based 
tools in order to determine the optimal primer sequences for amplification of the gene (IDT 
OligoAnalyzer and NCBI BLAST). 
3. Amplicons were restricted to between 250 and 300 base pairs in size, as increased amplicon 
length would have led to decreased resolution and sensitivity with HRMA. 
4. Predicted melting patterns of amplicons were checked using POLAND (Sterger, 1994).  
PCR primer optimisation 
On arrival, all ordered primers were diluted in a 1 x TE buffer, tested with control DNA samples; their 
subsequent high resolution melt reaction was optimised by running them through the Rotor-Gene 
analysis described above. Of the 18 primers that were ordered (to complement the 12 exons and 
their sub-components), six failed this initial trial run and further resisted adjustments to annealing 
temperatures. Hence, for these six primers, the Type-iT Kit had to be used to simultaneously 
optimise and amplify those six exons/exon-components. 
DNA amplification and screening 
All 18 exons/exon-components, with their respective flanking regions, were: amplified using these 
primers using the local laboratory protocol [Table 3]; screened for mutations using the Corbett 
Rotor-Gene 6000 High-Resolution Melting curve Analysis (HRMA) [see Figure 6]. Amplicons with 
abnormal melt curves were then sequenced.  
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Sequencing and identification of mutations 
Amplicons were: purified using local laboratory protocol [Table 4] in a Labnet Multigene 
Thermocycler (from Labnet International Incorporated); then sequenced in both forward and 
reverse directions on an AB13100 sequencer. Sequences were analysed using bio-informatics tools, 
including tools for: protein production (Polyphen, SIFT), secondary structure prediction, RNA 
prediction, as well as alignment tools.  
Figure 6. QIAGEN Rotor-Gene Q (Corbett Rotor-Gene 6000); Pure detection. 
a. Rotor-Gene Q                                                                  b. Cross-section of the Rotor-Gene Q 
 
The Rotor-Gene Q is an innovative real-time cycler that enables high-precision real-time PCR due to its unique 
rotary design. In its High Resolution Melt Analysis (HRMA), the resulting “Melt Curve Analysis” plot shows the 
first derivative (dF/dT) of the raw melting data. By default, the sign of the first derivative is inverted, showing 
the DNA melting points as positive maxima. Peak characteristics (i.e. peak temperature value, width) of known 
genotypes can be used to define “Peak Bins”. These “Peak Bins” enable automatic identification of particular 
genotypes. 
 
Table 3. Details of the DNA amplification and screening process 
a. List of reagents mixed for DNA amplification                  b. Rotor-gene cycling reaction conditions 
REAGENT  
(Stock Concentration) 
Volume in Solution 
(per DNA sample) 
Forward primer (20µM) 0.5 µl 
Reverse primer (20µM) 0.5 µl 
dNTPs (20µM) 1 µl 
GoTaq polymerase (5U/µl) 0.1 µl 
GoTaqFlexiBuffer (5x) 5 µl 
MgCl2 (25mM) 3 µl 
DNA (50 ng/µl) 1 µl 
EvaGreen dye 1 µl 
Distilled water 12.9 µl 
TOTAL 25µl 
 
Condition Temperature (Time)  
Initial denaturation 95
o
C – 10 seconds  
Denaturation 95
o
C – 5 seconds  
50 cycles Primer annealing 55
o
C – 10 seconds 
Template elongation 72
o
C – 10 seconds 
High Resolution Melt (HRM) 72
o
C – 95
o
C 
(0.1
o
C increments) 
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Table 4. Protocol applied for amplicon purification and DNA sequencing 
 
 
 
 
 
 
 
 
 
2.3 Methods Specific to Sub-Study of ECG Characteristics in PPCM 
The study design used here was a bi-directional cohort study. For prevalent cases the researchers 
looked retrospectively at the baseline and six-month follow-up ECG. For all other new cases that 
presented during the study period, baseline and follow-up ECGs were assessed prospectively. The 
retrograde component formed a considerable minority of the final analysis. 
A 12-lead resting ECG was performed by a trained technician and analysed by a reviewer blinded to 
all clinical data (GL6) using a standardised approach to ECG interpretation entitled the Minnesota 
Code Classification system (Prineas et al, 1982) [see Appendix 3c]. The code allows systematic 
classification of Q and QS patterns, axis deviation, R waves, ST depression and elevation and T wave 
changes along with conduction abnormalities in both atria and ventricles (Prineas et al, 1982; 
Blackburn et al, 1960). The abnormalities detected by the Minnesota Code were categorised into 
                                                          
6
GLL Geraldine Lee 
I. AMPLICON CLEANSING AND PURIFICATION   
Reagents added 
(Volume in stock) 
Volume added   
(per sample of DNA) 
Reaction conditions  
Exonuclease I (20 000U/ml) 0.1 µl 37
o
C – 1 hour  
Shrimp alkaline phosphatase [SAP] (1U/ml) 1 µl 75
o
C – 15 minutes  
Amplicon product 5 µl 4
o
C – 15 minutes  
Distilled water 13.9   
TOTAL 20µl   
    
II. SEQUENCING     
Reagents added Volume added   
(per sample of DNA) 
Reaction conditions  
Primer (respective to that amplicon product) 2 µl   
Terminator mix 2 µl   
Buffer 4 µl   
Amplicon product 3 µl   
Distilled water 9 µl   
TOTAL 20µl   
Sequencing process    
Initial denaturation  95
o
C – 5 minutes  
Denaturation  96
o
C – 30 minutes  
25 cycles Primer annealing  50
o
C – 15 minutes 
Template Elongation  60
o
C – 4 minutes 
 
56 
 
major abnormalities and minor variations from the “normal” 12-lead ECG, using the classification 
system previously applied by De Bacquer et al (1998). Separate analyses for ST segment depression, 
arrhythmia or AV block, bundle branch block and left axis deviation were also performed. Major 
abnormalities were thus defined as those with: Q waves; ST segment depression; T wave inversion; 
complete or second degree AV block; complete left or right bundle branch block; frequent 
premature beats; atrial fibrillation; flutter. Minor abnormalities were defined as: borderline Q 
waves; left or right axis deviation; high amplitude R waves; border-line ST segment depression; T-
wave flattening and low QRS voltage [See Table 5]. 
 
Table 5. Minnesota Code major and minor ECG criteria 
[Adapted from Lee et al, 2008] 
Major ECG criteria Minor ECG criteria 
Q-wave abnormalities Borderline Q-waves 
ST-segment depression Left or right axis deviation 
T-wave inversion High amplitude R-waves 
2
o
 or 3
o
 AV-block Borderline ST-depression 
Complete LBBB or RBBB T-wave flattening 
 Low QRS voltage 
*LBBB: Left Bundle Branch Block; RBBB: Right Bundle Branch Block 
 
 
 
2.4 Methods Specific to Sub-Study of Bromocriptine Therapy in PPCM 
The study design of the Bromocriptine sub-study was purely that of a clinical randomised controlled 
trial. It was conducted in the 12-month period between January 2007 and January 2008. Only newly 
diagnosed PPCM patients were approached for inclusion in the study; this being done within 24 
hours of first diagnosis. Only women who had delivered recently (within the past month) could be 
included. For the purposes of this Phase II trial, the researchers had to be able to prove therapeutic 
efficacy of Bromocriptine in at least those with more severe forms of PPCM (i.e. those who stand to 
benefit the most). Hence the third difference to the diagnostic criteria described above was that 
patients were included only if the echocardiographic ejection fraction at presentation was equal to 
or less than 35%. 
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The 10 patients randomised to standard therapy (PPCM-Std group) were treated as outlined in the 
General Methods section above. The 10 patients randomised to standard therapy plus 
Bromocriptine (PPCM-Br) received Bromocriptine 2.5 twice daily for two weeks, followed by 2.5 mg 
daily for six weeks in addition to standard heart failure therapy. 
Cardiac MRI (CMR) was performed for 4 - 6 weeks post-diagnosis in patients receiving Bromocriptine 
to detect possible mural thrombi. Studies were performed using a 1.5 Tesla MRI scanner (General 
Electric, Milwaukee, Wisconsin, USA) with a cardiac-dedicated phased-array coil. The CMR studies 
were ECG triggered by standard software. Studies consisted of steady-state-free precession (SSFP) 
and spin echo (SE). Short axis, transverse and coronal views were obtained. SSFP sequences were 
performed to assess regional wall motion abnormalities and LVEF. Slice thickness was 8mm, no gap, 
matrix 256 × 256, FOV 400mm, voxel size 1.6mm × 1.6 mm × 8mm. The total time required for the 
investigation was 30 - 45 minutes. Gadolinium enhancement was not studied. Ventricular 
parameters were assessed in a standard manner by one observer using commercially available 
software (CAAS MRV, Pie Medial Imaging, Maastricht, Netherlands). The CMR studies were assessed 
by two independent experienced observers who determined the presence or absence of intra-
cavitary thrombi. 
For all patients recruited, eight millilitres of blood was withdrawn from an ante-cubital vein and 
collected in pre-chilled tubes containing ethylenediaminetetraacetic acid (EDTA) or clot activator and 
mixed rapidly. Plasma or serum was separated by centrifugation at 2500 rpm for seven minutes 
within 10 minutes of collection. Aliquots were stored at minus -80 degrees Celsius for possible future 
analysis. High sensitivity C-reactive protein (hsCRP) was measured as per standard laboratory 
techniques.  In addition, prolactin, NT-proBNP, full blood count, liver function and serum creatinine 
were also measured.  Serum levels of 16kDa prolactin were measured by immuno-precipitation, 
followed by Western blotting.  Cathepsin D activity was assayed with the Sensolyte 520 cathepsin D 
assay kit (MoBiTec).  
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Given that this was the first controlled clinical study on the effects of Bromocriptine in PPCM, and 
that our PPCM patients presented early in the post-partum period, it was important to attempt 
some systematic evaluation of the consequences of not breast-feeding on the young infants. 
Standard growth monitoring charts issued by the South African Department of Health and 
maintained by primary physicians were obtained for purposes of evaluating the newborn children of 
mothers included in this study. These charts listed the weight of each child at birth and at regular 
intervals to six months and beyond. Weights were plotted on World Health Organization (WHO) 
weight-for-age Child Growth Standard charts for girls and boys (WHO).  
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3. RESULTS 
 
Over the three-year period in which the doctorate research was conducted, and during the 
preceding ten months spent in training and in preparation for the work that would form the 
contents of this thesis, over a hundred patients with PPCM were studied; and a considerable number 
that were initially suspected of having PPCM, but were later given other primary diagnoses. Of those 
PPCM patients found eligible for any of the sub-studies in question: 78 were included in the final 
ECG characterisation of PPCM; 10 were randomised alongside 10 controls to assess the efficacy of 
Bromocriptine therapy; and 51 were approached for the study of familial aggregation of IDCM in 
PPCM. In a minority of cases, and only where there were no clinical or ethical contra-indications, 
some patients were enrolled in more than one sub-study. 
 
 
3.1 Overview of PPCM; the Experience in Africa and in Comparison with the World 
       “Peripartum Cardiomyopathy in Africa: Challenges in diagnosis, prognosis and therapy” 
 
3.2 Results of the Familial Aggregation Sub-Study 
3.2.1     Case series and commentary:  
“Familial Dilated Cardiomyopathy in Peripartum Cardiomyopathy: A tale of two cases” 
 
3.2.2 Full report on the family screening study:  
“One-third of PPCM cases may be Familial Dilated Cardiomyopathy” 
 
3.2.3 A report on our screening of PPCM patients for Lamin A/C mutations:  
 
 
3.3 Results of the ECG Sub-Study:  
 “The 12-Lead ECG in Peripartum Cardiomyopathy” 
 
3.4 Results of Sub-Study on the Use of  Bromocriptine in Peripartum Cardiomyopathy: 
 “Evaluation of Bromocriptine in the treatment of acute severe Peripartum Cardiomyopathy: A     
  proof-of-concept pilot study” 
 
3.5 Results on the Study of the Predictors of Outcome in Peripartum Cardiomyopathy:  
        “Predictors of outcome in 176 South African patients with Peripartum Cardiomyopathy” 
NB. Except for section 3.2.2 and 3.2.3, figures and tables in the results section are numbered according to their respective published article. 
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3.1 Overview of PPCM; The Experience in Africa and in Comparison to the World  
 
 
 
 
“Peripartum Cardiomyopathy in Africa: challenges in diagnosis, prognosis and therapy” 
 
 
Tibazarwa K, Sliwa K 
 
 
[Prog Cardiovasc  Dis. 2010 Jan-Feb; 52(4):317-25] 
 
 
This publication was important for this doctorate .The article was written at a time when many new 
theories had emerged regarding the causes and outcome patterns of PPCM (eg. Elkayam et al, 2001; 
O’Connell et al, 1986 versus Fett, 2005; and so forth); but where it remained unclear how these 
merged with the older theories (eg. Falase et al, 1985). 
The article was also written to address what seemed to be an increasing divide on the diagnostic 
approach towards PPCM; initially between Western Societies and developing societies. However, the 
article also served to highlight that the increased research efforts into PPCM across the two 
hemispheres had actually narrowed the differences in the clinical pictures seen; hence allowing for 
similar diagnostic approaches to be used to improve research and clinical practice. 
The article formed a comprehensive review on the diagnosis and management of PPCM, as well as 
on the challenges faced in Africa and across the world in managing such a disease diagnosed mainly 
by exclusion of other underlying causes. 
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09.11.003any other determinable cause for cardiac failure and in
the absence of demonstrable heart disease before the last
month of pregnancy, and bears echocardiographic evidence
of left ventricular systolic dysfunction.4 Restriction to this
particular puerperal period serves to rule out preexisting
causes of cardiomyopathy that may be exacerbated by
pregnancy rather than arising as a result of pregnancy.4,5
Most cases presentwithin the first 4months postpartum,4,6,7
with only 10% presenting in the last month antepartum.4,7
The incidence reportedly varies from 1 in 3000 to 4000
deliveries in Western societies8 to 1 in 1000 in developing
societies,7 with the highest incidence of 1 in 300 live births
being reported in Haiti.9 The apparent rise in the incidence
across all geographic borders is most likely due to the
improved awareness and diagnostic measures.8 In a large
African center, PPCM formed 1.5%of all patients with heart
failure attending the center during the space of 1 year.10
Although studies in the United States show PPCM to
occur more in women of African descent and those older
than 30 years,11 PPCM has been reported across the world,317
Abbreviations and Acronyms
NYHA-FC = New York
Heart Association functional
class
PPCM = peripartum cardio-
myopathy
TNF-α = tumornecrosis fac-
tor α
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parities.4,6 The younger
age of patients with
PPCM in developing
nations6,7 may reflect the
younger age of the bulk
of reproductive activity in
developing nations. Mul-
tiple gestation within the
index pregnancy has beenimplicated toward causing PPCM in 7% to 10%,12 whereas
multiparity is a more widely documented predisposing
factor to the development of PPCM.8,13 However, recent
studies have suggested that the effect of multiparity is far
less significant in the development of PPCM.9 Peripartum
cardiomyopathy also appears to occur more commonly in
women who breast-feed for longer.14
Peripartum cardiomyopathy is an important cause of
mortality and chronic debilitating morbidity, affecting
relatively young women in the reproductive age group. It
is the second most common etiology of cardiomyopathy-
related cardiac transplant in women in the United States15
and hence poses a considerable burden on the health,
economic, and other social sectors of society.Diagnosis
Peripartum cardiomyopathy is a diagnosis of exclu-
sion. However, there is no agreement on the exclusion of
preeclampsia. Unfortunately, the inclusion of patients
with varying degrees of gestational hypertension, in the
index as well as prior pregnancies, has contributed greatly
to the discrepancy in reported characteristics of PPCM.
This may also form the basis for the difference in the
puerperal time of presentation. Studies comprising greater
proportions of patients with preeclampsia, and of greater
severity, tend to have far greater concentrations of PPCM
cases presenting in the last month of pregnancy.7,16,17 In
contrast, studies with smaller proportions of patients with
preeclampsia tend to document a postpartum peak in the
presentation of PPCM, with reported onset of symptoms
most commonly being 2 to 62 days postpartum.8,9,18
Important differential diagnoses are the common
complications of late pregnancy, whose presentation
may mimic that of PPCM and include preeclampsia,
amniotic or pulmonary embolism, HELLP syndrome
(hemolysis, elevated liver enzymes, and low platelet
count occurring in association with preeclampsia),19 and
anemia-induced puerperal heart failure. Perhaps the most
important of these is the first, as patients with preeclampsia
have often been included amid patients considered to have
PPCM, whereas others have included women with
hypertension without documenting the presence of
proteinuria or edema.Symptoms
Most patients report severe shortness of breath of the
order New York Heart Association functional class
(NYHA-FC) III to IV,20 presenting with lower limb
swelling, some with right upper quadrant pain as well as
other symptoms of acute heart failure (Fig 1).
Signs
Most patients will manifest the grades III to IV
functional class by being overtly tachypneic in the clinic
or hospital room (Fig 1). Most patients21 have a mild
resting tachycardia.18 Blood pressure averages are usually
normal, with larger prospective studies reporting mean
systolic and diastolic blood pressures of 116 ± 20 mm Hg
and 76 ± 14 mm Hg, respectively.18 Bedside examination
often suggests a dilated cardiomyopathy in the lateral and/
or downward displacement of the apex, with dyskinetic
apex, and sometimes palpable gallop rhythm.22
Arterial blood gas and pulse oximetry are important in a
first assessment of the severity of respiratory insufficiency.
Complications
Thromboembolic complications are common.21,23,24
Often these will manifest in the form of pulmonary
embolism and stroke; these usually result from embolized
mural thrombi in the dilated myopathic chambers of the
heart. Rarely, this has culminated in embolic retinal artery
occlusion that caused immediate onset of unilateral
blindness in the patient with PPCM.23 Bearing in mind
that pregnancy itself potentiates a state of hypercoagula-
bility,24 the added risk in PPCM is a major concern.
Although anticoagulation has been recommended in
patients with PPCM with left ventricular ejection fractions
of less than 35%,25 there remains no systematic data to
support this practice for PPCM or for other forms of left
ventricular dysfunction in sinus rhythm.26
As with other forms of cardiomyopathy, arrhythmias
are a common complication of PPCM and are further
described later.
Routine biochemical tests
The full blood count is usually normal (given that
significant anemia has been ruled out as a separate
potential cause of heart failure), with normal electro-
lytes and biomarkers of renal function. In advanced cases,
congestive cardiac failure will cause renal insufficiency
and a prerenal biochemical profile. Most patients have
normal liver function tests and, if raised, represent the
acutely congested liver through raised canalicular enzyme
levels, with only slightly raised transaminase levels.
Although older studies had suggested micronutrient
deficiency could play a role in the development of
PPCM,11 many of these were smaller descriptive studies.
Fig. 1. Clinical characteristics of peripartum cardiomyopathy (PPCM). Reprinted with permission.21
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with PPCM has shown micronutrient deficiencies not
to differ significantly between cases and controls.6 These
included selenium and vitamins A, B12, C, and E as well
as betacarotene.6 Hence, these tests are no longer consi-
dered necessary in the workup of patients with PPCM.
To date, many centers in developing countries have
considered HIV serology to be an important baseline
investigation, as HIV positivity formed an exclusion
criteria for clinical studies in the face of HIV-associated
cardiomyopathy bearing clinical resemblance to PPCM.
However, novel data report that patterns of left ventricular
function and mortality were similar between patients with
PPCM with and without HIV coinfection.17
Urine samples need to be assessed for albumin and other
proteinuria, as an essentialmeans of ruling out preeclampsia.
Although such proteinuria presence helps to confirm the
diagnosis of preeclampsia, its absence does not rule it out.Electrocardiogram
Most patients present in sinus rhythm,18,27 with nonspe-
cific ST-segment and T-wave abnormalities that resolve for
most patients within the first 6 months of treatment.18
Arrhythmias in PPCM occur as with cardiomyopathies
and heart failure in general18 and include atrial fibrillation,
frequent premature ventricular systoles, ventricular
tachyarrhythmias, and bundle branch block,28 the later
occurring more frequently among long-term cases.16Although ventricular arrhythmias have been reported in
up to one fifth of patients thought to have PPCM,29 one
of the few comparative studies showed the more life-
threatening complex ventricular arrhythmias to occur almost
as often in PPCM (60%) as in its closest variant, idiopathic
dilated cardiomyopathy (76% of patients).30 Another study
suggests that subsequent pregnancy in patients with PPCM
might result in deterioration of ventricular arrhythmias,
through various mechanisms including triggering premature
ventricular extrasystoles as the cardiomyopathy worsens in
subsequent pregnancy.31 This arrhythmic deterioration is
thought to either precede and hence facilitate decompensa-
tion of heart failure or else be triggered by alreadyworsening
left ventricular dysfunction in asymptomatic patients.31
Furthermore, they suggest that ventricular arrhythmias
occurring in the acute phase of PPCM are likely to improve
with left ventricular recovery, whereas those in patients not
recovering will more likely require intervention.31
Radiologic
Chest roentgenogram
Typically, the chest x-ray will show cardiomegaly,
pulmonary congestion (including upper lobe diversion and
Kerly-B lines), and occasionally, right-sided pleural effusion
in keeping with more severe congestive cardiac failure.
Echocardiography
Echocardiography has become the mainstay for the
definitive diagnosis of PPCM. Diagnosis requires
Fig. 2. Progression from shortest to longest time required for left ventricular systolic function recovery in peripartum cardiomyopathy. Reprinted
with permission.48
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dysfunction (ejection fraction b 45%).1 Echocardiography
allows for visual estimations of global and regional
cardiac chamber function to assess systolic and diastolic
functions and thrombotic complications of PPCM as well
as to rule out other organic heart disease. Although most
reports document elevated left ventricular end-diastolic
diameters in PPCM, averaging 6 cm in most studies, not
all patients will present with dilated left ventricles; hence,
the current definition of PPCM does not mandate the
presence of left ventricular dilatation.
Magnetic resonance imaging
For the last few years, MRI has received increasingly
favorable attention in the evaluation of patients with
PPCM. This is due to the ability to elicit the presence of
myocardial fibrosis using late enhancement imaging in
cardiac MRI, a marker of the persistence of left ventricular
dysfunction.32 Given the poor understanding of the
pathophysiology of PPCM and the conflicting data on
myocarditis as the causative process, there has been hope
that cardiac MRI would also help to clarify the
pathogenetic mechanisms. Further attributes of cardiac
MRI are its ability to assess myocardial kinesia and
ejection fraction and view the shapes, sizes, and contents
of the cardiac chambers through the use of cine cardiac
MRI.32 One study of more than 1000 consecutive patients
with heart failure assessed 8 women considered to have
PPCM yet found no specific pattern of PPCM on cardiac
MRI, no late enhancement, and no difference in MRI
features between patients recovering within the first 2
years and those who failed to recover systolic function.33
However, the PPCM sample size was small making more
research mandatory.Cardiac catheterization
As with other forms of heart failure, cardiac catheter-
ization and angiography remain the gold standard for
determination of systolic function. Yet, few systematic
reports of PPCM have conducted hemodynamic studies;
those existing having shown decreased cardiac output
and high filling pressures but normal coronary arterio-
grams (Fig 2).11
Immunohistochemistry
Increasingly, studies have suggested myocarditis to be
a key pathogenetic process in the development of
PPCM.30,34-36 Endomyocardial biopsies have strongly
supported this theory,30 as has the demonstrable clinical
and histologic improvement of patients with PPCM on
immunosuppressive therapy30 such as prednisone
and azathioprine.34
The specific etiology of the underlying myocarditis
remains to be confirmed. For many years, the enhanced
suppressor cell activity during pregnancy was thought to
predispose pregnant women exposed to cardiotropic
viruses to more severe forms of viral myocarditis.30
Common pathogens implicated include Coxsackie and
encephalomyelocarditis viruses30 as well as Parvovirus B
19.37 Adenovirus, human simplex virus 6, Epstein-Barr
virus, and cytomegalovirus DNA have been isolated in
endomyocardial biopsies of patients with PPCM.38
However, myocarditis could simply reflect the immune
response from any other form of myocardial damage. In
essence, the molecular components of the inflammatory
process in PPCM has been found to be very similar to that
of idiopathic dilated cardiomyopathy, with elevated tumor
necrosis factor α (TNF-α) and C-reactive protein levels
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levels despite treatment.14
The aforementioned etiology is not restricted to PPCM
but may form the basis for a variety of the dilated
cardiomyopathies. For one, the prevalence of myocardial
inflammation in PPCM appears to be similar to that of
age-matched patients with idiopathic dilated cardio-
myopathy39 and has so far failed to predict outcome in
PPCM.40 Secondly, viral clearing has been associated with
clinical improvement in both PPCM and idiopathic dilated
cardiomyopathy.13
Unique to PPCM, however, are certain immune
activation processes, such as the additional finding of
elevated levels of the apoptotic marker Fas/Apo-1 that
predicts mortality7 and is considered causative.13 Class G3
immunoglobulins,28,41 which act against cardiac myosin,13
bear the subclass IgG3. This IgG3s subclass bears pro-
inflammatory characteristics and may be associated with
higher NYHA-FC at presentation.41 Although idiopathic
dilated cardiomyopathy demonstrates highly selective
up-regulation of the IgG3s subclass of G3 immunoglobu-
lins, the humoral response in PPCM is not subclass
restricted, with class G and all subclass immunoglobulins
being raised in PPCM.41 Sliwa et al7,13 identified increased
plasma levels of the inflammatory cytokine TNF-α,
C-reactive protein, and a plasma marker of apoptosis,
Fas/Apo-1, in a large population of newly diagnosed
patients with PPCM. Furthermore, C-reactive protein levels
on presentation demonstrate linear correlations with left
ventricular end-diastolic and end-systolic diameters and,
inversely, with left ventricular ejection fraction.7 Given the
ethnic variations in serum levels of C-reactive protein, it
was hence proposed that an increase in the intensity of an
inflammatory response could be one of the many factors
contributing to the development of PPCM.13
Groundbreaking data into the pathogenesis of PPCM
have implicated prolactin cleavage to play a key role.42
Recent findings showed that a 16-kDa fragment of prolactin
may induce myocardial damage42 offering new treatment
options in PPCM by blocking prolactin with bromocriptine.
Genetics
Only few studies have assessed the genetics of peri-
partum cardiomyopathy,11,43 with the occurrence in twins
of PPCM having been reported by Constanzo-Nordin and
O'Connell.44
Polymerase chain reaction testing has been recom-
mended in assessing the role of cardiotropic viruses in
inflammatory cardiomyopathies such as PPCM, not just in
endomyocardial biopsy tissue but possibly also in the
study of peripheral blood samples, particularly for IgM
detection during the viremic phase.45
Persistent microchimerism has been implicated in the
etiopathogenesis of PPCM.46 This is the presence of fetalcells in maternal circulation and suggests possible cross-
reactivity of any antibodies generated by the mother in
response to the circulating paternal antigen, irrespective of
the sex of the fetus.6 Unfortunately, current methods
of fetal cell detection are limited to the demonstration of
Y-chromosomal DNA, hence, relying on detection of fetal
male chromosomal DNA in maternal plasma within a
narrow period from term pregnancy to a few days
postpartum.6 This test remains to be validated in the
evaluation of PPCM. However, high levels of fetal
microchimerism in mononuclear cells has been found in
patients with PPCM bearing high titers of autoantibodies;
these levels of fetal microchimerism are significantly
higher than that in control non-PPCM mothers during the
third trimester of pregnancy, at term, and in the first week
postpartum.46 Most of these autoantibodies happen to be
against human cardiac tissue proteins of 37, 35, and 25
kD,28,38 leading to autoimmune myocarditis13,28 and
thereby emphasizing the need to facilitate detection tools
for fetal microchimerism.
Another possible precipitant of apoptosis in PPCM and
heart failure in vitro is the proapoptotic pathway resulting
from overexpression of the 2 gene proteins Nix and
BNip3.47 Up-regulation of BNip3 was also observed in
postpartum ventricular tissue of mice with a cardiomyo-
cyte-specific deletion of the signal transducer and activator
of transcriptin-3 (STAT3, STAT3-KO mice) and was
associated with a high degree of myocardial apoptosis.42
However, this is yet to be confirmed in humans.Prognosis
Recovery from PPCM has often been limited to
achievement of left ventricular ejection fraction more
than 50%,9,48 whereas the term “full recovery” in PPCM
has been considered to be achievement of both NYHA-FC
I and left ventricular ejection fraction more than 50%.9,16
Historically, most studies have suggested that full
recovery of left ventricular function occurs in up to 50%
of patients.5,27,30,49 Larger and more recent prospective
studies of patients from lower- and middle-income cohorts
suggest only a quarter will fully recover by the end of the
first 6 months,9,16 whereas 10% to 15% would die by
6 months.7,17 Long-term prospective outcome studies have
shown overall recovery in a quarter of all patients with
PPCM, most of these are achieved only 18 to 24 months
after diagnosis (Fig 2).17,48 Long-term overall mortality rates
in Haiti, Turkey, and South Africa are estimated at 15%9 to
30%,16,17 with average death occurring at 54 ± 41months in
one study16 but within the first couple of months in another
study.9 This is markedly higher than the mortality rates of
0% to 6%28,40,50,51 and 9%27 reported in the United States.
Interestingly, two of these US studies demonstrate low
mortality rates, one of 0%mortality,28 and the other a 5-year
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myocarditis within their PPCM cohorts of 50%40 and
29%,28 respectively. The cohort by Felker et al40 from the
United States further showed PPCM to bear far better
prognosis than all other forms of cardiomyopathy.
Earlier studies consistently showed greater chance of
survival in patients with higher ejection fractions and smaller
left ventricular end-diastolic diameters at baseline.7,30
Suggested left ventricular cutoff values predicting favorable
outcomes at 6 months after first presentation are higher than
27% for the ejection fraction and 5.5 cm or less for the end-
diastolic diameter.16 Strikingly, recent data imply that the
impact of baseline and 6-month left ventricular dimensions
and functions in predicting outcome falls away among long-
term patients with PPCM, that is, those who failed to recover
fully by 6 months.9,48 These long-term outcome studies
present the unifiedmessage that the natural history of PPCM
goes far beyond what our 6-month prognoses were
suggesting in earlier years. They show that although a
minority of only 25% of PPCMwill recover, most will only
do so from 18 to 24 months onward.
Perhaps inclusion criteria that strictly excludes preex-
isting cardiovascular disease such as preeclampsia applied
in some of the more recent prospective studies of PPCM
has facilitated this revelation, which further strengthens
the theory that the higher rates of rapid recovery in earlier
studies could possibly be attributed to the reversible
effects of gestational hypertension. However, it may
remain true that inherent differences in the sociogenetic
predispositions of patients with PPCM between the United
States27,40 and less developed societies9,16,17 account for
the better prognosis in the former group.
Consistent among studies of PPCM is the high risk of
relapse with subsequent pregnancy,27,52 with remarkable
levels ofmortality postpartum, alongside a strong association
between TNF-α and deteriorating left ventricular function.52
A recent publication by Forster at al49 in an African
cohort showed that significantly higher baseline N-terminal
pro-B-type natriuretic peptide, failure to decrease oxidized
low-density lipoprotein, interferon γ, and prolactin were all
associated with poor outcome in patients with newly
diagnosed PPCM, suggesting a potential role of these
factors in the pathophysiology of PPCM and allowing
further exploration of target substances for monitoring and
treatment programs.Therapy
Medical management and therapy of patients with
PPCM is similar to other forms of heart failure and has
been reviewed in detail.1
Administration of diuretics is indicated in the presence
of symptoms secondary to fluid retention, whereasionotropic agents are recommended in the presence of
peripheral hypoperfusion (particularly hypotension, de-
creased renal function). Temporary mechanical circulatory
assistance should be used in patients with acute heart
failure who are not responding to conventional therapy.
Generally favorable outcomes have been attributed to the
young age of recipients and to the relatively short duration
of heart failure, resulting in minimal end-organ damage.
Conventional pharmacologic therapy with angiotensin-
converting enzyme inhibitor or angiotensin receptor
blockers and, if hemodynamically stable, β-adrenergic
blockade are effective in the treatment of PPCM. Because
of the potential hazardous effects on the fetus, hydralazine
(with or without additional nitrates) should replace
angiotensin-converting enzyme inhibitor use during preg-
nancy. Digitalis, an ionotropic agent, is also safe during
pregnancy and may help to maximize contractility and rate
control. However, its use requires close monitoring of the
patient, which may prove difficult in low-resource
environments. Cardiac transplantation has been performed
successfully in patients with PPCM.
Given the potentially inflammatory nature of PPCM
with up-regulated inflammatory cytokines as TNF-α,
interleukin 6, and Fas-Apo-1, there may be a role for
immunomodulatory therapy. A prospective study of 59
consecutive women with PPCM reported a significant
reduction in TNF-α and improved outcome in patients
receiving the immunomodulating agent pentoxifylline in
additional to conventional therapy that included angioten-
sin-converting enzyme inhibitors and β-blockers.53
However, further research into the pathomechanisms
of PPCM by Hilfiker-Kleiner et al42 revealed the coexist-
ence of systemic oxidative stress and significantly higher
prolactin levels in patients with PPCM; this supports the
notion of the previously published concept that oxidative
stress-mediated prolactin cleavage into its detrimental
16-kDa form is crucial for the initiation of PPCM and
subsequent release of inflammatory cytokines. This sug-
gests that inhibition of prolactin with bromocriptine may
prevent a prolonged inflammatory response via activation
and perpetuation of the inflammatory cascade. A recent pilot
study in newly diagnosed patients with PPCM suggested
that this process can be ameliorated or even abolished
by administering the prolactin inhibitor bromocryptine.54,55Challenges to improving diagnosis and prognosis
in Africa
The lack of uniformity in case definitions of PPCM
may result from clinicians differing in opinion about what
constitutes an alternative cause of heart failure in patients
evaluated for the diagnosis of PPCM, and it is fuelled also
by the shortage of large studies for this rare disease.
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PPCM with various levels of gestational hypertension
from those who are hypertension naive.
In an attempt to address this deficit, the American
College of Cardiology guidelines now classifies PPCM as
an entity of its own,1 whereas the European Society of
Cardiology has taken active measures toward this
process.56 To benefit from this success of recognizing
PPCM as a disease of its own, awareness of PPCMmust be
raised among clinicians and across societies, as this has
been shown to contribute significantly to delayed diagnosis
and underreporting of PPCM.1,57 This will make a great
impact in developing societies, where levels of awareness
on cardiovascular disease are disproportionately lower
than the actual prevalence of cardiovascular disease,20
particularly so in Africa58 and more so for PPCM.
The plight against poverty-related infectious disease
has overridden many African countries' ability to pay
sufficient attention to heart failure. Despite the greatest
burden of heart failure in Africa caused by 2 infectious
diseases, rheumatic heart disease and tuberculous
pericarditis,59 inequitable access to facilities permitting
the definitive diagnosis and management of these patients
have contributed to the paucity of research data on the
epidemiology of the many various forms of heart failure in
sub-Saharan Africa. To date, no population-based epide-
miologic studies on PPCM from Africa have been
published.60 Like idiopathic dilated cardiomyopathy,
PPCM is a diagnosis of exclusion. To confirm that the
case fits the definition as per Lampert et al2 mandates the
use of sophisticated echocardiography. The exhaustive
requirements for serologic tests, imaging, and, in more
mature women, cardiac catheterization to rule out
coronary artery disease falls beyond the capacity of most
tertiary health centers in sub-Saharan Africa. Patients in
rural areas continue to have grossly inequitable access to
health facilities capable of even the most basic of these
investigations. Recently, however, joint efforts to increase
global awareness of the burden of cardiac disease in Africa
has, to some extent, facilitated access to practical
solutions, such as partially subsidized portable echocardi-
ography equipment, and regional sharing of laboratory
services for the more rare disease tests.
Across the world, a major challenge to clinicians
remains the gross overlap between the clinical features of
PPCM and the dyspnea, fatigue, and pedal edema of
normal pregnancy.18,25,61 In this regard, recent studies
have suggested that electrocardiogram be used as a simple
screening tool for heart failure in women presenting
peripartum with the aforementioned symptoms, whereas
women with abnormal electrocardiograms would merit
further investigations for PPCM.18
Globally, the gap in available data on PPCM remains
vast, and the shortage of long-term outcome studies is alsoevident. We are only aware of 7 long-term outcome
studies,9,15-17,27,48,62 2 of which were retrospective in
nature.15,62 Much of this should be overcome with new
research into the etiology of PPCM and also by the
creation and use of registries.63Summary
Peripartum cardiomyopathy is a form of heart failure
often with a more devastating outcome in developing
societies. We have highlighted important theories on the
pathogenesis of PPCM, which have already served to shed
light on agents such as bromocriptine and potent
antiinflammatory agents that are currently being evaluated
in clinical trials. However, practical challenges in the
diagnosis and prognosis of PPCM remain, specifically so
in resource-poor settings. Contributing to these challenges
is the lack of consensus regarding etiologic mechanism
and clinical criteria permissible for PPCM. We would like
to emphasize, again, the need for concerted efforts and
population-based data, as per a registry, to overcome the
statistical barriers in evaluating the epidemiologic char-
acteristics of PPCM.Statement of Conflict of Interest
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3.2        Results of the Familial Aggregation Sub-Study 
 
 
3.2.1 Case series and commentary:  
 
 “Familial Dilated Cardiomyopathy in Peripartum Cardiomyopathy: a tale of two cases” 
 
 
 
Tibazarwa K, Sliwa K,Wonkam A,Mayosi BM 
 
 
 
 
[Cardiovascular Journal of Africa. 2013; 25(5): pp. e4-e7] 
 
 
 
 
 
This paper singles out just two of a series of cases of PPCM that were found to have relatives 
with FDCM. The paper discusses the implications of these findings and compares how the 
findings relate to recent data that emerged from two studies in developed societies.  
 
Being framed as a letter to the editor, the article presents a detailed debate on the existing 
evidence of some PPCM cases being FDCM manifesting post-partum; it proceeds to outline a 
number of thought-provoking recommendations.  
 
This paper was important for this PhD in that it maps out current theories and debates that 
are a major aspect of the research, i.e. addressing the genetic contribution to PPCM - at both 
clinical and molecular level. Despite being restricted to the length-limits of a case report 
publication, the manuscript forms a platform onto which the authors could do an in-depth 
review of the various concepts published on the genetics of PPCM and synthesise 
suggestions in terms of approaching the genetics of PPCM going forward. 
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Case report
Peripartum cardiomyopathy and familial dilated 
cardiomyopathy: a tale of two cases
K TIBAZARWA, K SLIWA, A WONKAM, BM MAYOSI
abstract
Peripartum cardiomyopathy (PPCM) is a form of pregnancy-
related heart failure that is associated with considerable 
morbidity and mortality. Most patients present with acute 
postpartal heart failure that otherwise resembles the clini-
cal presentation of dilated cardiomyopathy (DCM). There 
is increasing recognition that PPCM may be due to genetic 
factors in a significant proportion of cases. There is evidence 
that at least 7% of cases of PPCM may be part of the spec-
trum of familial DCM. We report on two cases of PPCM, 
with relatives demonstrating familial DCM, both patients 
displaying autosomal dominant patterns of inheritance, and 
showing severe cardiomyopathy among proband and affected 
relatives. Family screening for familial DCM should be indi-
cated in all cases of unexplained PPCM.
Keywords: peripartum cardiomyopathy, genetics, familial dilat-
ed cardiomyopathy, Africa
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Cardiovasc J Afr 2013; 24: e4–e7
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Peripartum cardiomyopathy (PPCM) causes heart failure in 
women of child-bearing age. We describe two African patients 
with PPCM, diagnosed according to standard criteria,1 who 
underwent comprehensive screening of first-degree relatives 
and were found to have familial disease. Informed consent was 
obtained from both patients and the study protocol conformed 
to the ethical guidelines of the 2008 Declaration of Helsinki 
as reflected in a priori approval by the human research ethics 
committee of the University of Cape Town. 
Case report 1 
A 22-year-old mother of two presented 27 days postpartum with 
one week of symptoms and was diagnosed with PPCM. Despite 
treatment, she died at home within six months. Family screening 
found her mother to have asymptomatic dilated cardiomyopathy 
(DCM) (Fig. 1). 
After opting for conservative management, the mother 
developed symptomatic DCM a year later, presenting in florid 
heart failure. Cardiac catheterisation and other investigations 
excluded coronary artery disease (CAD). The index case’s 
half-sister admitted to a history of dizziness, low blood 
pressure and occasional fainting episodes in crowds but had no 
echocardiographic evidence of DCM. 
Case report 2 
A 23-year-old mother of two presented two months postpartum 
with PPCM. Family history revealed an unspecified heart 
condition in her mother, who died shortly after a cerebro-
vascular accident at age 60 years (Fig. 2). Her sister apparently 
developed heart failure four years after her first delivery at 19 
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years of age and deteriorated after the birth of her second child 
10 years later. This sister soon suffered a stroke and died one year 
after the second childbirth. 
Active family screening revealed symptomatic DCM in 
her 39-year-old brother, without CAD; and asymptomatic 
left ventricular (LV) systolic dysfunction in her 22-year-old 
sister. Screening one elder sister showed Wolf-Parkinson-White 
syndrome. 
These two cases of PPCM have at least one family member 
with DCM, and therefore meet the definition of familial 
cardiomyopathy.2 The presentation in both cases is compatible 
with autosomal dominant inheritance.
PPCM and idiopathic dCM
The distinction of PPCM from idiopathic DCM may be difficult 
because both conditions are characterised by LV dysfunction 
with no apparent cause. Indeed, some investigators have proposed 
that PPCM may simply be idiopathic DCM manifesting in 
late pregnancy, this being a time when the haemodynamic 
changes of pregnancy could overwhelm the heart.3 Along this 
hypothesis, increased preload leads to LV dilatation and cardiac 
insufficiency, a theory partly supported by earlier studies in 
which a number of cases presented in the last month antepartum 
or immediately postpartum. 
However, such theory is not supported by studies showing 
that PPCM with no gestational hypertension present on average 
at two months postpartum,4-6 having developed symptoms within 
two months postpartum.6,7 By this time, these haemodynamic 
changes of pregnancy would have ceased.4 However, cohorts 
with predominantly postpartum-onset PPCM display prognoses 
similar to those of idiopathic DCM, with far slower recovery 
than in PPCM phenotypes with predominantly gestational 
hypertension.1,7
Even though most women with asymptomatic or mildly 
symptomatic idiopathic DCM tolerate pregnancy uneventfully,8 
as with other pre-existing heart disease, any subclinical 
cardiomyopathy may be associated with the worsening of 
symptoms in the second trimester of pregnancy when the 
haemodynamic stress on the heart is maximal.4 However, recent 
attempts to broaden the traditional gestational period defining 
PPCM6 have renewed the controversy. Clear consensus on case 
definition is vital before clinical and epidemiological patterns 
can be reliably described. 
Studies show 20–50% of all idiopathic DCM cases to have 
familial disease.9-11 Although women have been shown in some 
studies to be equally affected as men,9,12 more studies suggest a 
male predominance.10 However, less than a handful of studies 
report on the incidence and outcomes of pregnancy in women 
with familial DCM.8 To the best of our knowledge, no study 
has systematically investigated all immediate relatives of PPCM 
patients to ascertain the prevalence of familial DCM among 
these patients.
PPCM and familial dCM
There have been several reports of familial disease in PPCM.1,13,14 
Two Western studies and one South African case series suggest 
that a subset of PPCM patients may be part of the spectrum 
of familial DCM presenting in the peripartum period.10,14,15 
Surprisingly, PPCM patients in each of these two Western 
studies almost uniformly presented postpartum, with only 
one case in each study presenting within the last six weeks 
of term pregnancy (i.e. only one to two weeks from the 
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traditionally defined time of onset of PPCM).14,15 These studies 
were weakened by their exclusion of patients who recovered LV 
function within the first year, thereby cutting out 25–50% of the 
spectrum of PPCM patients and favouring the possibility that 
only FDCM phenotypes were retained, as the latter rarely recover 
LV function. 
Nonetheless, these findings raise two pertinent questions. 
First, other than postulations of late-pregnancy oxidative stress 
triggering the PPCM phenotype, how did these putative familial 
DCM cases surpass the expected time of presentation for 
pre-existing heart disease in the second trimester? Second, could 
the genetic polymorphisms or mutations identified so far in 
PPCM cases with familial disease be a co-incidental finding, 
while the real culprits for PPCM phenotypes lie in other genetic 
mutations inadequately sought for beyond those known to cause 
familial DCM?
Familial DCM manifests in an age-dependent manner with 
incomplete disease penetrance.9 Therefore, in the absence of 
long-term, population-based studies, answering our second 
question will remain a challenge. As heterogeneous as familial 
DCM is, over 40 defective genes have been associated with 
inherited DCM, although they account for a minority of familial 
DCM cases.16 
Genome-wide association studies (GWAS) may succeed in 
identifying pathogenic mutations for PPCM. The only known 
attempt at GWAS in PPCM patients was done in Utah,17 
and revealed 10 single-nucleotide polymorphisms (SNPs) that 
may play a role in the pathogenesis of PPCM.17 Of these, 
one SNP (located on chromosome 12) demonstrated genome-
wide significance for PPCM, likely triggering disease through 
abnormal immune modulation.17 The strength of the study 
lies in its efforts to exclude patients with co-morbidities that 
would confound the diagnosis of PPCM, and for screening 
a variety of controls, including post-menopausal controls,17 
to enable discovery of PPCM-associated loci relevant to the 
at-risk population of pregnant/potentially pregnant females.17 
Furthermore, the authors went as far as to describe 30 other SNPs 
which appeared to predict the absence of PPCM,17 suggesting a 
route for the exploration of protective mechanisms to PPCM.
Recent advances favouring PPCM as an independent disease 
shows in vitro and in vivo evidence of an abnormal 16-kDa 
prolactin pathway intertwined with oxidative stress.18 However, 
given that oxidative stress, together with signal transducer 
and activation of transcription factor-3 (STAT-3) depletion, 
as implicated in this model may be common to most forms 
of severe heart failure, including idiopathic DCM,19 the only 
component to this pathway that might remain unique to PPCM 
is that fuelling production of the 16-kDa fragment of prolactin. 
However, linking this abnormal prolactin pathway exclusively to 
PPCM would require proof of its absence in women with familial 
DCM, including relatives who subsequently fall pregnant and 
deteriorate. 
Despite the GWAS described above17 having failed to find 
any SNP or other variation on the STAT-3 gene to account 
for PPCM, it introduced the possibility of an association 
between polymorphic variations (SNPs) on the STAT-5 gene and 
PPCM. This is important because STAT-5 is a known culprit in 
idiopathic DCM,19 making the thought of it playing a role in the 
development of PPCM an interesting possibility.
Novel data further suggest that imbalances between cardiac 
pro-angiogenic factors PGC-1α and vascular endothelial growth 
factor (VEGF), and anti-angiogenic factors such as the VEGF 
inhibitor soluble Flt1 may result in PPCM, and that this association 
is more profound in the presence of gestational hypertension 
and multiple pregnancy.20 If indeed these mechanisms become 
validated, it would be essential to establish any genetic bases for 
these abnormalities.
Conclusion
There are several lessons to be learned from this detailed family 
study of two cases with PPCM. First, we emphasise the need 
for family screening of PPCM and idiopathic DCM patients,10 
with long-term follow up of screened persons, particularly of 
females of child-bearing age. There is a need for well-structured 
incidence studies of PPCM and idiopathic DCM, with baseline 
echocardiograms of primary relatives (irrespective of symptoms), 
pre-pregnancy echocardiography of all women being followed up 
(irrespective of underlying co-morbidities), and follow up with 
echocardiography every two to five years.21 This exercise could 
mould routine practice, given the high prevalence of familial 
DCM, its lethal course, and the suggested benefits of treating 
asymptomatic relatives with LV dysfunction.11
Aside from the GWAS reported several years ago,17 the search 
for genetic abnormalities in PPCM has remained narrowed 
towards screening for mutations (or SNPs) associated with 
familial DCM. It would be recommended to expand on the 
reported GWAS by testing the clinical impact of the SNPs 
already suspected to be associated with PPCM.17 Furthermore, 
in the hope of identifying new SNPs accountable for PPCM 
through target-gene search or GWAS, it may be logical to start 
comparing genotypes of extreme phenotypic presentations of 
both PPCM and idiopathic DCM (i.e. mild versus severe) within 
and across their respective diagnostic groups. 
In addition, in the search for PPCM-specific genetic 
abnormalities, the co-existence of the abnormal 16-kDa prolactin 
cascade would need to be evaluated in familial DCM patients 
who deteriorate in pregnancy, and the genetic abnormalities 
programming this abnormal pathway further explored. Lastly, 
next-generation sequencing (NGS) is a recently developed, 
massively parallel, large-scale sequencing technology that has 
been used for rapid gene cloning and mutation detection. Taking 
advantage of the larger size of families in Africa, NGS with 
exome selection could be used to identify the causative genes 
and to improve both genetic and clinical delineation of DCM 
and PPCM.
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3.2.1 Full report on the family screening study:  
 
 
 
“One-third of PPCM cases may be Familial Dilated Cardiomyopathy” 
 
 
 
 
Tibazarwa K, Sliwa K, Wonkam A, Boulle A, Mayosi BM 
 
 
[Presented at the Annual SAHA Congress – October 2011] 
 
 
 
 
This study was novel in it being the first large series of PPCM patients to undergo detailed 
systematic family screening of eligible first degree relatives for the presence of familial DCM. 
Our findings support the notion that over a third of PPCM cases bear familial DCM; a 
proportion similar to the prevalence of familial DCM amongst so-called idiopathic DCM 
patients. This in turn supports the notion that at least this sub-set of PPCM patients may  
form part of the spectrum of familial DCM. 
 
The study was also novel in its attempt to compare the prevalence of familial DCM amongst 
PPCM patients with that in women presenting with pregnancy-associated heart failure in the 
context of current or prior history of hypertension. Interestingly, we demonstrate the latter 
group of women to also be at risk of familial disease - albeit at a far lower risk than PPCM 
patients.  
 
Through this study, we were able to recommend with confidence that routine family 
screening may be as merited in PPCM as it is in DCM. 
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“One-third of PPCM cases may be Familial Dilated Cardiomyopathy” 
 
Rationalé 
Non-systematic studies have revealed that siblings of PCM patients demonstrate left ventricular 
dilatation and left ventricular dysfunction. Furthermore, despite a number of scientific contributions 
towards understanding possible predisposing factors for PPCM, its clinical resemblance to idiopathic 
DCM remains undeniable, including recent revelations that PPCM cases defined strictly as per the 
standard diagnostic criteria (Sliwa et al, 2010) may follow a similar natural history to idiopathic DCM. 
In our continued efforts to evaluate how the two can be clinically differentiated, we assessed familial 
occurrence of DCM in patients with PPCM in an attempt to compare it with that known for 
idiopathic DCM.   
 
Results 
A total of 51 families of un-related PPCM patients were approached for family screening [Figure 7]. 
However, over half of these family screening attempts failed for a variety of reasons, ranging from 
reluctance to come to hospital to pre-entry exclusion of first degree relatives on the basis of 
concomitant disease, such as hypertension, diabetes, HIV infection and so forth. 
For purposes of this paper, detailed analysis of PPCM patients (i.e. probands) was restricted to the 
18 families with at least one first degree relative eligible and successfully screened for the presence 
of DCM. From these 18 probands, a total of 44 relatives were successfully screened, giving a mean of 
2.4 relatives screened per proband. 43% of screened relatives were male, without there being any 
statistically significant difference in the proportion of female relatives compared to males. 
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Tables 6 to 8 show the demographic and clinical profiles for PPCM cases and for all relatives, 
including echocardiographic findings [Table 8]. The mean age of probands was 28 years (± 7 years); 
the group of relatives did not differ significantly in age from the group of probands (median age 24 
years, IQR 18-34 years; p= 0.3). 
Of the 18 probands: a total of 4 probands (22%) had at least one relative with definite 
echocardiographic evidence of DCM, rendering them positive for familial disease; a further 3 (16%) 
had at least one relative with possible DCM, rendering them possible bearers of familial disease [see 
Figure 7]. In these families with definite and possible familial disease, we cannot preclude the 
potential for an underlying genetic cause for development of the PPCM phenotype in the proband, 
as would be required to fulfil it being a diagnosis of exclusion; hence we consider these cases to be 
familial DCM.NB: This brings the total prevalence of familial dilated cardiomyopathy amongst first 
degree relatives of PPCM patients to 39%. 
Relatives across the three different categories of being affected did not differ from each other 
significantly in their demographic and basic clinical profile. Both autosomal dominant and autosomal 
recessive patterns of inheritance were seen amongst the families of patients with PPCM [Figure 8]. 
Interestingly, one of the patients presenting with PPCM and manifesting hypertensive heart failure 
in pregnancy (HHFP, i.e. pregnancy-associated heart failure with current or prior history of 
hypertension) also demonstrated possible familial disease (HHHP). This was in the form of autosomal 
dominant pattern of inheritance. 
A full list of pedigrees for families of patients screened can be seen in section 7 of the Appendix 
section at the very end of this thesis. 
 
 
 
67 
 
Figure 7. Flowchart illustrating participant flow from recruitment to diagnosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total PPCM patients approached for family screening 
51 
Patients diagnosed with PPCM, but: 
found to have chronic/essential HT 
7 
Patients diagnosed with PPCM but: 
found to have PIH in index pregnancy 
2 
Patients diagnosed with PPCM with: 
-No other potential cause for HF 
- ≥ One 1
o
 relative successfully screened 
21 families 
Patients diagnosed with PPCM with: 
- no other potential cause for HF 
- ≥ one 1
o
 relative successfully screened 
-≥ one 1
o
 relative with no exclusion criteria 
-18 families 
Patients diagnosed with PPCM with: 
- no other potential cause for HF 
- ≥ one 1
o
 relative successfully screened 
- exclusion criteria among all relatives 
screened 
-3 families 
Confirmed 
familial 
disease 
4 families 
Possible 
familial 
disease 
3 families 
No  
familial 
disease 
11 families 
≥ one 1
o
 relative 
with any other 
CVD* 
8 families 
≥ one 1
o
 
relative with 
any other CVD* 
2 families 
≥ One 1
o
 
relative with 
any other CVD* 
3 families 
Patients diagnosed with PPCM, but: 
no eligible relative available for screening 
21 families 
Possible 
familial 
disease 
1 family 
No  
familial 
disease 
8 families 
≥ One 1
o
 
relative with 
any other CVD* 
1 family 
≥ One 1
o
 
relative with 
any other CVD* 
4 families 
CVD Cardiovascular Disease; HT Hypertension; HF Heart Failure; PIH Pregnancy-Induced Hypertension 
 
*Relatives known or found to have other CVD during the active screening process included ones with HT (the vast majority), 
rheumatic heart disease, type II diabetes mellitus, and heart disease due to other underlying conditions 
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Table 6.Bio-demographic profile of PPCM probands and their first degree relatives screened 
 PROBANDS 1
ST
 DEGREE RELATIVES 
  All Relatives 
 
p 
 
Age (years)  
 
28 ± 7 
 
24 (IQR 18-34) 
 
 
0.339 
 
Parity  
 
1.5 (IQR 1-2)  
 
1 ± 1.7
#
 
 
0.007 
 
 
   
 
BMI (kg/m
2
)  
 
27  ± 6 
 
28 ± 7 
 
 
0.625 
 
Pulse rate  
 
97 ± 18 
 
70 ± 11 
 
<0.001 
 
Blood pressure 
• Mean systolic (mmHg) 
• Mean diastolic  (mmHg) 
 
 
105 ± 15 
68 ± 7 
 
 
118 ± 13 
  75 ± 8 
 
 
 
0.003 
0.006 
*Standard deviation (± SD); Inter-quartile range (IQR)                                       #Applies to female relatives only 
 
 
 
 
 
Table 7. Heart failure symptomatology in screened first degree relatives of PPCM patients 
Symptom Prevalence among probands Prevalence among 1
st
 degree relatives  p 
 
Dyspnoea 
(NYHA FC II or greater) 
 
 
100% 
 
2% 
 
<0.001 
Dizziness 
 
31% 3% 0.240 
Palpitations 
 
44% 6% 0.099 
Chest pain 
 
25% 10% 0.809 
Lower limb swelling 
 
56% 0% 0.001 
Other  
(eg. Abdominal pain) 
56% 0%           - 
 
NYHA FC II – New York Heart Association Functional Class II 
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Table 8a.Echo-cardiographic characteristics of PPCM patients in comparison with their relatives 
 
Echocardiographic measurement Proband 1
st
 Degree Relatives p 
    
LVISd (cm) 0.9 
(IQR 0.8-1.1) 
0.9 ± 0.2 1.000 
LVEDd (cm) 6.2 ± 0.7 4.8 ± 0.4 <0.001 
LVPWd (cm) 0.95 
(IQR 0.7-1.1) 
0.9 ± 0.2 0.712 
LVISs (cm) 1.1 
(IQR 0.9-1.4) 
1.3 ± 0.3 0.108 
LVEDs (cm) 5.0 ± 0.7 3.2 ± 0.4 <0.001 
LVPWs (cm) 1.3 
(IQR 1-1.2) 
1.4 ± 0.4  
Fractional shortening (%) 19 ± 8 34 ± 6 <0.001 
Ejection fraction (%) 33 ± 14 61 ± 9 <0.001 
Mitral valve area (cm
2
) 3.7 ± 1.5 3.3 ± 0.8 0.410 
Pressure half time (cm/s) 101 ± 73 76 ± 16 0.105 
Deceleration time (cm/s) 205 
(IQR 134-676) 
247 
(IQR 216-310) 
0.710 
Aortic root (cm) 2.4 ± 0.5 2.6 ± 0.4 0.19 
Left atrial diameter (cm) 3.9 ± 0.9 3.3 ± 0.7 0.02 
Mild-severe valve regurgitation 
(% of sub-group population) 
 Mitral 
 Tricuspid 
63% 
44% 
3% 
16% 
<0.001 
0.040 
Dilated right-sided chamber(s), 
 [% of population] 
6% 6% 0.543 
Raised right ventricular systolic pressure  
(% of population) 
63% 0% 0.063 
 
LVISD - Left ventricular septal width in diastole; LVEDd – Left ventricular end-diastolic diameter; LVPWD - Left ventricular posterior wall 
width in diastole; LVISs – Left ventricular septal width in systole; LVEDs Left ventricular end-systolic diameter; LVPWs – Left ventricular 
posterior wall width in systole. 
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Table 8b.Summary of key abnormal echo findings among first degree relatives of PPCM patients 
 
Echo-cardiographic measurement 
 
 
Proband  Relatives  
Dilated LV in diastole 100%  19% <0.001 
Dilated LA in diastole 25%  13% 0.186 
Reduced ejection fraction 81%  6% <0.001 
Mitral regurgitation 63%  3% <0.001 
Tricuspid regurgitation 44%  16% 0.040 
 
[LVLeft ventricle;  LA Left atrium] 
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Figure 8. Pedigrees where relatives of PPCM probands screened positive for DCM 
 
2a. Two families suggesting autosomal dominant pattern of inheritance 
 
 
2b. Two families suggesting autosomal recessive pattern of inheritance  
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LV dilatation only 
 
 
 
Arrhythmia detected on screening 
  
Possibly affected from verbal history 
  
Deceased 
                                      
                                     Gender not documented 
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3.2.2 A report on our screening of PPCM patients for Lamin A/C mutations:  
 
This sub-study addressed a specific component of the genetic aetiology of PPCM; it sought to 
establish the prevalence of one of the most notorious genetic mutations associated with its clinical 
simulant familial DCM. This concerns the Lamin A gene (LMNA), which codes for the Lamin A and C 
proteins found in muscular tissue. A number of LMNA mutations are known to be associated with 
more aggressive clinical presentations of DCM due to the increased occurrence of deadly 
arrhythmias, heart failure and higher mortality. These three disease outcomes are common in PPCM 
patients of this study, although so far there hasn’t been any clear clinical parameter that could 
predict which patients would be likely to do worse. Thus, we postulated that patients doing worse in 
this regard may bear an underlying genetic predisposition to doing worse, such as harmful mutations 
to the Lamin A/C gene. 
Despite two recent studies, one from the Netherlands (Van Spaendonck et al, 2010) and the other 
from USA (Morales et al, 2010) having attempted to screen their PPCM patients for this mutation, 
this study remains the first to systematically screen a large number of prospectively recruited PPCM 
patients with the primary intention of genetic analysis.  Although our results differed from those 
from Western societies, as indicated above (Van Spaendonck et al, 2010; Morales et al, 2010), in that 
we did find Lamin A/C abnormalities to be prevalent in our PPCM patients, all were well-
documented SNPs, with the vast majority reported to be non-pathogenic. 
Our experiment failed to demonstrate any novel mutation on the LMNA gene. However, given that 
the only other genetic abnormality of pathologic potential in PPCM was found on a different 
chromosome using Genome Wide Association Studies in the United States, our study remain the first 
to perform a systematic exon-sequencing of the LMNA gene in a statistically significant number of 
PPCM patients. Our sample size was not particularly small. Yet a larger sample size may have helped 
to overcome any under-estimation of the occurrence of pathogenic Lamin A/C mutations amongst 
the PPCM patients. 
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A report on our screening of PPCM patients for Lamin A/C mutations 
 
 
 
The Lamin A Gene (LMNA) 
The Lamin A/C gene codes for both the Lamin A and Lamin C proteins. We refer to the 
portions encoding for Lamin A as LMNA [see Figure 9 below]. 
 
Figure 9. The Lamin A Gene (LMNA) and its constituent exons 
[Adapted from Parks et al, 2008; and Perrot et al, 2009] 
 
 
The LMNA gene is shown (LMNA). The Lamin A protein is coded by exons 1−12 and has a 
total of 664 amino acids in length. Lamin C is coded by exons 1−9 and an alternatively 
spliced exon 10, and is 572 amino acids long. White boxes are coding, while grey-shaded 
boxes are un-translated regions. Lamin A protein results from alternative splicing that adds 
exons 11 and 12 and removes the Lamin-C-specific portion of exon 10 (the latter being 
shown as the upper of the two boxes marked exon 10). 
 
Screening for LMNA mutations in PPCM patients 
Genetic screening for mutation on the Lamin A/C gene (LMNA) was successfully conducted 
in 38 PPCM patients alongside two separate pairs of controls matched for sex and ethnicity, 
as described in the methods section above. 
I. Bio-demographic profile of PPCM probands 
Table 9 shows the bio-demographic profile of the 38 PPCM patients recruited. None of the 
patients had hypertension or raised blood pressure on presentation. 
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Table 9. Bio-demographic profile of the 38 PPCM patients 
 Proband 
Age (years)  28 ± 7 
Parity  1.5 (IQR 1-2)  
Of African Descent 95% 
  
BMI (kg/m
2
)  27  ± 6 
Pulse Rate  96 ±  18 
Blood Pressure 
• Mean systolic (mmHg) 
• Mean diastolic  (mmHg) 
 
104 ± 16 
68 ± 7 
 
 
II. Results of genetic screening for mutation to the Lamin A/C gene 
As per the methods, primers were designed to cover all the exonic region of the LMNA gene, 
but parts of the intron on either side of the exon were included. 12 exons were identified 
for the LMNA gene, each complete with the appropriate flanking regions. 
As many runs of the amplification process were done as was deemed necessary to ensure 
the best possible result in amplified material. Sequencing analyses were performed on all 
amplified tracings where high-resolution melt analysis curves suggested the presence of a 
possible variation. PPCM patients demonstrated abnormalities in 6 of the 12 exons [see 
Table 10], most of which were within the intronic region of that exon.  
Amidst these 6 exons, a total of 9 mutations were observed; 78% of which were intronic, 22% 
synonymous. All of the 7 intronic changes were known SNPs [see Figure 10]. Of the two 
synonymous variations, one was reported by dbSNP to be non-pathogenic, whilst the other 
remained untested; according to both dbSNP and 1000 genomes databases. Still, the fact 
that both are polymorphisms makes the likelihood of the untested one being non-
pathogenic very high. 
Of marked importance, however, is the absence of any novel mutation amidst our PPCM 
patients.  
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Table 10. Sequencing analysis for mutations in Lamin A/C gene in PPCM patients 
 
Location No. of Patients with Mutations Nucleotide change 
Amino acid 
change 
Mutation type Documented in Literature Pathogenic* 
Exon 3 
10 Heterozygous/6 Homozygous c.639+56G>T - Intronic dbSNP: rs11264442 No (dbSNP, Mutation Taster) 
13 Heterozygous/2 Homozygous c.639+73C>T - Intronic dbSNP: rs11264443 Untested (1000 Genomes) 
Intron 4 
13 Heterozygous/1 Homozygous c.810+13G>T - Intronic dbSNP: rs11264444 No 
13 Heterozygous/1 Homozygous c.810+61C>T - Intronic dbSNP: rs11264445 No 
Intron 6 
3 Homozygous/14 Heterozygous c.1157+16G>A - Intronic dbSNP: rs534807 No (dbSNP, Mutation Taster) 
8 Heterozygous c.1097+50A>G - Intronic dbSNP: rs16837198 No 
Exon 7 6 Heterozygous c.1338T>C p.D446 Synonymous dbSNP: rs505058 No (dbSNP), Untested (1000 Genomes) 
Exon 10 1 Heterozygous c.1698C>T p.H566 Synonymous 
dbSNP: rs4641 
HGMD-PUBLIC: CM003892 
Untested (1000 Genomes) 
Intron 11 2 Heterozygous c.1968+26A>G - Intronic dbSNP: rs80264244 Untested 
 
*The pathogenicity of the given abnormality was determined by searching relevant published genetic databases, namely: Ensemble NCBI dbSNP,  
Human Gene Dabatabase (HGMD), Mutation Taster and 1000 Genomes. 
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Figure 10. Illustrated: localisation of the variations in the Lamin A gene found in patients with    
                                         Peripartum Cardiomyopathy                                                      
[Adapted from Parks et al, 2008; and Perrot et al, 2009] 
 
 
 
 
 
 
 
 
A. Locations of the SNP variations are shown below the respective intron/exon. 
 
 
 
 
 
 
          B. Sequencing electropherogram showing heterozygosity for one of the known SNPs seen on   
               the LMNA gene in PPCM patients 
 
 
 
 
 
 
c.639+56G>T 
c.639+73C>T 
c.810+13G>T 
c.810+61C>T 
c.1157+16G>A 
c.1097+50A>G 
c.1338T>C 
c.1698C>T 
c.1968+26A>G 
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3.3 Results of the ECG Sub-Study 
 
“The 12-lead ECG in Peripartum Cardiomyopathy” 
 
 
Tibazarwa K, Lee G, Mayosi BM, Carrington M, Stewart S, Sliwa K 
 
[Cardiovasc J Afr. 2012 Feb 16;23:1-8. doi: 10.5830/CVJA-2012-006] 
 
 
 
Presented at SAHA Annual Congress in Durban (October 2008) 
Presented at: HFA (ESC) in Nice, France (May 2009); ESC Congress in Barcelona, Spain (August 2009); 
ICEPS in Athens, Greece (December 2011) 
 
 
This study was original in that it provided the first large series of PPCM patients that were 
systematically assessed for the ECG characteristics of PPCM at baseline and, where possible, at six 
months after commencement of treatment.  
Here, we showed that while the ECG in PPCM did not appear to bear characteristics unique to PPCM, 
it appeared useful as a screening tool for clinicians to tease out peripartal women with some form of 
heart failure from those without any heart disease. 
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Cardiovascular Topics
The 12-lead ECG in peripartum cardiomyopathy
KEMI TIBAZARWA, GERALDINE LEE, BONGANI MAYOSI, MELINDA CARRINGTON, SIMON STEWART, 
KAREN SLIWA
Abstract
Background: The value of the 12-lead electrocardiogram 
(ECG) to provide prognostic information in the deadly and 
disabling syndrome peripartum cardiomyopathy (PPCM) is 
unknown.
Aims: To determine the prevalence of major and minor ECG 
abnormalities in PPCM patients at the time of diagnosis, and 
to establish whether there are ECG correlates of persistent 
left ventricular dysfunction and/or clinical stability at six 
months of follow up, where available. 
Methods: Twelve-lead ECGs were performed at the point of 
diagnosis on 78 consecutive women presenting with PPCM 
to two tertiary centres in South Africa and 44 cases (56%) at 
the six-month follow up. Blinded Minnesota coding identified 
major ECG abnormalities and minor ECG changes.
Results: The cohort mainly comprised young women of black 
African ancestry (90%) [mean age 29 ± 7 years and median 
body mass index 24.3 (IQR: 22.7–27.5) kg/m2]. The major-
ity of cases (n = 70; 90%) presented in sinus rhythm (mean 
heart rate 100 ± 21 beats/min). At baseline, at least one ECG 
abnormality/variant was detected in 96% of cases. Major 
ECG abnormalities and minor changes were detected in 49% 
(95% CI: 37–60%) and 62% (95% CI: 51–74%) of cases, 
respectively; the most common being T-wave changes (59%), 
p-wave abnormality (29%) and QRS-axis deviation (25%). 
Of the 44 cases (56%) reviewed at six months, normalisa-
tion of the 12-lead ECG occurred in 25%; the most labile 
ECG features being heart rate (mean reduction of 27 beats/
min; p < 0.001) and abnormal QRS axis (36 vs 14%; p = 
0.014). On an adjusted basis, major T-wave abnormalities 
on the baseline 12-lead ECG were associated with lower 
left ventricular ejection fraction (LVEF) at baseline (aver-
age of –9%, 95% CI: –1 to –16; p = 0.03) and at six months 
(–12%; 95% CI: –4 to –24; p = 0.006). Similarly, baseline 
ST-segment elevation was also associated with lower LVEF 
at six months (–25%; 95% CI: –0.7 to –50; p = 0.04).
Conclusions: In this unique study, we found that almost all 
women suffering from PPCM had an ‘abnormal’ 12-lead 
ECG. Pending more definitive studies, the ECG appears to 
be a useful adjunctive tool in both screening and prognostica-
tion in resource-poor settings.
Keywords: peripartum cardiomyopathy, ECG, baseline, follow 
up, comparative study, South Africa
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Peripartum cardiomyopathy (PPCM) is a form of heart failure 
(HF) with poorly understood aetiology, occurring between the 
last trimester of pregnancy and up to the first five to six months 
postpartum.1,2 Despite an early definition,3 later modified by 
Pearson and colleagues,4 there is no consensus regarding PPCM 
as a single entity among the leading cardiology societies.5 The 
European Society of Cardiology recently declared PPCM a 
distinct disease entity,1 although it may take time before wider 
awareness of PPCM facilitates more timely diagnosis and pro-
active treatment. This is unfortunate given that PPCM causes 
left ventricular (LV) dysfunction, is more common in particular 
populations (e.g. African women6) and is associated with poor 
clinical outcomes and survival rates.7,8 
Some studies suggest the incidence of PPCM is one in 
3 000 live births. However, one African study found it to be one 
in 1 000 live births.9 There is also a very high risk of relapse in 
subsequent pregnancies,10,11 even following full recovery of LV 
function after the first pregnancy.6 Therefore, early and definitive 
diagnosis of PPCM is essential to limit the high risk of morbidity 
and mortality in both current and subsequent pregnancies.
Definitive diagnosis and subsequent management of PPCM 
requires a high index of suspicion. It also usually requires refer-
ral to a tertiary centre for echocardiographic studies and special-
ist cardiological management. Anecdotal evidence suggests that 
many women who initially present with signs and symptoms 
indicative of PPCM are diagnosed with ‘non-specific symptoms 
of the puerperal period’. The misdiagnosis of PPCM (often lead-
ing to clinical deterioration and in some instances death) repre-
sents a clear target for early intervention and prevention. Until 
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specific aetiologies are identified, PPCM remains a diagnosis 
of exclusion. 
Women in their peripartum period suspected with PPCM 
require rigorous investigation; a costly and laborious process for 
the patient and healthcare provider. This is particularly difficult in 
a resource-poor environment. Although screening with (point-of-
care derived) brain natriuretic peptide (BNP) levels may offer a 
means of detecting elevated atrial pressures secondary to systolic 
dysfunction (particularly given the age of those affected6,12,13), 
for example, technical and cost issues remain that prohibit their 
use. In settings such as sub-Saharan Africa where resources are 
scarce but the incidence of PPCM is high, the advantages of 
finding alternative screening tools for this condition that truncate 
the need for more extensive investigations, while being simple 
and inexpensive to apply, are abundantly clear.2,14
Although there is a paucity of electrocardiographic data 
specifically relating to PPCM, an ‘abnormal’ 12-lead electrocar-
diogram (ECG) is common in individuals with HF syndrome, 
with common anomalies including supraventricular arrhythmias, 
bundle branch block, and sinus bradycardia.15 Given the above, 
we undertook a prospective, pilot study of the 12-lead ECG in 
a consecutive cohort of newly diagnosed women with PPCM 
in South Africa. Specifically, the primary aim of this study was 
to describe the baseline ECG characteristics in PPCM patients, 
noting the type and prevalence of major and minor ECG abnor-
malities. We also sought to analyse six-month follow-up ECGs 
(where available) of PPCM patients to determine potential ECG 
correlates of persistent LV dysfunction and/or clinical stability, 
where possible, as repeat ECGs are not part of the routine follow 
up of PPCM patients.
Methods
Consecutive patients presenting with de novo PPCM to two 
tertiary centres in South Africa (Chris Hani Baragwanath 
Hospital, Johannesburg, and Groote Schuur Hospital, Cape 
Town) between January 2003 and August 2008 were studied. 
Patients were referred from primary and secondary health facili-
ties, as well as internally from other departments. Only patients 
aged ≥ 17 years who fulfilled the diagnostic criteria for PPCM4 
were considered eligible for the study. For recruitment, previ-
ously described16 inclusion and exclusion criteria had to be met.
Ethical approval was obtained from each of the local ethi-
cal committees of the universities of Cape Town and the 
Witwatersrand, respectively, prior to the commencement of the 
study. This study complied with all the requirements of the 
Declaration of Helsinki. All patients were offered treatment and 
follow up as per the local standard of tertiary care.
A total of 78 women presenting with PPCM were studied. 
Of these, 56% had follow-up ECG data and were included in 
the comparative study analyses. Of those patients who had 
not had six-month ECGs (n = 34), three patients died (3.9%). 
Importantly, patients with repeat six-month ECG data did not 
differ significantly with respect to baseline heart rate, NYHA 
functional class, and left ventricular ejection fraction (LVEF) 
from the remaining cohort. 
All patients with the provisional diagnosis of PPCM under-
went a thorough medical interview and examination, and were 
investigated to confirm the diagnosis at baseline. All patients had 
a 12-lead ECG and echocardiography. Additional investigations 
were performed on a case-by-case basis. Data were captured on 
standardised case report forms.
A 12-lead resting ECG was performed by a trained techni-
cian and analysed by a reviewer blinded to all clinical data 
(GL), using the Minnesota code classification system.17 The 
code allows systematic classification of Q and QS patterns, 
axis deviation, R waves, ST depression and elevation, T-wave 
changes, along with conduction abnormalities in both atria 
and ventricles.17,18 The abnormalities detected by the Minnesota 
code were pooled into major abnormalities and minor variations 
from the ‘normal’ 12-lead ECG using the classification system 
previously applied by de Bacquer and colleagues19 (Table 1). 
Separate analyses for ST-segment depression, arrhythmia or 
atrio-ventricular (AV) block, bundle branch block and left-axis 
deviation were also performed.
Standard methods for two-dimensional Doppler transthoracic 
echocardiography were applied as per the American Society 
of Echocardiography guidelines.20 LV systolic dysfunction was 
defined by echocardiographic documentation of left ventricular 
ejection fraction (LVEF) ≤ 45%. All studies were saved onto 
TABLE 1. MAJOR ABNORMALITIES AND MINOR 12-LEAD 
ECG VARIATIONS BASED ON MINNESOTA CODING
Major ECG abnormality Minor ECG variations
Q-wave abnormalities Borderline Q waves
ST-segment depression Left- or right-axis deviation
T-wave inversion High-amplitude R waves
2o or 3o AV block Borderline ST-segment depression
Complete LBBB or RBBB T-wave flattening
Frequent premature atrial or 
ventricular beats
Low QRS voltage
Atrial fibrillation or flutter
AV = atrio-ventricular; LBBB = left bundle branch block; RBBB = 
right bundle branch block. (Adapted from de Bacquer et al., 1998).19
TABLE 2. BASELINE CLINICAL AND DEMOGRAPHIC 
PROFILE
Socio-demographic profile
Mean age (years) 29 ± 7*
Proportion black African (%) 90
Obstetric profile
Median parity 2 (IQR 1–3)**
Median postpartum period at presentation 
(days)
18 (IQR 6–30)**
Clinical presentation
Proportion with New York Heart Associa-
tion functional class III or IV (%)
64
Median body mass index (kg/m2) 24.3 (IQR 22.7–27.5)**
Mean pulse rate 99 ± 19*
Blood pressure (mmHg)
Mean systolic
Mean diastolic 
116 ± 20*
76 ± 14*
2D Doppler echocardiography
Median intra-ventricular septal thickness 
in diastole (cm) 
Mean left ventricular end-diastolic diam-
eter (cm) 
Mean ejection fraction (%) 
0.9 (IQR 0.8–1.1)**
5.8 ± 0.7*
30.5 ± 9*
*Standard deviation (± SD); **interquartile range (IQR).
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hard-drive facilities, and a random sample of these was reviewed 
by a cardiologist blinded to the clinical details of these patients, 
to confirm the accuracy of parameters describing cardiac struc-
ture and function.
Statistical analyses
All data analyses were performed with STATA-8.21 For numeri-
cal variables, we report on the mean [standard deviation (SD)] 
for normally distributed variables, and median [inter-quartile 
range (IQR)] for non-parametric variables. Comparison between 
baseline and follow-up ECGs was done using paired t-tests 
for normally distributed numerical variables, Mann-Whitney/
Wilcoxon signed rank tests for non-parametric paired numeri-
cal variables, and chi-squared tests for categorical variables and 
proportions. Multivariate analysis was conducted using linear 
and logistic regression for numerical and categorical outcome 
variables, respectively.
Results
Table 2 summarises the clinical and demographic profiles of the 
78 women with de novo PPCM, 10 of whom experienced a first-
ever detected episode of mildly raised blood pressure at some 
stage during the index pregnancy. The case report and Fig. 1 
describe such a typical case. 
Interestingly, no patients under the age of 17 years presented 
to either study unit and 90% of patients included were young 
women of African ancestry. Of the 10% that were of non-black 
African ethnicity, almost all were of mixed ancestry, with only 
one Caucasian patient. The majority of respondents were normo-
tensive and experienced onset of symptoms in the postpartum 
period (median 18 days, IQR 6–30 days). However, 8% of 
respondents reported the onset of symptoms prepartum, of which 
only two were hypertensive (one mild and the other with moder-
ate hypertension, defined as per standard protocol).22-24 
Table 3 summarises baseline ECG abnormalities/variations 
from normal (n = 78). The majority of cases (90%) were in sinus 
rhythm, although mean heart rate was markedly elevated, with 
45% of cases in sinus tachycardia (defined as those ≥ 100 beats/
min, given that our patients’ maximum heart rate was 134 beats/
min). Only three patients (4%) had completely normal ECGs; 
excluding those with an elevated heart rate, this increased to 
nine patients (12%). Overall, 49% (95% CI: 37–60) of cases had 
a major Minnesota ECG abnormality detected, while 62% (95% 
CI: 51–74) had a minor ECG variant. A combined total of 63 
(81%; 95% CI: 70–89%) cases had one or both forms of abnor-
mality detected on their 12-lead ECG. Of the major abnormali-
ties, major T-wave anomalies (38%), followed by abnormal QRS 
axis (26%) were the most common (Fig. 2). T-wave anomalies 
were also the most common of all documented ECG abnormali-
ties overall (59%), followed by atrial abnormalities (29%). 
Univariate analysis showed no association between LV systol-
ic function and baseline ECG readings. However, on adjustment 
for age, functional class, echocardiographic LV dimensions, and 
all the other ECG parameters listed in Table 3, major T-wave 
abnormalities correlated negatively with left ventricular systolic 
dysfunction. The presence of major T-wave changes was associ-
ated with a clinically relevant 9% (95% CI: 1–16; p = 0.03%) 
reduction in LVEF compared to those without T-wave changes.
At six months, a number of clinical parameters had improved 
Case report: the ECG in PPCM
Our patient presented to hospital one week after giving birth through spontaneous vaginal delivery, reporting a five-week 
history of shortness of breath equivalent to New York Heart Association functional class II, two-pillow orthopnoea associ-
ated with cough, bilateral leg swelling, and mild dizziness. On further interrogation, there was a positive family history 
of sudden ‘unexplained’ death of her grandmother. Our patient denied any consumption of alcohol or tobacco products. 
Clinical examination revealed central and peripheral signs of fluid overload. The pulse rate was 92 beats per minute, 
this being weak, with occasional irregularities suggestive of ventricular extrasystoles. Her blood pressure was 97/72 
mmHg, her apex beat displaced laterally, and the abdominal examination proved there to be tender hepatomegaly. 
Positive findings on cardiac auscultation included a loud, split, second heart sound, and systolic murmur best heard over 
the mitral and tricuspid areas. Chest auscultation revealed bilateral basal crepitations. 
Chest X-ray demonstrated four-chamber cardiomegaly and pulmonary congestion, while her ECG abnormalities 
included right-axis deviation, with poor R-wave progression and diffuse T-wave inversion (Fig. 1a). Echocardiography 
showed dilated cardiac chambers, markedly reduced systolic ventricular function (EF 35%), moderate to severe functional 
mitral regurgitation, trace tricuspid regurgitation, and a small clear pericardial effusion. Tissue Doppler imaging revealed 
no further evidence of diastolic dysfunction.
Further tests permitted the exclusion of other common causes of dilated cardiomyopathy, as well as important differ-
ential diagnoses. The working diagnosis remained that of peripartum cardiomyopathy. 
The patient was started on carvedilol, enalapril, spirinolactone and furosemide. Given the high risk for thrombo-
embolic phenomena presented with the ejection fraction of 35% and below, she was started on warfarin. Despite being 
seen several times in between, six weeks later she continued to manifest the subtle arrhythmia of moderate-frequency 
ventricular extrasystoles, with suboptimal heart rate control; hence digoxin was introduced. 
Following regular follow-up visits, after six months she reported that she was well, without any heart-failure symptoms. 
Her blood pressure had normalised to 113/64 mmHg and heart rate to 58 beats/min, while the pulse rhythm remained 
irregular as if with ventricular extrasystoles (now at low frequency). The mitral regurgitation murmur had diminished to 
grade 1. On ECG, the axis had now normalised, and although there remained diffusely inverted T-waves, their depths 
had improved, and this inversion normalised in limb lead I. The patient now qualified for left ventricular hypertrophy by 
voltage criteria using this same lead I (Fig. 1b). Echocardiography showed persistent but improved LV dilatation, minimal 
functional tricuspid and mitral regurgitation, with improvement of LV systolic function to an EF of 49%. 
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in surviving cases subjected to study follow up (n = 44) (Table 4). 
Overall, 55% had no residual evidence of LV systolic dysfunc-
tion (p < 0.001), although 10% still reported functional impair-
ment (NYHA class II or more). Overall, 25% of this sub-set of 
cases had a normal 12-lead ECG at six months. 
According to univariate analyses, no difference between 
Fig. 1. A typical ECG in PPCM at baseline (a) and after six months (b).
a.
b.
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‘clinically stable/responded to treatment’ (i.e. recovered LV func-
tion) versus non-responders (persistent LV dysfunction) were 
found in respect of any ECG parameter. However, on an adjusted 
basis, major T-wave changes and major ST-segment depres-
sion found on the baseline 12-lead ECG subsequently corre-
lated with persistently impaired systolic function at six months. 
Specifically, the presence of major T-wave changes at baseline 
was associated with a markedly lower LVEF at six months 
(–12%, 95% CI: –4 to –21; p = 0.006) compared to those without 
T-wave changes at baseline. In addition, ST-segment elevation at 
baseline was associated with an even greater reduction in LVEF 
at six months (–25%, 95% CI: –0.7 to –50; p = 0.044) compared 
to those without this ECG pattern at baseline.
Discussion
To the best of our knowledge, this is the first study to systemati-
cally describe the 12-lead ECG in de novo cases of PPCM. Our 
main aim was to examine the potential utility of the 12-lead 
ECG (a relatively inexpensive and easy-to-apply diagnostic tool) 
in detecting underlying LV dysfunction in confirmed cases of 
de novo PPCM in African women. This would require a high 
underlying level of ECG abnormalities in such a cohort in order 
to discriminate against (presumably) more normal 12-lead ECGs 
in African women experiencing healthier pregnancies.
Of the 78 cases studied, 49% demonstrated major ECG 
abnormalities, usually associated with significant underlying 
cardiac pathology, while 62% demonstrated one or more forms 
of minor variation/abnormality, potentially indicative of the 
same. We also attempted to examine whether the 12-lead ECG 
is a useful tool for discriminating between those cases who 
respond to treatment (by the resolution of initially observed ECG 
Fig. 2. Prevalence of Minnesota major criteria at baseline 
in 78 PPCM patients.
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TABLE 3. 12-LEAD ECG AT BASELINE IN 78 PPCM PATIENTS
ECG characteristic No. (%) (n = 78)
Rate and rhythm Mean heart rate (beats/min) ± SD 100 ± 21
Proportion in sinus rhythm 70 (90%; 95% CI: 81–95)
Proportion with sinus tachycardia 35 (45%; 95% CI: 34–57)
Proportion with arrhythmias 
•	 premature ventricular complex 
•	 supraventricular tachycardia 
•	 sinus arrhythmias 
3 (4%; 95% CI: 0.8–11)
1 (1%; 95% CI: 0.03–7)
4 (5%; 95% CI: 1–13)
 Axis QRS axis 
•	 abnormal 
•	 left axis 
•	 right axis 
•	 indeterminate 
20 (26%; 95% CI: 16–37)
9 (12%; 95% CI: 5–21)
8 (10%; 95% CI: 5–19)
3 (4%; 95% CI: 0.8–11)
Conduction PR interval > 220 ms 1 (1%; 95% CI: 0.04–7)
Proportion with bundle branch block (BBB)
•	 left BBB 
•	 right BBB
9 (12%; 95% CI: 5–21)*
4 (5%; 95% CI: 1–13)
1 (1%; 95% CI: 0.03–7)
Proportion with prolonged QTc (> 470 ms) 4 (5%; 95% CI 1–13)
Repolarisation Proportion with T-wave abnormalities
•	 major 
•	 minor
46 (59%; 95% CI: 47–70)**
30 (38%; 95% CI: 28–50)
24 (31%; 95% CI: 21–42)
Proportion with ST-segment changes 
•	 major ST-segment changes 
•	 minor ST-segment changes 
•	 ST-segment elevation
1 (1%; 95% CI: 0.03–7)
3 (4%; 95% CI: 0.8–11)
1 (1%; 95% CI: 0.03–7)
Hypertrophy Proportion with left ventricular hypertrophy
[Defined by Minnesota codes III1 and (IV1-3 or V1-3)]
7 (9%; 95% CI: 4–18)
Atria Proportion with atrial abnormalities 
•	 left atrium 
•	 right atrium 
•	 bi-atrial 
23 (29%; 95% CI: 20–41)**
8 (10%; 95% CI: 5–19)
11 (14%; 95% CI: 7–24)
4 (5%; 95% CI: 1–13)
*This sum exceeds that of individual BBB as some patients manifested incomplete BBB (either left or right).
**This sum exceeds that of individual sub-categories as some patients manifested features of each sub-category.
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abnormalities) and those who had persistent LV dysfunction. In 
this respect, we found that the presence of two major abnormali-
ties (T-wave inversion and ST-segment depression) and a third 
Minnesota code criterion not listed as one of the major or minor 
criteria (ST-segment elevation) found on the baseline 12-lead 
ECG correlated with persistently poor LV systolic function at 
six months. T-wave inversion also correlated with LV systolic 
function at baseline. 
Typically, LV systolic functional recovery in PPCM is a 
slow and drawn-out process that enters the second year of treat-
ment.2 On this basis, while LVEF in those patients subjected to 
six-month follow up improved overall, just under half still had 
defined impaired LV dysfunction, and this represents a major 
therapeutic target for treatment. Therefore, long-term follow 
up using the ECG in PPCM might well show ECG reversal 
to normality as late as 18 months after first diagnosis, as our 
long-term echocardiographic data suggest.8 Moreover, we have 
identified potentially useful markers (i.e. major T-wave inversion 
and/or ST-segment depression on the 12-lead ECG) as simple but 
important prognostic markers that might trigger more intensive/
aggressive treatment and follow up in PPCM cases.
Our findings and the overall utility of the 12-lead ECG in this 
clinical setting require careful interpretation when fundamental 
investigations such as echocardiography remain inaccessible to 
most hospitals and patients in sub-Saharan Africa. Serum levels 
of NT-proBNP are known to strongly predict the degree of heart 
failure,12 yet this test is still not available in most referral hospi-
tals in Africa where PPCM is prevalent. Surprisingly, because of 
vast differences in sensitivity and specificity in detecting HF, it 
has been suggested that the overall cost-effectiveness of measur-
ing serum NT-proBNP becomes comparable to that of screening 
for HF using the 12-lead ECG alone,25,26 due mainly to the rela-
tively low specificity of the 12-lead ECG.26 
The scarcity of the serum NT-proBNP test in our setting 
almost mandates using something as inexpensive and easy as 
the 12-lead ECG to screen for PPCM, even if its sensitivity and 
specificity prove to be imperfect. These data will be particu-
larly useful if (after comparing ECG patterns in healthy African 
women, derived from the Heart of Soweto cohort27) the 12-lead 
ECG has the potential to be applied as a ‘rule-out’ test (i.e. 
high specificity to identify all truly negative for PPCM cases). 
Unfortunately, the ability to combine 12-lead ECG with typical 
symptoms of HF (to increase its accuracy in detecting PPCM) is 
confounded by their parallel presence in the late stages of preg-
nancy (but not typically post-partum). 
As indicated, our data suggest that baseline major T-wave 
abnormalities were associated with poorer LV systolic function 
at baseline, and, alongside baseline ST-segment depression, they 
were also associated with persistent LV systolic dysfunction in 
the short to medium term (i.e. six months). In Western countries, 
major ST-segment depression and T-wave abnormalities are often 
regarded as indications of myocardial ischaemia, bearing consist-
ent prognostic significance for cardiovascular disease mortality 
across prospective studies, especially for men.28 
We remain wary of the fact that gender differences in ECG 
findings often show women to have a higher prevalence of 
TABLE 4. COMPARING BASELINE AND SIX-MONTH ECG  CHARACTERISTICS IN  
44 PPCM PATIENTS WITH FOLLOW-UP DATA
Baseline
% of population
6-month follow up
% of population
p-value
Rate and rhythm Mean heart rate (beats/min) ± SD 104 ± 18 77 ± 14 < 0.001
Proportion in sinus rhythm 84 (95% CI: 70–93) 66 (95% CI: 50–80) 0.049
Proportion with sinus tachycardia 48 (95% CI: 32–63) 7 (95% CI: 1–19) < 0.001
Proportion with arrhythmias 
•	 premature ventricular complex 
•	 sinus arrhythmias 
2 (95% CI: 0.06–12)
7 (95% CI: 1–19)
2 (95% CI: 0.06–12)
27(95% CI: 15–43)
1.0
0.011
 Axis Proportion with QRS axis being:
•	 abnormal 
•	 left axis 
•	 right axis 
•	 indeterminate 
36 (95% CI: 22–52)
18 (95% CI: 8–33)
11 (95% CI: 4–25)
7 (95% CI: 1–19 )
14(95% CI: 5–27)
7 (95% CI: 1–19)
5 (95% CI: 0.6–15)
2 (95% CI: 0.06–12)
0.014
0.107
0.237
0.306
Conduction Proportion with bundle branch block (BBB)
•	 left BBB 
•	 right BBB
20 (95% CI: 10–35)*
9 (95% CI: 3–22)
2 (95% CI: 0.06–12)
18 (95% CI: 8–33)
9 (95% CI: 3–22)
2 (95% CI: 0.06–12)
0.787
1.0
1.0
Repolarisation Proportion with T-wave abnormalities
•	 major 
•	 minor
45 (95% CI: 30–61)**
30 (95% CI: 17–45)
16 (95% CI: 7–30)
27(95% CI: 15–43)
34 (95% CI: 20–50)
9 (95% CI: 3–22)
0.123
0.647
0.334
Proportion with ST-segment changes 
•	 major ST changes 
•	 minor ST changes 
•	 ST-segment elevation
0
2 (95% CI: 0.06–12)
2 (95% CI: 0.06–12)
0
0
0
–
0.315
0.315
Hypertrophy Proportion with left ventricular hypertrophy
[Defined by Minnesota Codes III1 and (IV1-3 or V1-3)]
7 (95% CI: 1–19 ) 7 (95% CI: 1–19 ) 1.0
Atria Proportion with atrial abnormalities 
•	 left atrium 
•	 right atrium 
•	 bi-atrial 
20 (95% CI: 10–35)**
5 (95% CI: 0.6–15)
9 (95% CI: 3–22)
7 (95% CI: 1–19 )
9 (95% CI: 3–22)
2 (95% CI: 0.06–12)
7 (95% CI: 1–19)
0
0.133
0.557
0.694
0.078
*This sum exceeds that of individual BBB as some patients manifested incomplete BBB (either left or right).
 **This sum exceeds that of individual sub-categories as some patients manifested features of each sub-category.
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ST-segment depression or T-wave changes, such as to question 
the true significance of any association between ST-segment 
depression and T-wave abnormalities with coronary heart disease 
(CHD) mortality in women.28 However, we are greatly reassured 
by the number of large, population-based studies that show major 
ST-depression to be the most predictive ECG characteristic of 
cardiovascular disease (CVD) and CHD mortality, lending an 
average two-fold risk of CVD and CHD mortality, and, as with 
our study, predicting these outcomes from their mere presence 
at baseline.19
Studies reporting on the ECG in prognostication of PPCM 
remain scarce, with two from Nigeria suggesting it to be a weak 
predictor of recovery and long-term prognosis in PPCM.29,30 
However these studies did not use echocardiography to confirm 
the diagnosis of PPCM,30 and had a greater proportion of 
patients with hypertension than those without.29,30 Given recent 
insight that patients with the PPCM phenotype who present with 
hypertension appear to follow a different natural history to those 
without,2 any comparisons between data from PPCM patients 
with hypertension with those without hypertension should be 
interpreted with great caution. 
Systematic reports of ECG abnormalities associated with 
idiopathic dilated cardiomyopathy (IDCM), which bears some 
resemblance to PPCM, are few. One such study of IDCM report-
ed that the ECG was found to be normal in up to 25% of affected 
relatives of IDCM patients (who by definition suffer from famil-
ial DCM), although these were not all newly diagnosed IDCM 
cases.31 Hence, as in our study, an overwhelming majority had 
abnormal ECGs. 
It remains fair to say that the shortage of studies systemati-
cally reporting on the prevalence of ECG anomalies in PPCM 
may account for most for our inability to corroborate our find-
ings with other available evidence, yet no reports contradict 
our findings. Overall, therefore, our data can only suggest that 
the 12-lead ECG in PPCM may be sensitive to underlying LV 
dysfunction and/or that it can serve as a marker of more exten-
sive cardiac insult early in the disease process.
Lastly, we note that the 1% prevalence of first-degree heart 
block, usually not considered to bear any significant risk to 
adverse CVD outcome, except for its association with lamin A/C 
mutation in familial DCM, may in our PPCM cohort merely 
reflect the 1–2% prevalence in normal young adults.32 However, 
after recent reports implicating this so-called benign form of 
heart block in the general population with increased risk of atrial 
fibrillation and adverse CVD outcome 20 years down the line,32 
and suggestions that post-exercise measurements of PR intervals 
may be more prognostic within five-year follow-up periods 
than resting ECG PR intervals,32 it would be useful to revise the 
prognostic implications of first-degree heart block post exercise 
in patients with underlying myocardial disease and congestive 
cardiac failure as in PPCM. 
Furthermore, evaluation of this conduction disorder may be 
of particular importance in PPCM, in view of several reports of 
first-degree AV block being among one of the earliest signs of 
lamin A/C mutation, which in turn commonly leads to a pheno-
type of apparently unexplained DCM.33 It is worth considering 
that the prognostic implications behind each of the criteria for 
major and minor ECG abnormalities/variants derived from the 
Minnesota code appear more applicable in the screening of high-
risk persons only,34 as in this clinical context. 
This pilot study has a number of limitations that require 
comment. Firstly, the Minnesota code may not be sufficiently 
validated for the detection of heart disease in pregnant women. 
Moreover, the ‘normal’ 12-lead ECG in African women is yet 
to be definitively described. Whether the combined presence 
(81% of cases) of major abnormalities and minor variations is 
sufficient to support further investigation of the 12-lead ECG as 
a screening tool (particularly when there are few data to describe 
the ‘normal’ 12-lead ECG in pregnant and non-pregnant African 
women), is open to debate. 
In determining the sensitivity of ECG changes over time, 
relative to underlying LV dysfunction, we had valid data for only 
56% of the cohort. Although our PPCM patients who did not 
have follow-up ECGs did not differ in clinical and echocardio-
graphic outcome from those with follow-up data, the possibility 
that the former group may have been clinically worse off than 
those with six-month data cannot be excluded, given that greater 
proportions of the former manifested minor T-wave anomalies, 
and that their left ventricular diameters and BMI at baseline 
appeared greater than those who had six-month ECGs. However, 
in light of the lower prevalence of QRS-axis deviation and 
bundle branch block among the former group, interpretation of 
the similarity of patients with and without follow up with regard 
to ECG characteristics becomes speculative.
Further data are required to better characterise the 12-lead 
ECG as a marker of LV dysfunction in this specific clinical (and 
ethnic) context, before any firm recommendations can be made 
in respect of obtaining a 12-lead ECG at the conclusion of each 
pregnancy in sub-Saharan Africa.
Conclusions
Despite a number of limitations, this still represents a unique 
study that will prove to be invaluable in determining the future 
role of the 12-lead ECG as an inexpensive and simple ‘rule-out’ 
screening tool for PPCM, and perhaps an important tool for 
increasing the intensity of subsequent treatment and manage-
ment. Overall, we found the majority (96%) of PPCM patients 
presented with ‘abnormal’ 12-lead ECGs, which improved 
significantly to 75% after the first six months of treatment. Over 
80% of patients displayed either major abnormalities or minor 
variations using the Minnesota code. Of these, sinus tachycardia 
and QRS-axis deviation were most likely to be attenuated after six 
months. Even though these ECG abnormalities were mostly non-
specific and similar to those of other dilated cardiomyopathies, 
our study further suggests the ECG to be useful in simple moni-
toring of clinical progress during treatment and prognostication. 
Specifically, the baseline presence of major T-wave and 
ST-segment abnormalities in the context of PPCM patients may 
place these patients at similar risk of adverse outcomes to those 
with myocardial ischaemia. More definitive studies are required 
to determine if this simple and relatively inexpensive tool will 
prove to be of particular clinical use in the setting of PPCM. Any 
progress in this regard will be welcome, given the persistently 
poor health outcomes associated with PPCM in resource-poor 
settings.
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3.4 Results of the Sub-Study on Bromocriptine Therapy in PPCM 
 
 
“Evaluation of Bromocriptine in the treatment of acute severe Peripartum Cardiomyopathy:  
a proof-of-concept pilot study” 
 
 
Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, McMurray  J, Yamac H, Labidi S, 
Struhman I, Hilfiker-Kleiner D 
[Circulation. 2010 Apr 6;121(13):1465-73.] 
 
Recent experiments by a group of scientists in Germany  showed that  in a mouse model of PPCM, 
Bromocriptine appeared to  prevent the development of PPCM in mice at risk (Hilfiker-Kleiner et al, 
2007: Cell).‘Mice at risk’ in this case were considered to be those with increased levels of the 
detrimental 16 kilo-Dalton prolactin (16kDa), which has been implicated in the pathogenesis of 
PPCM (Selle et al, 2009: Future Cardiol). 
Based on these findings, we conducted a proof of concept study, which formed the first ever 
randomised controlled trial of therapeutic use of the dopamine-antagonist Bromocriptine in the 
medical treatment of humans with PPCM. The study compared 10 newly diagnosed PPCM patients 
that were randomised to receive Bromocriptine therapy in addition to standard heart failure 
therapy, to another 10 newly diagnosed patients who received standard heart failure therapy alone.  
Although the study may have been relatively small, there was clear evidence of the beneficial effects 
of adding Bromocriptine to standard heart failure therapy, based on the improvements seen in both 
the quality and quantity of life. Beyond the clinical effects on the patient (mother), this study went 
80 
 
further to evaluate the potential for harm of Bromocriptine therapy on the biometric measurements 
of growth of young infants of PPCM mothers. It proved that with careful counselling, mothers who 
do not breastfeed because of the Bromocriptine therapy could still raise healthy babies. 
This study had a major clinical impact, being the basis on which the European Society of Cardiology 
developed guidelines for the management of PPCM. 
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Heart Failure
Evaluation of Bromocriptine in the Treatment of Acute
Severe Peripartum Cardiomyopathy
A Proof-of-Concept Pilot Study
Karen Sliwa, MD, PhD; Lori Blauwet, MD; Kemi Tibazarwa, MD; Elena Libhaber, PhD;
Jan-Peter Smedema, MD, MMed(Int); Anthony Becker, MD; John McMurray, MD, FESC;
Hatice Yamac, MD; Saida Labidi, MSc; Ingrid Struman, PhD; Denise Hilfiker-Kleiner, PhD
Background—Peripartum cardiomyopathy (PPCM) is a potentially life-threatening heart disease that occurs in previously
healthy women. We identified prolactin, mainly its 16-kDa angiostatic and proapoptotic form, as a key factor in PPCM
pathophysiology. Previous reports suggest that bromocriptine may have beneficial effects in women with acute onset of
PPCM.
Methods and Results—A prospective, single-center, randomized, open-label, proof-of-concept pilot study of women with
newly diagnosed PPCM receiving standard care (PPCM-Std; n10) versus standard care plus bromocriptine for 8 weeks
(PPCM-Br, n10) was conducted. Because mothers receiving bromocriptine could not breast-feed, the 6-month
outcome of their children (n21) was studied as a secondary end point. Blinded clinical, hemodynamic, and
echocardiographic assessments were performed at baseline and 6 months after diagnosis. Cardiac magnetic resonance
imaging was performed 4 to 6 weeks after diagnosis in PPCM-Br patients. There were no significant differences in
baseline characteristics, including serum 16-kDa prolactin levels and cathepsin D activity, between the 2 study groups.
PPCM-Br patients displayed greater recovery of left ventricular ejection fraction (27% to 58%; P0.012) compared
with PPCM-Std patients (27% to 36%) at 6 months. One patient in the PPCM-Br group died compared with 4 patients
in the PPCM-Std group. Significantly fewer PPCM-Br patients (n1, 10%) experienced the composite end point of poor
outcome defined as death, New York Heart Association functional class III/IV, or left ventricular ejection fraction
35% at 6 months compared with the PPCM-Std patients (n8, 80%; P0.006). Cardiac magnetic resonance imaging
revealed no intracavitary thrombi. Infants of mothers in both groups showed normal growth and survival.
Conclusions—In this trial, the addition of bromocriptine to standard heart failure therapy appeared to improve left
ventricular ejection fraction and a composite clinical outcome in women with acute severe PPCM, although the number
of patients studied was small and the results cannot be considered definitive. Larger-scale multicenter and blinded
studies are in progress to test this strategy more robustly. (Circulation. 2010;121:1465-1473.)
Key Words: cardiomyopathy  heart failure  hormones  parturition  pregnancy
Peripartum cardiomyopathy (PPCM) is characterized bynew onset of heart failure between 1 month before and 5
months after delivery in previously healthy women.1 The
clinical presentation and management of PPCM and its
outcome have been reviewed recently.1,2 Only 23% to 54% of
patients show recovery of cardiac function within 6
months.3–6 Investigation of a large cohort of PPCM patients
demonstrated that this condition is associated with a proin-
flammatory response, as evidenced by elevated plasma levels
of tumor necrosis factor-, Fas-Apo-1, interleukin-6, and
C-reactive protein (CRP).5,7,8
Editorial see p 1463
Clinical Perspective on p 1473
We recently reported that enhanced oxidative stress in a
mouse model for PPCM (mice with a cardiac-specific dele-
tion for signal transducer and activator of transcription-3)
triggers the activation of cathepsin D, a ubiquitous lysosomal
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enzyme that subsequently cleaves serum prolactin into its
antiangiogenic and proapoptotic 16-kDa form.9 This is asso-
ciated with endothelial inflammation, impaired cardiomyo-
cyte metabolism, and reduced myocardial contraction, sug-
gesting that oxidative stress, inflammation, and prolactin may
be interconnected and responsible for initiating PPCM.
Similarly, we found evidence for increased oxidative
stress, enhanced cathepsin D activity, and increased prolactin
cleavage in patients with acute PPCM.9 More recently, we
documented a close correlation between N-terminal brain
natriuretic peptide (NT-proBNP; a marker of ventricular wall
stress and heart failure), prolactin, and markers of oxidative
stress (oxidized low-density lipoprotein) and inflammation
(interferon-), further supporting the detrimental role of the
oxidative stress–prolactin axis.10
Importantly, blockade of prolactin with the dopamine-2D
agonist bromocriptine prevented the onset of PPCM in mice
and in 6 women at high risk of this condition as a result of
documented PPCM in a previous pregnancy.9 Several case
reports have also described seemingly beneficial effects from
the addition of bromocriptine to standard heart failure therapy
in patients with acute PPCM.9,11,12 Although these prelimi-
nary results suggesting beneficial effects of bromocriptine
treatment in patients with acute PPCM appear promising,
concerns have been raised about the risk of thrombotic
complications, including cerebral vascular incident and myo-
cardial infarction, related to bromocriptine therapy13–16 and
the consequences for the children of these patients because
the mothers are unable to breast-feed.17
The present work summarizes data from the first random-
ized study to assess the efficacy of bromocriptine on recovery
of left ventricular (LV) function, symptom status, and other
clinical measures in patients presenting within the first month
postpartum with new-onset symptomatic PPCM and an LV
ejection fraction (LVEF)35%. The progress of the newborn
children over the 6-month follow-up period was also studied.
All open-label efficacy assessments were made by indepen-
dent blinded investigators.
Methods
Study Design and Patient Recruitment
This study was approved by the Human Research Ethics Committee
of the University of the Witwatersrand, Johannesburg, South Africa,
and complies with the Declaration of Helsinki. All patients and
control subjects gave written informed consent before study entry.
Twenty consenting consecutive patients diagnosed with PPCM and
fulfilling the inclusion criteria were enrolled in the study. All patients
were included and randomized with a computer-generated random-
ization list within 24 hours of diagnosis.
The study was conducted at the Chris Hani Baragwanath
Hospital. Patients were referred from local clinics, secondary
hospitals, and the Department of Obstetrics at the Chris Hani
Baragwanath Hospital. History of preexisting cardiac symptoms
and signs, occurrence of preeclampsia, and mode of delivery were
obtained from the patient and confirmed by examination of the
obstetric card carried by each patient. Symptoms and signs were
recorded during first presentation at the cardiac unit at the Chris
Hani Baragwanath Hospital (baseline) and after a follow-up
period of 6 months. Clinical assessment, echocardiography, and
blood analysis were performed at baseline and at 6 months.
Cardiac magnetic resonance imaging (MRI) was obtained 4 to 6
weeks after diagnosis in patients receiving bromocriptine.
Inclusion criteria were symptoms of congestive heart failure that
developed in the last month of pregnancy or during the first month
postpartum, no other identifiable cause for heart failure, and LVEF
Table 1. Baseline Characteristics, Treatment, and 6-Month Results for 20 PPCM Patients
Patient Group
Age,
y
Parity,
n
Symptom Onset
Postpartum, d
Carvedilol
Dose, mg BID
Enalapril
Dose, mg/d
Furosemide
Dose, mg/d
Aldactone
Dose, mg/d
1 PPCM-Std 23 2 25 6.25 10 80 25
4 PPCM-Std 21 2 18 12.5 10 80 25
5 PPCM-Std 22 1 20 6.25 5 80 25
9 PPCM-Std 46 3 21 12.5 10 120 50
10 PPCM-Std 24 2 26 25 10 80 25
12 PPCM-Std 21 1 26 6.25 5 80 0
13 PPCM-Std 24 1 22 25 10 80 25
16 PPCM-Std 44 6 28 12.5 5 80 0
17 PPCM-Std 18 1 12 6.25 5 80 0
20 PPCM-Std 38 3 7 12.5 10 80 25
2 PPCM-Br 22 2 8 6.25 5 80 25
3 PPCM-Br 38 3 14 6.25 5 80 12.5
6 PPCM-Br 24 1 26 12.5 5 80 25
7 PPCM-Br 22 2 7 6.25 5 80 25
8 PPCM-Br 18 2 24 6.25 5 80 25
11 PPCM-Br 24 2 7 6.25 10 120 25
14 PPCM-Br 23 1 4 25 5 80 50
15 PPCM-Br 28 1 30 25 5 80 25
18 PPCM-Br 22 1 2 6.25 5 80 25
19 PPCM-Br 18 1 3 12.5 5 120 0
LVEDD indicates LV end-diastolic diameter; CHF, congestive heart failure; and NR, not reported.
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35% by transthoracic echocardiography. Exclusion criteria were
systolic blood pressure 160 or 95 mm Hg or diastolic
105 mm Hg; clinical conditions other than cardiomyopathy that
could increase plasma levels of inflammatory markers such as sepsis,
autoimmune disease, or HIV positivity; significant liver disease
(defined as liver transaminase levels 2 times the upper limit of
normal); history of peptic ulcer disease; history of psychiatric
disorders; impaired renal function (defined as urea and/or creatinine
1.5 times the upper limit of normal); and any clinical condition
that, according to the investigators, precluded inclusion in the study
such as ischemic heart disease or malignancy.
All patients received treatment with the diuretic furosemide and
the angiotensin-converting enzyme (ACE) inhibitor enalapril.
Patients with an LVEF 25% or LV thrombus received antico-
agulation therapy with warfarin for 6 months. Carvedilol was
added after resolution of overt heart failure. Enalapril and
carvedilol doses were titrated upward as tolerated during the first
4 weeks after diagnosis and then remained unchanged throughout
the remainder of the 6-month study period. Furosemide dose was
decreased as indicated according to clinical assessment during the
6-month study period. The 10 patients randomized to standard
therapy (PPCM-Std group) were treated as outlined above. The 10
patients randomized to standard therapy plus bromocriptine
(PPCM-Br) received bromocriptine 2.5 twice daily for 2 weeks
followed by 2.5 mg daily for 6 weeks in addition to standard heart
failure therapy. After the initial screening and baseline visits,
monthly outpatient visits were scheduled for clinical assessment
and evaluation of medication compliance.
Echocardiography, Cardiac MRI, Assessment of
New York Heart Association Functional Class, and
Noninvasive Blood Pressure Measurements
Patients were diagnosed by specialist physicians and cardiologists
working at the Chris Hani Baragwanath Hospital. Patients were
included in this trial within 24 hours after diagnosis once the
diagnosis was confirmed by a cardiologist (K.S.), who repeated the
echocardiography. Two-dimensional and targeted M-mode echocar-
diography with Doppler color-flow mapping was performed with
either a Hewlett Packard Sonos 5500 (Royal Philips Electronics,
Amsterdam, the Netherlands) or a VIVID i (General Electric
Company, Fairfield, Conn) echocardiography machine. Systolic and
diastolic LV dimensions were measured according to the American
Society of Echocardiography guidelines.18 Measurements of LV
dimensions and function were determined by use of the average of
3 cycles. Mitral effective regurgitant orifice area and Doppler
parameters of diastolic function were measured according to Amer-
ican Society of Echocardiography guidelines.19,20 Echocardiography
was recorded on video or a compact disk and stored within the
Soweto Cardiovascular Research Unit Division for further reference,
audit purposes, and repeat blinded analysis by a single operator.
Cardiac MRI was performed 4 to 6 weeks after diagnosis in
patients receiving bromocriptine to detect possible mural thrombi.
Studies were performed with a 1.5-T MRI scanner (General Electric,
Milwaukee, Wis) with a cardiac-dedicated phased-array coil. The
cardiac MRI studies were ECG triggered by standard software.
Studies consisted of steady-state free precession and spin echo.
Short-axis, transverse, and coronal views were obtained. Steady-state
free-precession sequences were performed to assess regional wall
motion abnormalities and LVEF. Slice thickness was 8 mm with no
gap, 256256 matrix, 400-mm field of view, and 1.61.68-mm
voxel size. The total time required for the investigation was 30 to 45
minutes. Gadolinium enhancement was not studied. Ventricular
parameters were assessed in a standard manner by 1 observer using
commercially available software (CAAS MRV, Pie Medial Imaging,
Maastricht, the Netherlands). The cardiac MRI studies were assessed
by 2 independent experienced observers who determined the pres-
ence or absence of intracavitary thrombi.
New York Heart Association (NYHA) functional class of each
patient at baseline and follow-up visits was evaluated by a physician
who was provided clinical data but was blinded to treatment
allocation and was unaware of the results of the laboratory tests.
Heart rate and systolic and diastolic blood pressures were measured
noninvasively with a Critikon Dinamap Vital Signs Monitor 1846
Table 1. Continued
Prolactin at
Baseline, g/L
Prolactin at
6 mo, g/L
NYHA Class
at Baseline
NYHA Class
at 6 mo
LVEDD at
Baseline, mm
LVEDD at
6 mo, mm
LVEF at
Baseline, %
LVEF at
6 mo, % Prespecified End Point of Poor Outcome
54 60 III III 46 43 33 40 Yes
11 NR II NR 61 NR 28 NR Yes (died 1 mo after baseline of sudden death)
9 NR IV NR 65 NR 18 NR Yes (died 1 mo after baseline of CHF)
16 16 IV III 62 60 24 22 Yes
50 48 II II 60 62 19 24 Yes
50 9 II I 59 52 34 50 No
5 NR II NR 62 NR 34 NR Yes (died 3 mo after baseline of CHF)
233 7 III III 57 43 32 44 Yes
52 NR IV NR 59 NR 14 NR Yes (died on index admission)
30 8 II II 60 74 32 37 No
135 8 IV I 33 44 34 58 No
122 6 II I 65 59 29 37 No
22 7 II I 68 65 30 62 No
56 7 II I 54 51 27 72 No
4 6 II I 56 48 30 56 No
91 25 III I 63 51 30 58 No
55 8 IV I 55 47 33 60 No
18 13 II I 49 34 32 75 No
NR NR III NR 55 NR 18 NR Yes (died on index admission)
5 12 III I 54 56 8 48 No
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and calculated as mean values from 5 readings. Measurements were
made after a 30-minute resting period in patients in the sitting
position with 2-minute intervals between successive measurements.
Research-Specific Blood Tests
Blood (8 mL) was withdrawn from an antecubital vein, collected in
prechilled tubes containing EDTA acid or clot activator, and mixed
rapidly. Plasma or serum was separated by centrifugation at 2500
rpm for 7 minutes within 10 minutes of collection. Aliquots were
stored at 80°C for possible future analysis. High-sensitivity CRP
(hsCRP) was measured as described previously.5,7,8 In addition,
prolactin, NT-proBNP, full blood count, liver function, and creati-
nine were measured. Serum levels of 16-kDa prolactin were mea-
sured by immunoprecipitation followed by Western blotting. Cathep-
sin D activity was assayed with the Sensolyte 520 Cathepsin D Assay
Kit (MoBiTec) as previously described.9
Analysis of Outcome
The prespecified combined end point of poor outcome was defined
as death, NYHA functional class III/IV, or LVEF35% at 6 months
as previously described.8
Assessment of Children
Standard growth monitoring charts issued by the South African
Department of Health and maintained by primary physicians were
obtained for the newborn children of mothers included in this study.
These charts listed the weight of each child at birth and at regular
intervals to 6 months and beyond. Weights were plotted on World
Health Organization weight-for-age Child Growth Standard charts
for girls and boys.21,22
Statistical Analysis
Data were analyzed with the SAS version 9.1 statistical program
(SAS Institute Inc, Cary, NC). Results are expressed as meanSD or
median (range). Comparison between groups at baseline and within
groups (baseline to 6 months) of class variables was analyzed by 2
test or the Fisher exact test when adequate. NT-proBNP data were
log transformed. To assess differences between the 2 treatment
groups, we analyzed mean changes (baseline to 6 months) in all
continuous variables with a t test or an exact Wilcoxon 2-sample test
when distribution was not normal. For within-group comparisons, a
paired t test or a sign test when distribution was not normal was
performed. Significance was assumed at a 2-sided value of P0.05.
Results
Baseline Characteristics and Treatment
Ninety-three patients with suspected PPCM were screened to
recruit 20 consecutive patients with confirmed PPCM who were
HIV negative and presented within 1 month postpartum. As
depicted in Tables 1 and 2, the baseline characteristics of patients
in the PPCM-Br and PPCM-Std groups were similar in terms of
age, parity, NYHA functional class, systolic and diastolic blood
pressures, heart rate, LV end-diastolic and end-systolic dimen-
sions, and LVEF. Median prolactin and median NT-proBNP
levels were comparable, whereas serum levels of 16-kDa pro-
lactin and cathepsin D activity were elevated to a similar degree
in all patients (Figure 1).
Treatment with standard heart failure medications was
similar between the PPCM-Br and PPCM-Std groups (Table
1). Median dose of enalapril in the PPCM-Br group was 5
mg/d (range, 5 to 10 mg/d) and in the PPCM-Std group was
10 mg/d (range, 5 to 10 mg/d). Median dose of carvedilol in
the PPCM-Br group was 6.25 mg twice daily (range, 6.25 to
25 mg) and in the PPCM-Std group was 12.5 mg twice daily
(range, 6.25 to 25 mg). Median dose of furosemide at 6
months was 80 mg/d (range, 80 to 120 mg). All patients,
including those with normalized LV systolic function, con-
tinued on medical therapy with ACE inhibitor and carvedilol
during the 6-month study period. Cardiac transplantation or
implantation of a LV assist device is not performed in state
hospital patients in the Gauteng province of South Africa.
Hemodynamic and Echocardiographic Parameters
Changes in systolic and diastolic blood pressures and heart
rate from baseline to 6 months were not significantly different
between the 2 treatment groups. In contrast, recovery of
LVEF between baseline and 6 months was greater in the
PPCM-Br group (31%) than in the PPCM-Std group (9%;
P0.012; Table 3 and Figure 2). Furthermore, the degree of
mitral regurgitation significantly improved in the PPCM-Br
group compared with the PPCM-Std group (P0.013), as did
several parameters of diastolic function (Table 3). No signif-
icant differences were observed in LV end-diastolic and
end-systolic dimension change from baseline to 6 months
between the 2 groups (Table 3).
NYHA Functional Class
All 9 surviving patients in the PPCM-Br group recovered to
NYHA functional class I at 6 months. In contrast, all patients
Table 2. Baseline Characteristics of PPCM-Br Versus
PPCM-Std Patients
PPCM-Br
(n10)*
PPCM-Std
(n10)* P
Clinical parameters
Age, y 246 2810 0.60
Parity, n (range) 1.5 (1–3) 2 (1–6) 0.52
Systolic blood pressure,
mm Hg
11623 11019 0.50
Diastolic blood pressure,
mm Hg
7016 7618 0.45
Heart rate, bpm 10213 10815 0.34
NYHA functional class, n (%) 1.00
II 5 (50) 5 (50)
III/IV 5 (50) 5 (50)
Echocardiographic parameters
LVEDD, mm 5510 595 0.25
LVESD, mm 469 526 0.16
LVEF, % 27.28.1 26.97.6 0.87
Mitral regurgitation (grade) 2.10.6 1.90.6 0.70
Mitral ERO, cm2 0.450.13 0.440.18 0.90
Laboratory parameters
Hemoglobin, g/dL 13.02.2 11.81.9 0.22
Creatinine, mol/L† 71 (6–109) 66 (5–96) 0.43
hsCRP, mg/L† 7.8 (1.1–58.0) 6.0 (4.0–115.3) 0.86
Prolactin, g/L† 49.9 (3.8–135.0) 30.0 (5.1–233.0) 0.87
Log NT-proBNP 8.541.14 8.451.24 0.88
LVEDD indicates LV end-diastolic diameter; LVESD, LV end-systolic diame-
ter; and ERO, effective regurgitant orifice.
*Values are meanSD unless otherwise specified.
†Values are median (range).
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from the PPCM-Std group who survived 6 months were in
NYHA functional class II (3 patients) or III (3 patients)
(Tables 1 and 4).
Survival
The single patient who died in the PPCM-Br group presented
in severe heart failure and survived only 7 days. All 9
remaining patients in the PPCM-Br group survived 6 months.
Four patients in the PPCM-Std group died during the 6-month
follow-up period: 1 died of heart failure during the index
admission, 2 died of heart failure 4 to 12 weeks after
diagnosis, and 1 experienced sudden cardiac death 1 month
after baseline assessment.
Laboratory Parameters
There was a difference in change of log NT-proBNP levels
from baseline to 6 months of borderline statistical signifi-
cance in the PPCM-Br patients compared with the PPCM-Std
patients (P0.05), whereas the reductions in prolactin and
hsCRP levels at 6 months were similar between the 2 groups
(Table 5).
Figure 1. Analysis of prolactin subforms
and cathepsin D activity in baseline serum
probes from PPCM patients. A, Represen-
tative Western blot showing 16-kDa pro-
lactin immunoprecipitated from serum
probes of PPCM patients and from serum
of a nulliparous (NP) control. Bar graph
depicts 16-kDa prolactin serum levels in
PPCM-Std (Std; n7) and PPCM-Br (Br;
n8) vs the mean value of NP (n3),
which was set at 100% (**P0.01 vs NP).
B, The specificity of the immunoprecipita-
tion (IP) was confirmed with anti-prolactin
antibodies (Prl), nonspecific immunoglobu-
lin G (IgG), and no antibody (neg) in a
PPCM serum probe, followed by detection
of 16-kDa prolactin by Western blot. C,
Bar graph depicting cathepsin D activity in
serum probes from PPCM patients
(PPCM-Std, n8; PPCM-Br, n9) at
baseline and in NP (n7). Mean value of
NP was set at 100% (**P0.01 vs NP).
Table 3. Comparison of Hemodynamic and Echocardiographic Parameters in PPCM-Br and PPCM-Std Patients at Baseline and 6 Months
PPCM-Br Baseline
(n10)*
PPCM-Br 6 Months
(n9)*
PPCM-Std Baseline
(n10)*
PPCM-Std 6 Months
(n6)* P†
Clinical parameters
Systolic blood pressure, mm Hg 11623 11813 11019 1159 0.78
Diastolic blood pressure, mm Hg 7016 749 7618 736 0.77
Heart rate, bpm 10213 647 10815 7915 0.22
Echocardiographic parameters
LVEDD, mm 5510 519 595 5612 0.50
LVESD, mm 469 3410 526 4511 0.18
LVEF, % 278 5811 278 3611 0.0007
Mitral regurgitation (grade) 2.10.6 0.220.44 1.90.6 1.51.0 0.0042
Mitral ERO, cm2 0.450.13 0.110.03 0.440.18 0.340.18 0.02
Left atrial diameter, cm 3.540.25 3.360.53 3.830.62 3.930.83 0.25
Mitral E velocity, cm/s 8619 6624 8923 8524 0.53
Mitral A velocity, cm/s 327 4819 336 4512 0.80
Mitral E velocity/A velocity ratio 2.820.76 1.631.13 2.730.68 1.940.67 0.82
Deceleration time, ms 11826 19759 13630 16836 0.08
Mitral medial annular (E) TDI velocity, cm/s 7.01.3 12.42.4 6.51.1 7.32.5 0.014
E/E (medial annular velocity) 12.53.0 5.42.5 14.04.6 12.44.6 0.08
Mitral lateral annular (E) TDI velocity, cm/s 7.21.1 12.42.5 6.60.97 7.32.5 0.007
E/E (lateral annular velocity) 12.02.0 5.42.5 13.84.2 12.13.9 0.051
Abbreviations as in Table 2, plus TDI indicates tissue Doppler imaging.
*Values are meanSD.
†Comparing the change from baseline to 6 months in PPCM-Br and PPCM-Std patients.
Sliwa et al Bromocriptine in Peripartum Cardiomyopathy 1469
 at University of Cape Town Libraries on November 15, 2012http://circ.ahajournals.org/Downloaded from 
Combined Measure of Poor Outcome
The combined measure of poor outcome that included LVEF
35% (surviving PPCM-Br, 0 of 9 [0%] versus surviving
PPCM-Std, 2 of 6 [33%]), NYHA functional class III/IV at 6
months (surviving PPCM-Br, 0 of 0 [0%] versus surviving
PPCM-Std, 3 of 6 [50%]), or death within 6 months (PPCM-
Br, 1 of 10 [10%] versus PPCM-Std, 4 of 10 [40%]) revealed
that the PPCM-Br patients had better outcome than the
PPCM-Std patients (P0.006; Figure 3).
Thrombi and Thromboembolism
No adverse effects, including thromboembolism, were re-
ported in either group. Cardiac MRI was performed at 4 to 6
weeks after diagnosis in 8 of the 10 patients in the PPCM-Br
group to assess for thrombus formation. MRI results were not
available for 1 patient who died before becoming stable
enough for the MRI, and the images acquired for a second
patient were not of sufficient quality for reliable assessment.
None of the remaining patients had intracavitary thrombi
(Figure 4).
Infant Growth Curves and Survival
All 21 children of the PPCM-Br and PPCM-Std patients
showed normal growth curves when plotted on the World
Health Organization standard weight-for-age growth charts
(Figure 5A and B). Although the survival of all 21 children
through the 6-month follow-up period was verified, weight-
for-age data at 6 months were available for only 13 children.
The mothers of 5 children died during the course of the study
and family members could not provide the children’s growth
charts, and the growth charts of the 3 other children with
missing data were incomplete because of challenges in the
delivery of quality care in the primary healthcare system in
South Africa. However, all children had weight data up to the
age of 3 months, and there were no significant differences in
growth curves between the children of the PPCM-Br patients
and those of the PPCM-Std patients.
Discussion
This prospective, single-center, randomized, open-label pilot
study with blinded efficacy assessments showed that the
addition of bromocriptine to standard heart failure therapy in
women with PPCM appeared to result in significantly greater
improvements in NYHA functional class, LV systolic and
diastolic function, and degree of functional mitral regurgita-
tion than seen with standard therapy alone. Bromocriptine
seemed to be well tolerated, and no thrombotic complications
were observed. Moreover, although bromocriptine stopped
lactation and breast-feeding in the PPCM patients, the growth
and survival of those infants were normal. However, our
study was very small, and these findings are in no way
definitive. On the other hand, these findings are encouraging
and suggest that a larger study should be considered.
This proof-of-concept pilot study was performed in a group
of homogeneous patients in terms of ethnic background, age,
time point of diagnosis, and baseline characteristics. Unfor-
tunately, blinding of the study was not possible because the
PPCM-Std group continued to nurse their infants while the
PPCM-Br group could not breast-feed because of
bromocriptine-induced cessation of lactation. However, in-
vestigators were blinded for data analysis. We believe that the
homogeneous patient cohort, well-balanced baseline charac-
teristics, and blinded assessment of outcomes to some extent
compensate for the small size of our study and its open-label
design.
The design of the present study was chosen on the basis of
our hypothesis that a cleaved form of the hormone prolactin
initiates and drives PPCM and that early pharmacological
blockade of prolactin with bromocriptine may improve the
condition of patients with acute onset of PPCM before
irreversible damage caused by cell death, fibrosis, and remod-
eling. Increased serum levels of 16-kDa prolactin and aug-
mented cathepsin D activity at baseline in PPCM patients
included in the present study support this hypothesis. The
rationale for the dose and length of bromocriptine therapy
was based on previous observations in animal models and a
previous pilot study,11 as well as several case reports in
patients with PPCM.12,23,24 We believe that some of the
apparently beneficial effects of bromocriptine result from
eliminating the detrimental 16-kDa prolactin form, the harm-
ful effects of which on the heart and the vasculature have
been described experimentally.11,24 In addition, both forms of
prolactin promote inflammation,24 a reaction that seems to be
associated with PPCM in this African cohort, because most
patients displayed increased serum levels of the inflammatory
marker hsCRP.5
Figure 2. Change in LVEF from baseline to 6 months among
survivors. Stars represent baseline LVEF for patients who died
during the study period.
Table 4. Comparison of NYHA Functional Class in PPCM-Br
and PPCM-Std Patients at Baseline and 6 Months
PPCM-Br
at Baseline
(n10),
n (%)
PPCM-Br
at 6 mo
(n9),
n (%)
PPCM-Std
at Baseline
(n10),
n (%)
PPCM-Std
at 6 mo
(n6),
n (%) P*
NYHA functional
class
0.008
I 0 9 (100) 0 0
II 5 (50) 5 (50) 3 (50)
III/IV 5 (50) 5 (50) 3 (50)
*Comparing the change from baseline to 6 months in PPCM-Br and
PPCM-Std patients.
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Apart from its prolactin blocking role, bromocriptine may
exert additional “off-target effects” in PPCM patients. For
example, effects of bromocriptine on hemodynamic parame-
ters in patients with heart failure were described 30 years
ago25 before treatment with ACE inhibitors and -blockers
was routine. Positive effects of bromocriptine on blood
pressure, vascular resistance, and plasma norepinephrine
levels have been described.25 Moreover, bromocriptine has
been shown to increase stroke volume index and to decrease
LV filling pressure.25,26 Whether these potential beneficial
effects of bromocriptine on hemodynamic parameters play a
role in contemporary patients with heart failure who are
treated with ACE inhibitors and -blockers remains to be
elucidated.
Bromocriptine may also affect metabolic parameters. We
observed that PPCM patients display increased oxidized
low-density lipoprotein serum levels compared with healthy
postpartum women,9 suggesting impaired antioxidative de-
fense mechanisms and potential metabolic perturbations. In
turn, Wexler and McMurtry 27 reported that, experimentally,
bromocriptine treatment reduced triglyceride, free fatty acid,
total cholesterol, and glucose levels in isoproterenol-induced
heart failure. Whether such parameters play a role in the
pathophysiology of PPCM is currently under investigation in
experimental models.
In addition, bromocriptine has been shown to inhibit
oxidative stress–induced cell death in neuronal cells by
dopamine D2 receptor–dependent transactivation of c-Src/
endothelial growth factor receptor and downstream PI3K-Akt
signaling, which results in upregulation of antiapoptotic
Bcl-2.28 Preliminary data show that bromocriptine treatment
increases Akt activation and upregulates Bcl-2 expression in
the heart of postpartum mice (D.H.-K., unpublished data,
2010), suggesting that bromocriptine may indeed have direct
cardioprotective effects. Taken together, these data show that
off-target effects of bromocriptine on metabolism, oxidative
stress, and cytoprotection may act in concert with its
prolactin-lowering capacity and may help to explain the
positive effects of prolonged treatment with bromocriptine
beyond an effective prolactin blockade.
We found that the overall mortality rate in the PPCM-Std
group was high. Other studies have demonstrated a lower
PPCM mortality rate (averaging 15%), including our own
series of 100 patients1,5,8 and the prospective long-term study
by Fett et al.4 One explanation for the differences in mortality
rate between the present study and our other series of 100
patients might be the inclusion criteria. In the present study,
patients were enrolled very early (within 24 hours after
diagnosis). This timely enrollment was not possible for the
previous cohort of 100 patients. As a consequence, some
patients in that study died between diagnosis and enrollment.
In addition, our previous study included patients diagnosed
Figure 3. Comparison of 6-month prespecified poor outcome,
including death, NYHA functional class (FC) III/IV, and LVEF
35% among survivors, and the combined end point includ-
ing all 3 of these end points for PPCM-Br vs PPCM-Std
patients (Pt).
Figure 4. Cardiac MRI (transverse view, steady-state free-
precession sequence) in a young African woman 2 months after
delivery demonstrates marked dilation of both ventricles and the
right atrium. LVEF is 8%.
Table 5. Comparison of Laboratory Parameters in PPCM-Br and PPCM-Std Patients at Baseline and 6 Months
PPCM-Br at Baseline
(n10)
PPCM-Br at 6 mo
(n9)
PPCM-Std at Baseline
(n10)
PPCM-Std at 6 mo
(n6) P†
Hemoglobin, g/dL† 13.02.2 12.71.5 11.81.9 13.01.4 0.58
Creatinine, mol/L‡ 71 (6–109) 78 (52–113) 66 (5–96) 62 (41–73) 0.86
hsCRP, mg/L‡ 7.8 (1.1–58.0) 4.7 (1.0–10) 6.0 (4.0–115.3) 1.8 (1.1–15.1) 0.18
Prolactin, g/L‡ 49.9 (3.8–135.0) 8.0 (5.9–25.0) 30.0 (5.1–233.0) 12.5 (7.4–60.0) 0.72
Log NT-proBNP† 8.541.14 5.620.80 8.451.24 6.640.60 0.056
*Comparing the change from baseline to 6 months in PPCM-Br and PPCM-Std patients.
†Values are mean1SD.
‡Values are median (range).
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between 4 weeks and 5 months postpartum. The development
of symptoms 4 weeks postpartum may be a manifestation
of milder forms of this disease.
In this study, the cause of death in the PPCM-Std group
was either heart failure or sudden cardiac death, with all
deaths occurring within 3 months of randomization. In
contrast, the 1 patient who died in the PPCM-Br group was
admitted with severe heart failure and died 7 days after
diagnosis while still in the intensive care unit.
The safety of bromocriptine treatment during pregnancy
has already been assessed by a survey of 1400 pregnant
women who took bromocriptine primarily in the first few
weeks of pregnancy and found no increased rates of abortion
or congenital malformations.29 In the postpartum phase,
bromocriptine has been used worldwide since 1980 to sup-
press lactation. However, concerns have been raised about a
potential risk for cerebral and cardiovascular complications,
as emphasized in some case reports describing stroke,13
seizure,15 coronary artery thrombosis,15 and coronary artery
vasospasm.14 Although these data were observational, bro-
mocriptine was withdrawn from the market in the United
States in 1994 for use as an agent to block lactation.
It is known that the postpartum period is associated with an
increased risk of thrombosis and myocardial infarction, prob-
ably because of changes in coagulation that may have
evolved as a protection from bleeding caused by miscarriage
and childbirth.30 We observed no adverse effects in any of the
9 surviving patients in the PPCM-Br group. However, the
number of patients studied was small, and because of poor
cardiac function, all patients in the present study received
subcutaneous low-molecular-weight heparin during their in-
dex admission. Therefore, although the data suggesting that
bromocriptine has a prothrombotic effect are not robust, we
cannot rule out such an effect.
There has been some concern that PPCM patients in
developing countries treated with bromocriptine will no
longer be able to breast-feed, which may increase the risk for
malnutrition and infection in their infants.17 The survival rate
of infants of the PPCM-Br patients was not affected, and no
serious illnesses were reported, although the number of
children we studied was very small. Normal weight gain from
birth to 3 months was observed in all infants and continued to
be normal during the 6-month follow-up period in those for
whom data were available. Although this was a small study
with only short-term follow-up, our results suggest no disad-
vantage to the infant of a PPCM patient who could not
breast-feed because of bromocriptine treatment. However, we
are aware that larger studies in Soweto and other developing
areas in the world are needed to support this statement.
Conclusions
In this trial, the addition of bromocriptine to standard heart
failure therapy appeared to improve LVEF and a composite
clinical outcome in women, although the number of patients
studied was small and the results cannot be considered
definitive. Larger-scale multicenter and blinded studies are in
progress to test this strategy more robustly.
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CLINICAL PERSPECTIVE
Peripartum cardiomyopathy (PPCM) is a potentially life-threatening heart disease that occurs in previously healthy women. We
identified prolactin, mainly its 16-kDa angiostatic and proapoptotic form, as a key factor in PPCM pathophysiology. Blockade
of prolactin with the dopamine-2D agonist bromocriptine had previously been shown to prevent the onset of PPCM in mice and
in women at high risk of this condition because of documented PPCM in a previous pregnancy. We recruited 20 women with
onset of severe acute PPCM during the first month postpartum within 24 hours of diagnosis and randomized them into 2 groups:
standard care (PPCM-Std; n10) or standard care plus bromocriptine for 8 weeks (PPCM-Br, n10). PPCM-Br patients
displayed greater recovery of left ventricular ejection fraction compared with PPCM-Std patients at 6 months. Four PPCM-Std
patients died; only 1 PPCM-Br patient did not survive. Significantly fewer PPCM-Br patients met the composite end point of
poor outcome defined as death, New York Heart Association functional class III/IV, or left ventricular ejection fraction 35%
at 6 months. Because the PPCM-Br mothers could not breast-feed, the outcome of their children was assessed. Infants of mothers
in both groups showed normal growth and survival at 6 months. Our findings suggest that the addition of bromocriptine to
standard heart failure therapy appears to improve left ventricular ejection fraction, functional class, and survival in women with
severe acute PPCM with no obvious detriment to their children.
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Correction
In the article, “Evaluation of Bromocriptine in the Treatment of Acute Severe Peripartum
Cardiomyopathy: A Proof-of-Concept Pilot Study” by Sliwa et al, which appeared in the April 6,
2010 issue of the journal (Circulation. 2010;121:1465–1473), there was a misspelling of one
author’s name. Ingrid Struhman should be spelled Ingrid Struman.
The online version of the article has been corrected. The authors regret the error.
DOI: 10.1161/CIR.0b013e3181e3a433
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ABSTRACT
Objective Identify novel prognostic factors for patients
with peripartum cardiomyopathy (PPCM).
Design and setting Prospective cohort study
conducted in a single tertiary care centre in South Africa.
Patients 176 African women with newly diagnosed
PPCM were studied.
Interventions Clinical assessment, echocardiography
and laboratory results were obtained at baseline and at
6 months.
Main outcome measures Poor outcome was defined
as the combined end point of death, left ventricular (LV)
ejection fraction (LVEF) < 35%, or remaining in New York
Heart Association (NYHA) functional class III/IV at
6 months. Complete LV recovery was defined as LVEF
≥55% at 6 months.
Results Forty-five (26%) patients had a poor outcome.
Multiple logistic regression analysis revealed that, after
adjustment for age, NYHA functional class, LVEF and
systolic blood pressure, increased left ventricular end
systolic dimension (LVESD), lower body mass index (BMI)
and lower total cholesterol at baseline were independent
predictors of poor outcome (adjusted OR 1.09, 95% CI
1.04 to 1.15, p=0.001; OR 0.89, 95% CI 0.83 to 0.96,
p=0.004, and OR 0.50, 95% CI 0.34 to 0.73, p=0.0004,
respectively). Thirty (21%) of the 141 surviving patients
with echocardiographic follow-up recovered LV function at
6 months. Multiple logistic regression analysis revealed
that, after adjustment for NYHA functional class, LVEF
and left ventricular end diastolic dimension, older age and
smaller LVESD at baseline were predictors of LV recovery
(OR 1.08, 95% CI 1.01 to 1.17, p=0.02 and OR 0.92,
95% CI 0.86 to 0.98, p=0.007, respectively).
Conclusions This study suggests that increased LVESD,
lower BMI and lower serum cholesterol at baseline may
be independent predictors of poor outcome in patients
with PPCM, while older age and smaller LVESD at
baseline appear to be independently associated with a
higher chance of LV recovery.
INTRODUCTION
Peripartum cardiomyopathy (PPCM) is a poten-
tially life-threatening disease that occurs in
women of child-bearing age. This disease is charac-
terised by new onset of heart failure between
several months before and 6 months after delivery
in previously healthy women. Although patients
with PPCM have a higher rate of spontaneous
recovery of left ventricular (LV) function than
patients with other forms of non-ischaemic cardio-
myopathy,1 normalisation of LV function at
6 months has been reported to occur in only
23–54% of them.1–5
Factors predicting poor outcome in case series
include degree of LV systolic dysfunction2 3 6 7 and
LV dilatation2 8 9 on presentation, as well as LV
thrombus.8 Identifying additional prognostic factors,
particularly factors that may be easily and relatively
inexpensively assessed, would be beneficial in provid-
ing optimal care for patients with PPCM.
Body mass index (BMI) has been shown to be a
predictor of outcome in patients with chronic heart
failure,10–13 as well as acute decompensated heart
failure,14 but this association has not previously
been assessed in patients with PPCM. Renal and
liver dysfunction have also both been shown to
predict poor outcome in patients with heart failure,
but, again, this association has not previously been
investigated in patients with PPCM. Inflammation
has been implicated in the pathogenesis and
prognosis of PPCM,5 15 and, while it has been
shown that lipoproteins play a role in regulating
cytokine production and the associated inflamma-
tory response,16 an association between cholesterol
and outcome in patients with PPCM has not previ-
ously been reported. We sought to determine
whether these variables, among others, may be pre-
dictors of outcome in patients with PPCM.
METHODS
Study design and patient recruitment
The study was conducted at Chris Hani
Baragwanath (CHB) Hospital, Soweto, South Africa.
Patients were referred from local clinics, secondary
hospitals and the Department of Obstetrics at CHB
Hospital. History of pre-existing cardiac signs or
symptoms, pre-eclampsia or eclampsia and mode of
delivery were obtained from the patient and con-
firmed by examining the obstetric card carried by
each patient. Signs and symptoms were recorded
during first presentation at the cardiac unit at CHB
Hospital (baseline) and after a follow-up period of
6 months. Clinical assessment, echocardiography and
blood analysis were performed at baseline and at
6 months.
Inclusion criteria were: (1) age ≥16 and ≤40 years;
(2) symptoms of congestive heart failure that devel-
oped in the last month of pregnancy or during the
first 5 months post partum; (3) no other identifiable
cause of heart failure; (4) LV ejection fraction (LVEF)
≤45% by transthoracic echocardiography; and
(5) sinus rhythm. Exclusion criteria were: (1) signifi-
cant organic valvular heart disease; (2) systolic blood
pressure >160 mmHg or diastolic blood pressure
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>100 mmHg; (3) clinical conditions other than cardiomyopathy
that could increase plasma levels of inflammatory markers;
(4) severe anaemia (haemoglobin <9 g/dl); and (5) any clinical
condition that, according to the investigators, precluded inclusion
in the study, such as ischaemic heart disease or malignancy.
Among the 176 patients included in the study, 164 (93%)
received treatment with furosemide and 141 (80%) were treated
with an ACE inhibitor. Digoxin was being taken by 113 (64%)
of the 176 patients. Patients with an LVEF < 25% or LV throm-
bus were treated with warfarin. Carvedilol was initiated in 100
(57%) of the 176 patients after resolution of overt heart failure.
ACE inhibitor and carvedilol doses were titrated upward as
tolerated throughout the 6-month study period. Furosemide
dose was titrated upward or downward as indicated according
to clinical assessment. This study was approved by the Human
Research Ethics Committee of the University of the
Witwatersrand, Johannesburg, South Africa and complies with
the Declaration of Helsinki. All study participants gave written
informed consent before study entry. A total of 176 consenting
consecutive patients diagnosed with PPCM and fulfilling the
inclusion criteria were enrolled in the study. All women were of
African descent.
Echocardiography, assessment of New York Heart Association
(NYHA) functional class, and non-invasive blood pressure
measurements
Two-dimensional and targeted M-mode echocardiography with
Doppler colour flow mapping were performed using either a
Hewlett Packard Sonos 5500 (Royal Philips Electronics,
Amsterdam, Netherlands) or a VIVID i (General Electric
Company, Fairfield, Connecticut, USA) echocardiography
machine. Systolic and diastolic LV dimensions were measured
according to the American Society of Echocardiography (ASE)
guidelines. LV dimensions and function were determined using the
mean of three or more cycles. Echocardiography was taped on
video or CD and stored within the Soweto Cardiovascular
Research Unit Division for further reference and audit purposes.
NYHA functional class of each patient at baseline and
follow-up visits was evaluated by a physician, who was pro-
vided with clinical data but blinded to the protocol and
unaware of the results of the laboratory tests. Blood pressure
and heart rate were measured non-invasively with a Critikon
Dinamap vital signs monitor 1846 and calculated as mean
values from five readings. Measurements were made after a
30 min resting period in the sitting position with 2 min inter-
vals between successive measurements.
Research-specific blood tests
Between 10 am and 12 noon, 8 ml blood was withdrawn from
an antecubital vein and collected in prechilled tubes containing
ethylenediaminetetra-acetic acid or clot activator and mixed
rapidly. Plasma or serum was separated by centrifugation at
2500 rpm for 7 min within 10 min of collection. Aliquots were
stored at −80°C. Full blood count, liver function, renal function
and total cholesterol were assessed.
Outcomes
Poor outcome was defined as the combined end point of death,
LVEF <35%, or remaining in NYHA functional class III/IV at
6 months. Complete LV recovery was defined as LVEF ≥55% at
6 months.
Statistical analysis
Database management and statistical analyses were performed
with SAS V.9.2 software. Continuous data are expressed as
mean±SD or median (range). Comparison of means and pro-
portions between groups at baseline was performed by inde-
pendent t test and χ2 statistics or Fisher exact test, respectively.
A Wilcoxon rank-sum test was used where data were not nor-
mally distributed. Differences in class variables and continuous
data between baseline and 6 months were assessed by a
McNemar test and a paired t test or sign test (data not nor-
mally distributed), respectively.
Univariate and stepwise multiple logistic regression analyses
were performed to establish independent predictors of poor
outcome and LV recovery with cholesterol, blood pressure and
echocardiographic variables in separate models after adjustment
for age and BMI. Univariate logistic regression was used to
examine associations with death. Significance was assumed at a
two-sided p value of <0.05.
RESULTS
Baseline characteristics
Baseline clinical characteristics are listed in table 1. Notably,
the mean age was 30.7±6.9 years, mean parity was 2 (range
1–7), mean BMI was 25.6±5.2 kg/m2, and most of the women
(82%) presented with NYHA functional class III or IV
symptoms.
Table 1 Baseline characteristics of study population (n=176)
Clinical characteristic Value
Age (years) 30.7±6.9
Parity, n (range) 2 (1–7)
BMI (kg/cm2) 25.6±5.2
Systolic blood pressure (mm Hg) 111±17
Diastolic blood pressure (mm Hg) 72±13
Heart rate (beats/min) 97.3±19.1
NYHA functional class, n (%)
I/II 33 (18)
III/IV 143 (82)
Echocardiography
LVEDD (mm) 59.5±7.3
LVESD (mm) 51.8±7.6
Ejection fraction (%) 27.1±8.1
E velocity (m/s) 0.89±0.25
A velocity (m/s) 0.49±0.20
E/A 2.02±0.89
Deceleration time (ms) 134.5±63.2
LV thrombus, n (%) 19 (11.1)
Laboratory
Haemoglobin (g/dl) 12.1±1.8
Creatinine (mmol/l) 84.1±20.5
Urea (mmol/l) 5.4±2.9
Total protein (g/l) 77.9±11.4
Albumin (g/l) 40.1±18.5
Total bilirubin (μmol/l) 17.3±26.8
Direct bilirubin (μmol/l) 9.2±23.2
Indirect bilirubin (μmol/l) 8.2±7.3
Alkaline phosphatase (U/l) 117.9±51.0
AST (U/l) 45.0±46.8
ALT (U/l) 54.7±67.1
GGT (U/l) 72.4±49.4
Total cholesterol (mmol/l) 4.0±1.1
Values are mean±SD unless otherwise specified.
ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; GGT,
γ-glutamyl transpeptidase; LV, left ventricular; LVEDD, LV end diastolic diameter; LVESD,
LV end systolic diameter; NYHA, New York Heart Association.
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Baseline versus 6-month characteristics among survivors
Table 2 lists the characteristics of the survivors among the
study population at baseline and 6 months. Mean LV end
systolic dimension (LVESD) decreased significantly from
51.3±7.6 mm to 42.3±9.5 mm (p<0.0001), while mean LV
ejection fraction (LVEF) increased significantly from 27.3±8.1%
to 43.3±12.5% (p<0.0001). Mitral inflow E/A decreased
significantly from 2.01±0.86 to 1.51±0.65, and mitral inflow
deceleration time increased significantly from 140.0±66.1 ms to
185±67.9 ms (p<0.0001 for both). Haemoglobin, renal func-
tion and liver function test results had all improved at
6 months. Total cholesterol results were not obtained in most
of the study population at 6 months; hence these results were
not tabulated.
Combined measure of poor outcome
During the 6-month study period, nine patients were lost to
follow-up, three patients moved to remote areas where
follow-up could not occur, and two patients did not undergo
LVEF assessment at 6 months. Of the remaining 162 patients,
45 (28%) met the prespecified combined end point of death
(21 patients, 13%), remaining in NYHA functional class III or IV
(13 patients, 9%) or LVEF <35% at 6 months (40 patients, 25%).
Predictors of poor outcome
Univariate analysis revealed that predictors of the prespecified
poor outcome include decreased systolic blood pressure,
increased LVESD, decreased LVEF, increased mitral inflow E/A,
decreased mitral inflow deceleration time, increased aspartate
transaminase and alanine transaminase, and decreased total
cholesterol (table 3).
Predictors of LV recovery
Thirty (21%) of the 141 surviving patients had fully recovered
LV function (LVEF ≥55%) at 6 months. Baseline characteristics
of patients who fully recovered versus patients who did not are
listed in table 4. Univariate analysis revealed that predictors of
LV recovery included older age, decreased LV end diastolic
dimension (LVEDD), decreased LVESD, higher haemoglobin
and lower creatinine (table 5). Stepwise multiple logistic regres-
sion analysis showed that, after adjustment for NYHA func-
tional class, medication, LVEF and LVEDD, older age and
smaller LVESD were predictors of LV recovery (adjusted OR
1.08, 95% CI 1.01 to 1.17, p=0.02 and OR 0.92, 95% CI 0.86 to
0.98, p=0.007, respectively).
Predictors of death
Univariate analysis showed that predictors of death included
younger age (OR 0.93, 95% CI 0.87 to 1.00, p=0.04), lower
Table 2 Clinical, echocardiography and laboratory variables at
baseline and 6 months among survivors (n=141)
Variable Baseline* 6 months* p Value
Clinical
Systolic blood pressure (mm Hg) 111±17 113±17 0.18
Diastolic blood pressure (mm Hg) 72±13 72±12 0.65
NYHA functional class, n (%)
I/II 30 (21) 128 (91) <0.001
III/IV 111 (79) 13 (9)
Echocardiography
LVEDD (mm) 58.9±7.3 54.0±8.6 <0.0001
LVESD (mm) 51.3±7.6 42.3±9.5 <0.0001
Ejection fraction (%) 27.3±8.1 43.3±12.5 <0.0001
E velocity (m/s) 0.91±0.26 0.80±0.22 <0.0001
A velocity (m/s) 0.49±0.20 0.57±0.18 0.0002
E/A 2.01±0.86 1.51±0.65 <0.0001
Deceleration time (ms) 140.0±66.1 185.1±67.9 <0.0001
LV thrombus, n (%) 17 (12) 0 <0.0001
Laboratory
Haemoglobin (g/d) 12.2±1.77 12.8±1.52 0.0004
Creatinine (mmol/l) 84.8±19.8 76.4±23.5 <0.0001
Urea (mmol/l) 5.2±2.5 4.4±1.6 0.002
Total protein (g/l) 77.8±11.5 82.2±8.9 0.003
Albumin (g/l) 40.4±19.8 43.7±13.5 <0.0001
Total bilirubin (μmol/l) 15.1±18.6 11.0±8.6 0.006
Direct bilirubin (μmol/l) 7.3±13.7 4.5±4.9 0.02
Indirect bilirubin (μmol/l) 8.0±7.3 6.1±4.4 0.002
Alkaline phosphatase (U/l) 118.2±51.5 97.4±36.4 <0.0001
AST (U/l) 42.0±33.5 26.4±12.9 <0.0001
ALT (U/l) 52.9±56.6 24.5±14.0 <0.0001
GGT (U/l) 74.6±50.3 52.8±40.8 <0.0001
Total cholesterol (mmol/l) 4.0±1.1 NR NR
*Values are mean±SD unless otherwise specified.
ALT, alanine transaminase; AST, aspartate transaminase; GGT, γ-glutamyl transpeptidase;
LV, left ventricular; LVEDD, LV end diastolic diameter; LVESD, LV end systolic diameter;
NYHA, New York Heart Association; NR, not reported.
Table 3 Univariate logistic regression analysis of predictors of poor
outcome (n=162)
Predictor Unadjusted OR 95% CI p Value
Clinical characteristic
Age (years) 1.02 0.95 to 1.07 0.52
Parity (number) 0.89 0.65 to 1.13 0.38
BMI (kg/cm2) 0.95 0.89 to 1.02 0.17
Systolic blood pressure (mm Hg) 0.97 0.95 to 0.99 0.02
Heart rate (beats/min) 1.01 0.99 to 1.03 0.16
NYHA functional class 1.43 0.85 to 2.43 0.18
Medication
Carvedilol (yes, no) 0.67 0.31 to 1.45 0.31
ACE inhibitors (yes, no) 0.71 0.38 to 1.34 0.29
Furosemide (yes, no) 0.81 0.24 to 2.78 0.74
Digoxin (yes, no) 1.31 0.68 to 2.52 0.42
Echocardiography
LVEDD (mm) 1.05 1.00 to 1.11 0.052
LVESD (mm) 1.07 1.02 to 1.12 0.009
Ejection fraction (%) 0.95 0.91 to 0.99 0.019
E/A 2.09 1.29 to 3.39 0.003
Deceleration time (ms) 0.99 0.99 to 1.01 0.09
LV thrombus 0.97 0.37 to 2.53 0.95
Laboratory
Haemoglobin (g/dl) 0.86 0.12 to 1.05 0.15
Creatinine (mmol/l) 1.01 0.99 to 1.03 0.35
Urea (mmol/l) 1.09 0.95 to 1.25 0.22
Total protein (g/l) 0.99 0.96 to 1.02 0.37
Albumin (g/l) 0.99 0.96 to 1.02 0.35
Total bilirubin (μmol/l) 1.01 0.99 to 1.03 0.29
Direct bilirubin (μmol/l) 1.01 0.99 to 1.04 0.37
Indirect bilirubin (μmol/l) 1.03 0.99 to 1.08 0.30
Alkaline phosphatase (U/l) 0.99 0.99 to 1.00 0.28
AST (U/l) 1.01 1.00 to 1.02 0.033
ALT (U/l) 1.01 1.00 to 1.02 0.03
GGT (U/l) 1.00 0.99 to 1.01 0.73
Total cholesterol (mmol/l) 0.53 0.36 to 0.77 0.001
Stepwise multiple logistic regression analysis revealed that, after adjustment for variables
including age, systolic blood pressure, medications, LVEF and NYHA functional class,
increased LVESD, lower BMI and lower total cholesterol at baseline were independent
predictors of the prespecified poor outcome (adjusted OR 1.09, 95% CI 1.04 to 1.15,
p=0.001; OR 0.89, 95% CI 0.83 to 0.96, p=0.004; and OR 0.50, 95% CI 0.34 to 0.73,
p=0.0004, respectively).
ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; GGT,
γ-glutamyl transpeptidase; LV, left ventricular; LVEDD, LV end diastolic diameter; LVESD,
LV end systolic diameter; NYHA, New York Heart Association.
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BMI (OR 0.83, 95% CI 0.72 to 0.95, p=0.007), increased
LVEDD (OR 1.08, 95% CI 1.01 to 1.15, p=0.02), increased
LVESD (OR 1.07, 95% CI 1.01 to 1.14, p=0.02), and higher
NYHA functional class (OR 2.35, 95% CI 1.12 to 4.94,
p=0.02). The mean age of the patients who died (n=21)
was 27.8±8.6 years, while the mean age of the patients
who survived but were not lost to follow-up (n=141) was
31.0±6.6 years. The mean BMI of the patients who died was
22.6±3.3 kg/m2, while the mean BMI of the patients who sur-
vived but were not lost to follow-up was 25.9±5.5 kg/m2.
DISCUSSION
This prospective single-centre study of 176 newly diagnosed
patients with PPCM summarises data on clinical, echocardio-
graphic and laboratory characteristics at the time of diagnosis
and after 6 months of standard clinical care. We confirmed pre-
vious findings in our collective5 that a relatively high percent-
age of patients (79%) had failed to normalise LV function at
6 months compared with collectives from the USA.3 8
Increased LVESD, lower BMI and lower total cholesterol were
identified as potential novel predictors of poor outcome on
stepwise multivariate logistic regression analysis. Older age
appears to be a novel predictor of LV recovery, while younger
age, lower BMI, increased LVEDD, increased LVESD and higher
NYHA functional class all seem to be predictors of mortality.
Numerous factors predicting morbidity and mortality in
patients with PPCM have previously been proposed but not
validated. These factors include degree of decreased LVEF and
LV dilatation at diagnosis,2 7 8 17 18 presence of LV thrombus,8
and being of African descent.8 19 Previous studies performed at
our own institution have shown that NYHA functional class,5
N-terminal prohormone of brain natriuretic peptide,20 and
increased plasma markers of inflammation and apoptosis5 20 at
diagnosis are predictors of poor outcome as well.
The present analysis, using a much larger sample size than
in most previous analyses, reveals different findings with regard
to some predictors of morbidity and mortality, but confirms
other findings. As previously reported,2 increased LVESD at
diagnosis was a significant predictor even when adjusted for
other variables in multivariate analysis. In contrast with previ-
ous reports, LVEF and LVEDD at diagnosis,2 3 6 8 9 NYHA func-
tional class5 and presence of LV thrombus8 were not predictors
of poor outcome. A novel finding in the present study was that
lower BMI and lower total cholesterol at baseline were both
associated with poor outcome.
Previous studies have shown that increased BMI is associated
with decreased all-cause mortality in patients with chronic
Table 4 Baseline characteristics for patients with complete recovery
of LVEF versus patients with non-recovery of LVEF (n=141)
Characteristic
Recovered
LVEF (n=30)*
Non-recovered
LVEF (n=111)* p Value
Clinical
Age (years) 33.2±5.9 30.4±6.6 0.035
Parity, n (range) 3 (1–4) 2 (1–7) 0.053
BMI (kg/cm2) 26.5±6.0 25.8±5.4 0.66
Systolic blood pressure (mm Hg) 117±17 110±17 0.08
Diastolic blood pressure (mm Hg) 75±13 72±12 0.17
NYHA functional class, n (%)
I/II 29 (97) 98 (89) 0.054
III/IV 2 (3) 12 (11)
Echocardiography
LVEDD (mm) 56.2±6.5 59.6±7.4 0.07
LVESD (mm) 48.1±6.3 52.2±7.8 0.026
Ejection fraction (%) 28.7±8.4 26.9±8.0 0.22
E velocity (m/s) 0.88±0.28 0.91±0.25 0.77
A velocity (m/s) 0.52±0.17 0.49±0.21 0.13
E/A 1.73±0.69 2.10±0.89 0.03
Deceleration time (ms) 141.5±59.2 139.7±68.0 0.74
LV thrombus, n (%) 6 (20) 11 (10) 0.20
Laboratory
Haemoglobin (g/dl) 12.8±1.8 12.0±1.8 0.035
Creatinine (mmol/l) 73.8±19.5 87.8±18.8 0.0005
Urea (mmol/l) 5.0±3.5 5.3±2.2 0.09
Total protein (g/l) 79.1±10.5 77.5±11.7 0.28
Albumin (g/l) 46.7±30.8 38.8±15.4 0.02
Total bilirubin (μmol/l) 12.6±7.8 15.8±20.6 0.88
Direct bilirubin (μmol/l) 5.3±4.6 7.9±15.3 0.97
Indirect Bilirubin (μmol/l) 7.4±4.5 8.1±7.9 0.83
Alkaline phosphatase (U/l) 132.2±63.2 114.4±47.4 0.33
AST (U/l) 36.6±18.7 43.5±46.4 0.93
ALT (U/l) 45.8±31.8 54.8±61.6 0.64
GGT (U/l) 79.1±47.9 73.4±51.1 0.40
Total cholesterol (mmol/l) 4.1±1.2 4.0±1.1 0.60
*Values are mean±SD unless otherwise specified.
ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; GGT,
γ-glutamyl transpeptidase; LV, left ventricular; LVEDD, LV end diastolic diameter; LVESD,
LV end systolic diameter; NYHA, New York Heart Association.
Table 5 Univariate logistic regression analysis of predictors of LV
recovery (n=141)
Predictor Unadjusted OR 95% CI p Value
Clinical characteristics
Age (years) 1.07 1.00 to 1.15 0.04
Parity (number) 1.26 0.96 to 1.65 0.09
BMI (kg/cm2) 1.02 0.95 to 1.10 0.54
Systolic blood pressure (mm Hg) 1.02 0.99 to 1.05 0.07
Heart rate (beats/min) 0.98 0.96 to 1.00 0.06
NYHA functional class 0.74 0.41 to 1.35 0.33
Medication
Carvedilol (yes, no) 0.80 0.35 to 1.80 0.58
ACE inhibitor (yes, no) 0.93 0.34 to 2.57 0.89
Furosemide (yes, no) 2.25 0.27 to 18.75 0.45
Digoxin (yes, no) 0.95 0.42 to 2.16 0.90
Echocardiography
LVEDD (mm) 0.93 0.88 to 0.99 0.025
LVESD (mm) 0.93 0.87 to 0.98 0.01
Ejection fraction (%) 1.03 0.98 to 1.08 0.27
E/A 0.56 0.31 to 1.02 0.057
Deceleration time (ms) 1.00 0.99 to 1.01 0.90
LV thrombus 1.93 0.60 to 6.25 0.27
Laboratory
Haemoglobin (g/dl) 1.33 1.05 to 1.69 0.02
Creatinine (mmol/l) 0.96 0.93 to 0.98 0.0008
Urea (mmol/l) 0.94 0.79 to 1.13 0.51
Total protein (g/l) 1.01 0.98 to 1.05 0.51
Albumin (g/l) 1.02 0.99 to 1.04 0.10
Total bilirubin (μmol/l) 0.99 0.95 to 1.02 0.42
Direct bilirubin (μmol/l) 0.98 0.92 to 1.03 0.40
Indirect bilirubin (μmol/l) 0.99 0.93 to 1.05 0.64
Alkaline phosphatase (U/l) 1.01 0.99 to 1.01 0.11
AST (U/l) 0.99 0.98 to 1.01 0.33
ALT (U/l) 0.99 0.99 to 1.01 0.45
GGT (U/l) 1.00 0.99 to 1.01 0.73
Total cholesterol (mmol/l) 1.10 0.76 to 1.61 0.61
ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; GGT,
γ-glutamyl transpeptidase; LV, left ventricular; LVEDD, LV end diastolic diameter; LVESD,
LV end systolic diameter; NYHA, New York Heart Association.
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heart failure.10 12 13 The potentially beneficial effect of being
overweight or obese has been termed the ‘obesity paradox’.
Several hypotheses have been proposed to account for this
paradox, including the suggestions that overweight and obese
patients may have higher metabolic reserve, reduced cytokine
and neuroendocrine activation, higher blood pressure, which
may allow more aggressive upward titration of medication, and
higher serum lipid levels. An association between higher BMI
and improved survival in patients with acute decompensated
heart failure has also been shown. An analysis of more than
100 000 patients enrolled in the Acute Decompensated Heart
Failure National Registry showed that higher BMI was asso-
ciated with lower in-hospital mortality.14 The mechanisms by
which a higher BMI may be protective for patients with either
acute or chronic heart failure remain unclear.
Several studies have reported an inverse relationship between
cholesterol and mortality in patients with chronic heart
failure.21–23 Rauchhaus and colleagues were among the first to
demonstrate this paradox in a derivative/validation study in
417 patients with chronic heart failure whereby lower serum
total cholesterol was independently associated with worse
prognosis.24 A more recent study demonstrated that higher
serum high-density lipoprotein (HDL) cholesterol and higher
serum triglycerides were associated with lower mortality in a
cohort of 833 outpatients with chronic heart failure due to
various aetiologies.25 In contrast with the results of these
studies, Christ and colleagues found that, in patients with idio-
pathic dilated cardiomyopathy, low cholesterol levels are
dependent on the severity of cardiac disease and do not inde-
pendently predict adverse outcomes in these patients.26
Low cholesterol has also been shown to be a predictor of
adverse outcomes in acute heart failure. Findings from the
Acute Heart Failure Database main registry show that low
total cholesterol was one of several predictors for in-hospital
mortality in patients admitted for acute heart failure.27 In a
cohort of 207 older patients, low cholesterol was associated
with increased length of hospital stay and was among the best
predictors of in-hospital mortality.28
Although the pathophysiological basis for the association of
low cholesterol and impaired prognosis has not been fully eluci-
dated, an ‘endotoxin–lipoprotein’ hypothesis has been pro-
posed.16 Patients with chronic heart failure have increased
cytokine activation, which depends, at least in part, on expos-
ure to bacterial endotoxins due to mesenteric venous conges-
tion.24 29 Lipoproteins serve as natural buffers because they
bind to endotoxins. This, in turn, leads to reduced lipopolysac-
charide activity and diminished immune activation.16
We have previously shown that patients with PPCM display
increased cytokine levels and that failure to decrease interferon
γ was associated with poor outcome.5 20 On the basis of the
results of the present study, low total cholesterol at diagnosis
may be a marker for increased immune activation in patients
with PPCM and portend a poor prognosis.
Predictors of LV recovery
In this study, only 21% of surviving patients had attained com-
plete LV recovery at 6 months. Predictors of LV recovery were
older age and smaller LVESD at diagnosis, confirming a previ-
ous study that reported that smaller LVESD at diagnosis is
associated with better LV recovery.2 Other studies have reported
that smaller LVEDD,8 9 higher LVEF,2 6 19 higher fractional
shortening9 and absence of LV thrombus8 at diagnosis may
predict LV recovery, but none of these factors predicted LV
recovery in our patient population. Of note, the LV recovery
rate at 6 months in this study was quite low compared with a
previous study of patients with PPCM in the USA, of whom
only 19% were black, which reported an overall LV recovery
rate of 54%.3 More recently, another study from the USA in
which 14 of 39 patients with PPCM were black reported that
normalisation of LV function at 6 months occurred in 56% of
white patients but only 30% of black patients.1 The LV recov-
ery rate in our study of black African patients with PPCM is
even lower than that reported for black patients living in the
USA, but similar to that reported in patients living in Haiti4
and Turkey.2 These findings suggest that patients of African
ancestry with PPCM may be less likely to normalise their LV
function at 6 months than patients of other racial or ethnic
backgrounds.
Differences in nutrition between patients from various
ethnic and sociodemographic backgrounds have not been evalu-
ated and may also play a role. Fett and colleagues30 have shown
that, among 32 Haitian patients with severe heart failure, only
6% had recovered at 6 months, but 100% had recovered by
48 months. The long-term recovery rate of the patients with
PPCM in the present study has not been assessed, but it may
be that predictors of late LV recovery may differ from predictors
of early LV recovery. This issue merits further investigation.
Age has not previously been reported as a predictor of LV
recovery. The reason(s) why older patients with PPCM in this
study had better LV recovery than younger patients remains
unclear. It is possible that younger patients mounted a more
severe immune response than older patients, resulting in more
extensive myocardial damage, thereby decreasing the probabil-
ity of functional recovery.
Predictors of mortality
Of the 162 patients with follow-up, 21 (13%) died within
6 months of diagnosis. Similar to previous reports, degree of LV
dilatation2 and higher NYHA functional class5 at diagnosis
were predictors of mortality in univariate analysis. Lower BMI
and younger age at diagnosis seemed to be independent predic-
tors of mortality, which are novel findings. Because of the rela-
tively low number of deaths in the current cohort, multiple
logistic regression analysis of mortality was not performed.
Studies including larger numbers of patients with PPCM are
warranted to further elucidate and validate predictors of death
among this patient population.
Limitations
Total cholesterol was measured at baseline for all patients, but
was not assessed at 6 months in the majority of patients, thus
not allowing comparison of change over time. In addition, only
total cholesterol was measured, so data on the levels of various
types of cholesterol including HDL, low-density lipoprotein,
triglycerides and non-HDL are not available. Assessment of
cholesterol types at baseline and at follow-up may provide add-
itional information in future studies. Finally, follow-up con-
cluded at 6 months. Longer follow-up would probably increase
our knowledge about predictors of poor outcome as well as LV
recovery in patients with PPCM.
CONCLUSION
In this study, larger LVESD and low total cholesterol were
found to be associated with a composite poor outcome in a
large cohort of African women with PPCM, while smaller
LVESD and older age were found to be associated with a better
chance of LV recovery. These results confirm and expand upon
previous findings by our group and others and merit further
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investigations on potential pathophysiological mechanisms
underlying these findings.
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4. DISCUSSION 
 
The research projects within this thesis were designed to address the knowledge gap regarding the 
aetiology, prognostic indicators and targeted treatment of PPCM. I have attempted to unfold more 
on the aetiology of PPCM: through the evaluation of any genetic contribution, at both clinical and 
molecular level; as well as through in-depth analysis of any electrocardiographic abnormalities that 
could shed more light on aetio-pathogenesis in this aspect, respectively. 
Given that my work began in an era when there was no insight as to how to treat PPCM differently 
to its closest disease simulant, DCM, it was important to explore the prognostic indicators for 
patients within the South African setting in the context of them being exposed to the local standard 
of care. However, through this renewed confirmation of the dismal outcome that many PPCM 
patients still endure, I needed to address the urgent task of exploring treatment modalities more 
specific to PPCM. By discovering a novel treatment modality effective in improving the outcome of 
PPCM, this in turn completed the research cycle by further reinforcing efforts to improve 
understanding of this aspect of the aetio-pathogenesis of PPCM. 
 
The Genetics of PPCM 
This thesis provides a detailed description of two cases of PPCM with at least one family member 
with DCM; this meets the definition of familial cardiomyopathy (Mestroni et al, 1999). Both families 
showed presentations compatible with autosomal dominant inheritance. On a larger scale, the 
research shows that almost one-quarter of PPCM patients belong to the spectrum of patients with 
active familial DCM, i.e. with at least one first degree relative with concurrent DCM. However, by 
including relatives who have early echocardiographic signs of DCM, who will  inevitably develop DCM 
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over time (as is evident in this study, as well as in literature (Baig et al, 1998; Mahon et al, 2005)), 
this raises the proportion of PPCM patients who portray familial DCM to almost 40%. 
To the best of my knowledge, this is the first study of its kind to have systematically performed 
thorough clinical evaluation of all accessible first degree relatives of PPCM; and it is also the first to 
suggest such a high prevalence of familial DCM amongst PPCM patients. This is of immense clinical 
importance in understanding the aetiology and natural history of PPCM patients with and without 
familial disease in terms of forming preventative efforts. There have been several reports of familial 
disease in PPCM (Sliwa et al, 2010; Pearl, 1995; van Spaendonck, 2010). Two Western studies and 
one South African case series suggest that a sub-set of PPCM patients may be part of the spectrum 
of familial DCM presenting in the perinatal period (Ntusi et al, 2011; Van Spaendonck et al, 2010; 
Morales et al, 2010). 
Familial DCM manifests in an age-dependent manner with incomplete disease penetration (Mahon, 
2005).  As heterogeneous as familial DCM is, over 40 defective genes have been associated with 
inherited DCM, although they account for a minority of familial DCM cases (Mayosi et al, 2007). 
Genome-Wide Association Studies (GWAS) may succeed in identifying pathogenic mutations for 
PPCM. The only known attempt at GWAS in PPCM patients was done in Utah; it revealed 10 single 
nucleotide polymorphisms (SNPs) that may play a role in the pathogenesis of PPCM( Horne et al, 
2011). Of these, one SNP (located on chromosome 12) demonstrated genome-wide significance for 
PPCM, likely triggering disease through abnormal immune-modulation. 
Recent advances favouring PPCM as an independent disease shows in vitro and in vivo evidence of 
an abnormal 16kDa prolactin pathway that is intertwined with oxidative stress (Yamac et al, 2010). 
However, given that oxidative stress, together with signal transducer and activation of transcription 
factor-3 (STAT-3) depletion, as implicated in this model, may be common to most forms of severe 
heart failure (including idiopathic DCM (Peng et al, 2012), the only component to this pathway that 
could remain unique to PPCM is that fuelling production of the 16kDa fragment of prolactin. Still, 
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linking this abnormal prolactin pathway exclusively to PPCM would require proof of its absence in 
women with familial DCM (including relatives who subsequently fall pregnant and deteriorate). 
Hence, in the scenario set by our family screening study, for us to write off the 22% – 39% of PPCM 
patients who demonstrated familial DCM as being female FDCM patients presenting in pregnancy, 
we would have had to prove clinical disease prior to pregnancy, as well as the absence of 
predominance of 16kDa prolactin in their serum post-partum. 
In continuation of these efforts to decipher the overlap between women with familial DCM 
presenting perinatally from PPCM patients who may have their own specific genetic predisposition 
to developing a form of familial DCM, there is a need for continued research into the clinical and bio-
molecular similarities - not just the differences. For example, despite the GWAS described above 
(Horne et al, 2011) having failed to find any single variation on the STAT-3 gene to account for PPCM, 
it introduced the possibility of an association between SNPs on the STAT-5 gene, a known culprit in 
idiopathic DCM (Peng et al, 2012) and PPCM. Furthermore, the GWAS authors also described 30 
other SNPs that appeared to predict the absence of PPCM16, suggesting a route for exploration of 
protective mechanisms against PPCM. 
Familial DCM is characterized by a marked phenotypic and genetic/allelic heterogeneity that is also 
typical for other cardiomyopathies (Burkett et al, 2005; Perrot et al, 2007). Probably the most 
common cause of FDCM is Lamin A/C deficiency (Malhotra, 2009; Perrot et al, 2009), as a result of 
harmful abnormalities in the Lamin A/C gene (LMNA). Lamin A/C is a complicated gene that can 
present with multiple phenotypes extended above and beyond the heart. More than ten clinically 
distinct disease phenotypes have been attributed to LMNA mutation ( termed ‘‘laminopathies’’), 
including accelerated aging disorders,  lipodystrophy syndromes, as well as striated muscle diseases,  
like muscular dystrophy and cardiomyopathy (Perrot et al, 2009). Although it remains unclear how 
mutations cause the syndrome of FDCM, an animal model suggests that known mutations tend to 
cause apoptosis, especially in the conduction system of the heart (Malhotra, 2009). In humans, 
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LMNA mutations in the heart have been associated with DCM phenotypes with more aggressive 
heart failure, arrhythmias and high mortality. Still, penetrance is variable and no clear marker has 
been identified to predict which patients will develop symptoms and which are at risk for sudden 
death (Malhotra, 2009). 
Two recent Western studies that attempted to screen PPCM patients for LMNA mutations reported 
no mutations (Van Spaendonck et al, 2010; Morales et al, 2010) - although their retrospective study 
design may have contributed to considerable under-estimation of the prevalence of LMNA 
mutations in PPCM patients. To date, the study reported in this thesis comprises the largest number 
of prospectively recruited PPCM patients to undergo genetic screening for LMNA mutation - yet we 
also failed to identify LMNA mutation in the cohort. Despite LMNA mutations being strongly 
correlated with various arrhythmias, as described above, no significant arrhythmia was recorded in 
the study cohort reported on in this thesis. However, whilst we do accept the limitation that some of 
our PPCM patients who died may have suffered an arrhythmia that was not recorded, it must be 
true that in PPCM, morbid outcomes are caused by factors other than LMNA gene abnormalities.  In 
FDCM families bearing pathogenic LMNA mutations, the discovery of individuals who are genotype-
negative yet phenotype positive has led to the suspicion that compound heterozyogosity may be 
more common in IDCM/FDCM than previously thought (Parks et al, 2008). Although the only 
anomalies that were found on the LMNA genes of this group of South African PPCM patients were 
SNPs that are likely harmless, one must keep an open mind when searching for causative mutation in 
the context of possible compound heterozygosity. 
One major limitation of this study was the limited access to adequate samples of patient blood for 
sufficient DNA analysis; especially that of patients who died, or re-located to farther provinces, and 
so forth. This suggests an inevitable potential for under-estimation of the prevalence of any LMNA 
mutation in our PPCM cohort. 
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The ECG in PPCM 
This is the first study to systematically describe the 12-lead ECG in de novo cases of PPCM. Our main 
aim was to examine the potential utility of the 12-lead ECG (a relatively inexpensive and easy-to-
apply diagnostic tool) in detecting underlying LV dysfunction in confirmed cases of de novo PPCM in 
African women. This would require a high underlying level of ECG abnormalities in such a cohort in 
order to discriminate against (presumably) more normal 12-lead ECGs in African women 
experiencing healthier pregnancies. 
Of the 78 cases studied: 49% demonstrated major ECG abnormalities, usually associated with 
significant underlying cardiac pathology; while 62% demonstrated one or more forms of minor 
variation/abnormality, potentially indicative of the same. We also attempted to examine whether 
the 12-lead ECG is a useful tool for discriminating between those cases that respond to treatment 
(seen as resolution of initially observed ECG abnormalities) and those who had persistent LV 
dysfunction. In this respect, we found that the presence of two major abnormalities (T-wave 
inversion and ST-segment depression) and a third Minnesota code criterion (not listed as one of the 
major or minor criteria (ST-segment elevation)) found on the baseline 12-lead ECG correlated with 
persistently poor LV systolic function at six months. T-wave inversion also correlated with LV systolic 
function at baseline. Typically, LV systolic function recovery in PPCM is a slow and drawn-out process 
that appears to take place during the second year of treatment (Tibazarwa et al, 2010). On this basis, 
while LVEF in those patients subjected to six-month follow up improved overall, just under half still 
had defined LV dysfunction. This represents a major therapeutic target for treatment. Therefore, 
long-term follow-up using the ECG in PPCM might well show ECG reversal to normality as late as 18 
months after first diagnosis, as our long-term echocardiographic data suggest (Sliwa et al, 2011). 
Moreover, we have identified potentially useful markers (i.e. major T-wave inversion and/or ST-
segment depression on the 12-lead ECG) as simple, but important, prognostic markers that might 
trigger more aggressive treatment and follow up in PPCM cases. 
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Our findings and the overall utility of the 12-lead ECG in this clinical setting require careful 
interpretation when fundamental investigations, such as echocardiography, remain inaccessible to 
most hospitals and patients in sub-Saharan Africa. Serum levels of NT-proBNP are known to strongly 
predict the degree of heart failure (Cardarrelli et al, 2003); yet this test is still not available in most 
referral hospitals in Africa where PPCM is prevalent. Surprisingly, because of vast differences in 
sensitivity and specificity in detecting HF, it has been suggested that the overall cost-effectiveness of 
measuring serum NT-proBNP becomes comparable to that of screening for HF using the 12-lead ECG 
alone (Lee et al, 2008; Galasko et al, 2006), due mainly to the relatively low specificity of the 12-lead 
ECG (Galasko et al, 2006). The scarcity of the serum NT-proBNP test in our setting almost mandates 
using something as inexpensive and easy to obtain as the 12-lead ECG to screen for PPCM, even if its 
sensitivity and specificity prove to be imperfect. These data will be particularly useful if (after 
comparing ECG patterns in healthy African women as derived from the Heart of Soweto cohort 
[Sliwa et al, 2008]) the 12-leadECG has the potential to be applied as a ‘rule-out’ test (i.e. high 
specificity to identify all truly negative for PPCM cases). 
Unfortunately, the ability to combine 12-lead ECG with typical symptoms of HF (to increase its 
accuracy in detecting PPCM) is confounded by their parallel presence in the late stages of pregnancy 
(but not typically post-partum). We remain wary of the fact that inherent gender-based differences 
in ECG findings may exist; with reports often showing women to have a higher prevalence of ST-
segment depression or T-wave changes than men, such that one might question the true significance 
of any association between ST-segment depression and T-wave abnormalities with mortality due to 
coronary heart disease (CHD) in women (Wu et al, 2008). However, we are greatly reassured by the 
number of large, population-based studies that show major ST-depression to be the most predictive 
ECG characteristic of cardiovascular disease (CVD) and CHD mortality, lending an average two-fold 
risk of CVD and CHD mortality, and, as with our study, predicting these outcomes from their mere 
presence at baseline (De Bacquer et al, 1998). 
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Studies reporting on the ECG in prognostication of PPCM remain scarce, with two from Nigeria 
suggesting it to be a weak predictor of recovery and long-term prognosis in PPCM (Boomsma et al, 
1989; Fillmore et al, 1977). However these studies did not use echocardiography to confirm the 
diagnosis of PPCM, and each study had a greater proportion of patients with hypertension than 
those without. Given recent insight gained that patients with the PPCM phenotype who present with 
hypertension appear to follow a different natural history to those without (Sliwa et al, 2010), usually 
with better prognosis in those with hypertension, any comparison between data from PPCM 
patients with hypertension to those without hypertension should be interpreted with great caution. 
 
The Treatment of PPCM Using Bromocriptine 
This prospective, single-centre, randomized, open-label pilot study with blinded efficacy assessments 
showed that the addition of Bromocriptine to standard heart failure therapy in women with PPCM 
appeared to result in significantly greater improvement than seen with standard therapy alone in all 
of the following: NYHA functional class; LV systolic and diastolic function; and degree of functional 
mitral regurgitation. Bromocriptine seemed to be well tolerated, and no thrombotic complications 
were observed. Moreover, although Bromocriptine stopped lactation and breast-feeding in the 
PPCM patients, the growth and survival of those infants were normal. However, our study was very 
small and these findings are in no way definitive. On the other hand, the findings are encouraging 
and suggest that a larger study should be considered. 
This proof-of-concept pilot study was performed in a group of homogeneous patients in terms of 
ethnic background, age, time of diagnosis and baseline characteristics. Unfortunately, blinding of the 
study was not possible because the PPCM-Std (Standard) group continued to nurse their infants 
while the PPCM-Br (Bromocriptine) group could not breast-feed because of Bromocriptine-induced 
cessation of lactation. However, investigators were blinded for data analysis. We believe that the 
91 
 
homogeneous patient cohort, well-balanced baseline characteristics and blinded assessment of 
outcomes to some extent compensate for the small size of our study and its open-label design. Apart 
from its prolactin blocking role, Bromocriptine may exert additional “off-target effects” in PPCM 
patients. For example, effects of Bromocriptine on hemodynamic parameters in patients with heart 
failure were described 30 years ago (Francis et al, 1983), before treatment with ACE inhibitors and 
blockers was routine.  Bromocriptine may also affect metabolic parameters. We observed that PPCM 
patients display increased oxidized low-density lipoprotein serum levels compared with healthy 
postpartum women (Hilfiker et al, 2007). This suggests impaired anti-oxidative defence mechanisms 
and potential metabolic perturbations. 
We observed no adverse effects in any of the nine surviving patients in the PPCM-Br group. 
However, the number of patients studied was small; and because of poor cardiac function, all 
patients in the study received sub-cutaneous low-molecular-weight heparin during their index 
admission. Therefore, although the data suggesting that Bromocriptine has a pro-thrombotic effect 
are not robust, we cannot rule out such an effect. 
 
Prognostic Indicators in PPCM 
Our prospective single-centre study of 176 newly diagnosed patients with PPCM summarises data on 
clinical, echocardiographic and laboratory characteristics at the time of diagnosis and after 6 months 
of standard clinical care. We confirmed previous findings in our collective that a relatively high 
percentage of patients (79%) had failed to normalise LV function at 6 months compared with 
collectives from the USA (Elkayam et al, 2005; Amos et al, 2006). Increased LVESD, lower BMI and 
lower total cholesterol were identified as potential novel predictors of poor outcome on stepwise 
multi-variate logistic regression analysis. Older age appears to be a novel predictor of LV recovery; 
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while younger age, lower BMI, increased LVEDD, increased LVESD and higher NYHA functional class 
all seem to be predictors of mortality. 
Numerous factors predicting morbidity and mortality in patients with PPCM have previously been 
proposed, but not validated. These factors include degree of decreased LVEF and LV dilatation at 
diagnosis, presence of LV thrombus and being of African descent. Previous studies performed at our 
own institution have shown that NYHA functional class, N-terminal pro-hormone of brain natriuretic 
peptide and increased plasma markers of inflammation and apoptosis at diagnosis are predictors of 
poor outcome as well (Blauwet et al, 2012). The present analysis, using a much larger sample size 
than in most previous analyses, reveals different findings with regard to some predictors of 
morbidity and mortality, but confirms other findings. As previously reported, increased LVESD at 
diagnosis was a significant predictor, even when adjusted for other variables in multi-variate 
analysis. In contrast with previous reports, LVEF and LVEDD at diagnosis, NYHA functional class and 
presence of LV thrombus were not predictors of poor outcome. A novel finding in the present study 
was that lower BMI and lower total cholesterol at baseline were both associated with poor outcome 
(Blauwet et al, 2012). Several studies have reported an inverse relationship between cholesterol and 
mortality in patients with chronic heart failure. Low cholesterol has also been shown to be a 
predictor of adverse outcomes in acute heart failure. Although the pathophysiological basis for the 
association of low cholesterol and impaired prognosis has not been fully elucidated, an ‘endotoxin–
lipoprotein’ hypothesis has been proposed. 
Sixteen patients with chronic heart failure have increased cytokine activation, which depends, at 
least in part, on exposure to bacterial endotoxins due to mesenteric venous congestion (Blauwet et 
al, 2012). Lipoproteins serve as natural buffers because they bind to endotoxins. This, in turn, leads 
to reduced lipopolysaccharide activity and diminished immune activation (Rauchhaus et al, 2000). 
We have previously seen that patients with PPCM display increased cytokine levels and that failure 
to decrease interferon-γ was associated with poor outcome (Sliwa et al, 2006; Forster et al, 2008). 
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On the basis of the results of the present study, low total cholesterol at diagnosis may be a marker 
for increased immune activation in patients with PPCM and it may portend a poor prognosis. 
In this study, only 21% of surviving patients had attained complete LV recovery at 6 months. 
Predictors of LV recovery were: older age and smaller LVESD at diagnosis. This confirmed a previous 
study that reported that smaller LVESD at diagnosis is associated with better LV recovery (Blauwet et 
al, 2012). Other studies have reported that smaller LVEDD, higher LVEF, higher fractional shortening 
and absence of LV thrombus at diagnosis may predict LV recovery; but none of these factors 
predicted LV recovery in this patient population. It should be noted that the proportion of LV 
recovery reported in this study of black African patients with PPCM was even lower than that 
reported for black patients living in the USA, but similar to that reported in patients living in Haiti 
and Turkey (Blauwet et al, 2012). These findings suggest that patients of African ancestry with PPCM 
may be less likely to normalise their LV function at 6 months than patients of other racial or ethnic 
backgrounds.  
Differences in nutrition between patients from various ethnic and socio-demographic backgrounds 
have not been evaluated and may also play a role. Fett and colleagues (Fett et al, 2005) showed that 
among 32 Haitian patients with severe heart failure: only 6% had recovered at 6 months; but 100% 
had recovered by 48 months. The long-term recovery rate of patients with PPCM in the present 
study reported in this thesis has not been assessed, but it may be that predictors of late LV recovery 
differ from predictors of early LV recovery.  This issue merits further investigation. 
Age has not previously been reported as a predictor of LV recovery. The reason(s) why older patients 
with PPCM in this study had better LV recovery than younger patients remains unclear. It is possible 
that younger patients mounted a more severe immune response than older patients, resulting in 
more extensive myocardial damage, thereby decreasing the probability of functional recovery.  
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Of great importance is the acknowledgement of the community of international experts of the need 
to review all existing data on PPCM, merging old evidence with the new, to form comprehensive 
guidelines on the management of PPCM. It is through such efforts that in 2010, the European Society 
of Cardiology published a position statement on the aetiology, diagnosis, and management of PPCM;  
this having being compiled by a variety of  experts consisting of cardiologists, obstetricians, 
intensivists, and imaging specialists, and incorporating modifications in the definition and diagnostic 
criteria of PPCM as per the emerging evidence (Sliwa et al, 2010). 
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5. CONCLUSIONS AND THE WAY FORWARD 
 
This PhD has contributed considerably in narrowing the knowledge gap on the aetiology, risk factors, 
prognostic indicators and treatment of PPCM through a collection of observational and experimental 
studies. 
There are several lessons to be learnt from our detailed family study of two cases with PPCM. First, 
we emphasise the need for family screening of PPCM and idiopathic DCM patients with long-term 
follow up of screened persons, particularly of females of child-bearing age. There is a need for well-
structured incidence studies of PPCM and idiopathic DCM, with baseline echocardiograms of primary 
relatives (irrespective of symptoms), pre-pregnancy echocardiography of all women being followed-
up (irrespective of underlying co-morbidities) and follow-up with echocardiography every 2-5 years. 
This exercise could mould routine practice, given: the high prevalence of familial DCM; its   
association with poor outcome; and the suggested benefits of treating asymptomatic relatives with 
LV dysfunction. 
From a bench perspective, aside from the GWAS reported several years ago, the search for genetic 
abnormalities in PPCM has remained focused on screening for mutation (or SNP) associated with 
familial DCM. It is recommended that researchers expand on the reported GWAS by testing the 
clinical impact of the SNPs already suspected to be associated with PPCM.  Until much larger studies 
can officiate the lack of harmful LMNA mutations in PPCM patients, information about the genotype 
in an individual from a PPCM family could still be useful for the clinician, especially when dealing 
with ‘‘pre-symptomatic’’ relatives unsure of their risk of developing DCM (Perrot et al, 2009). 
However, during such a search, one must be vigilant not to assume that identification of a single 
gene mutation is sufficient to explain FDCM; instead, it could greatly confound FDCM gene discovery 
using one-locus linkage analysis or candidate gene approach (Parks et al, 2009). 
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Given the high prevalence of FDCM amongst the PPCM patients in the study, the encouragement for 
more definitive identification of the underlying causative gene through whole-genome exome 
sequence couldn’t be greater. 
 
In exploring risk-factors at the bedside, the study on the use of ECG in the assessment of PPCM 
represents a unique study that will prove to be invaluable: in determining the future role of the 12-
lead ECG as an inexpensive and simple ‘rule-out’ screening tool for PPCM; and perhaps as an 
important tool for increasing the intensity of subsequent treatment and management. 
Overall, we found the majority (96%) of PPCM patients presented with ‘abnormal’ 12-lead ECGs, 
which improved significantly to 75% after the first six months of treatment. Over 80% of patients 
displayed either major abnormalities or minor variations using the Minnesota code. Of these, sinus 
tachycardia and QRS-axis deviation were most likely to be attenuated after six months. Even though 
these ECG abnormalities were mostly non-specific and similar to those of other dilated 
cardiomyopathies, this study further suggests the ECG may be useful in simple monitoring of clinical 
progress during treatment and prognostication. Specifically, the baseline presence of major T-wave 
and ST-segment abnormalities in the context of PPCM patients may place these patients at a similar 
risk of adverse outcomes to those with myocardial ischaemia. More definitive studies are required to 
determine if this simple and relatively inexpensive tool will be of particular clinical use in PPCM. Any 
progress in this regard would be welcome, given the persistently poor health outcomes associated 
with PPCM in resource-poor settings. 
In addressing the treatment of PPCM, our ground-breaking proof-of-concept trial showed that the 
addition of Bromocriptine to standard heart failure therapy appeared to improve LVEF and a 
composite clinical outcome in women; although the number of patients studied was small and hence 
the results cannot be considered definitive. Larger-scale multi-centre and blinded studies are in 
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Clinical Features 
- CCF (Acute or Subacute) 
- Dilated LV; Bedside & imaging 
- Hypotension 
- Arrhythmia 
Complications 
-Thromboembolism;   
  cerebral/pulmonary/digital infarcts 
- Ischaemic Organ Failure;  
  Renal failure/ ischaemic hepatitis 
- Prolonged heart failure (50-75%) 
- Death (15-30%) 
progress to test this strategy more robustly. Finally, regarding the prognostic indicators of PPCM, we 
have shown that larger LVESD and low total cholesterol were found to be associated with a 
composite poor outcome in a large cohort of African women with PPCM, while smaller LVESD and 
older age were found to be associated with a better chance of LV recovery. These results confirm 
and expand upon previous findings by this group and others and merit further investigation on 
potential pathophysiological mechanisms underlying these findings. Figure 11 below summarises 
these findings together with those known for PPCM, and their contribution towards clinical features 
and the management of PPCM. 
 
Figure 11. An illustration of the important aetio-pathogenic factors implicated in PPCM and their          
                  impact on clinical features and management 
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CLINICAL 
- Most present 1st 3 months postpartum 
- Previous PCM 
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(22%-39%) 
BIOCHEMICAL 
- Oxidative stress/inflammation/apoptosis 
 
 
- Excess abnormal Prolactin (16kDa) 
Targets for Intervention 
-Treat as per standard for IDCM 
1o PREVENTION 
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- Discourage lactation in those at risk 
- Bromocriptine; Dual benefit 
    Block 16kDa prolactin 
  May improve haemodynamics &   
       oxiditave stress, ± cardioprotection 
2o PREVENTION 
- Early accurate diagnosis (by exclusion) 
- Early Rx of HF & PPCM complications 
- Vigilant follow-up & dose optimisation 
- Avoid undue lipid-lowering 
Abnormal ECG 
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Although the studies towards this thesis have gone far in contributing to narrowing the knowledge 
gaps for PPCM, much still remains unsolved. Except for the trial of Bromocriptine, there are very few 
comparative observational studies on PPCM. Most literature, as with the group’s other studies, 
comprises descriptive assessment of particular risk factors. It is be important to increase the number 
of comparative studies for these risk factors, including: direct comparison and clinical effect on the 
ECG and serum cholesterol levels in African women in the postpartum period; or the prevalence of a 
predominance of 16kDa Prolactin amongst healthy post-partum mothers as well as those at risk or 
known to have IDCM and FDCM. In addition to this, the paucity of data on the long-term outcome of 
PPCM, including patients with subsequent pregnancies, continues to limit many of the conclusions 
that one could draw from any such comparative study. It is thus highly recommended that long-term 
outcome data is pursued ( for up to a decade of observation, if possible) in order to optimise our 
understanding of the risk factors, clinical characteristics and management of PPCM. 
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Appendix 1. PPCM Consent Forms  
 
 
Consent for PPCM Study (general) – Form 1a Johannesburg 
 
 
Familial Aggregation Study in Peripartum and Idiopathic Dilated Cardiomyopathy 
 
Cardiac Clinic 
E25 Groote Schuur Hospital 
Observatory 7925 
Tel: (021) 404-6361 
Fax (021) 448-7062 
 
Department of Cardiology 
Chris Hani Baragwanath Hospital 
Soweto, Johannesburg. 
Tel: (011) 933-8197 
Fax: (011) 938-8945 
Informed Consent Form 
I agree to participate in the study of genetic and environmental factors that may cause heart 
muscle disease (cardiomyopathy) either in the last month of pregnancy/ the first five month post-
partum for postpartum cardiomyopathy (PCM) or otherwise for idiopathic dilated cardiomyopathy 
(DCM). I understand that I will be interviewed about my medical history, family history, social 
history and medications, and that my heart will be examined by an ultrasound scan and, if 
indicated, a nuclear medicine scan called the MUGA scan. In addition, I will have a blood sample 
drawn consisting of 12 tubes of blood. Most of this blood will be used to conduct routine tests for 
this heart condition, while 2 of the tubes will be used to test genetic factors that may increase the 
risk of heart muscle disease.  Participation in this study will take about 90 minutes.  
No extra visits will normally be required. However, if abnormalities are detected during the course 
of this study, I will be informed of the findings and referred to the appropriate health care team for 
further treatment. 
I understand that my participation in this study is entirely voluntary. All information gathered in 
this study is strictly confidential, and will only be used for research relating to the heart diseases 
‘Peripartum Cardiomyopathy’ and ‘Idiopathic Dilated Cardiomyopathy’ and their determinants. 
This information (including genetic material) will not be used to generate any profit. As well, 
genetic material will not be used for the purpose of gene alteration, and, prior to blood sampling, I 
will sign a separate DNA consent form that governs the use of genetic material under the rules of 
the University of Cape Town Research Ethics Committee.  
I will not be identifiable in any published report. I understand that I am free to refuse to participate 
or withdraw from the study at any time, without jeopardising the future care of my relatives or 
myself. If I have any questions, I may contact Dr. Tibazarwa or Sister Mtshifulo at either of the 
address printed on the top of this page. Other investigators involved in this study that you may 
contact are Prof. K. Sliwa and Prof. B. Mayosi, reachable at the above two addresses, respectively. 
I agree to participate in the study and I have been given a copy of this form. 
 
_____________________             ___________________   ____________________ 
Subject name                                  Subject signature             Date 
_____________________             ___________________   ____________________ 
(If necessary) Witness name          Witness signature            Date 
_____________________             ___________________   ____________________ 
Investigator name                          Investigator signature       Date
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Consent for PPCM Study (general) – Form 1b Cape Town 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Familial Aggregation Study in Peripartum and Unexplained Dilated Cardiomyopathy 
(Cape Town Cohort) 
Cardiac Clinic 
E25 Groote Schuur Hospital 
Observatory 7925 
Tel: (021) 404-6361 
Fax021) 448-7062 
 
Department of Cardiology 
Chris Hani Baragwanath Hospital 
Soweto, Johannesburg. 
Tel: (011) 933-8197 
Fax: (011) 938-8945 
Informed Consent Form 
I agree to participate in the study of genetic and environmental factors that may cause heart 
muscle disease (cardiomyopathy) either in the last month of pregnancy/ the first five month post-
partum for postpartum cardiomyopathy (PCM) or otherwise for idiopathic dilated cardiomyopathy 
(DCM). I understand that I will be interviewed about my medical history, family history, social 
history and medications, and that my heart will be examined by an ultrasound scan. In addition, I 
will have a blood sample drawn consisting of 5 tubes of blood. Most of this blood will be used to 
conduct routine tests for this heart condition, while 2 of the tubes will be used to test genetic 
factors that may increase the risk of heart muscle disease.  Participation in this study will take 
about 90 minutes.  
No extra visits will normally be required. However, if abnormalities are detected during the course 
of this study, I will be informed of the findings and referred to the appropriate health care team for 
further treatment. 
I understand that my participation in this study is entirely voluntary. All information gathered in 
this study is strictly confidential, and will only be used for research relating to the heart diseases 
‘Peripartum Cardiomyopathy’ and ‘Idiopathic Dilated Cardiomyopathy’ and their determinants. 
This information (including genetic material) will not be used to generate any profit. As well, 
genetic material will not be used for the purpose of gene alteration, and, prior to blood sampling, I 
will sign a separate DNA consent form that governs the use of genetic material under the rules of 
the University of Cape Town Research Ethics Committee.  
I will not be identifiable in any published report. I understand that I am free to refuse to participate 
or withdraw from the study at any time, without jeopardising the future care of my relatives or 
myself. If I have any questions, I may contact Dr. Tibazarwa or Sister Ttshifularo at either of the 
address printed on the top of this page. Other investigators involved in this study that you may 
contact are Prof. K. Sliwa and Prof. B. Mayosi, reachable at the above two addresses, respectively. 
I agree to participate in the study and I have been given a copy of this form. 
 
_____________________             ___________________   ____________________ 
Subject name                                  Subject signature             Date 
_____________________             ___________________   ____________________ 
(If necessary) Witness name          Witness signature            Date 
_____________________             ___________________   ____________________ 
Investigator name                          Investigator signature       Date
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 Consent for PPCM (Bromocriptine sub-study)  Form 1c 
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UNIVERSITY OF THE WITWATERSRAND  
HUMAN RESEARCH ETHICS COMMITTEE  
 
 
PATIENT INFORMATION LEAFLET AND INFORMED CONSENT 
 
Each patient must receive, read and understand this document before any study-related 
procedure!  
 
 
STUDY NUMBER:   
 
STUDY TITLE:  Prevention of irreversible left ventricular remodelling in patients 
with postpartum cardiomyopathy by addition of bromocriptine to 
standard heart failure therapy 
 
SPONSOR:  Soweto Cardiovascular Research Unit  
Division of Cardiology 
Chris Hani Baragwanath Hospital 
Soweto 2013 
 
INVESTIGATOR:  Prof. Karen Sliwa-Hähnle, 
Subinvestigators:  Dr. Olaf Forster, Dr. Kemi Tibazarwa 
   Dr. L. Motsekuoa 
 
INSTITUTION:  Soweto Cardiovascular Research Unit  
Division of Cardiology 
Chris Hani Baragwanath Hospital 
Soweto 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TIME AND DATE OF FIRST INFORMED CONSENT DISCUSSION: 
 
Date (dd/mm/yyyy): 
 
Time: 
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INTRODUCTION:  
Good day, my name is Prof. Karen Sliwa-Hähnle / Dr. Olaf Forster/Dr. Tibazarwa. I am a 
Medical Doctor at the Division of Cardiology, Chris Hani Baragwanath Hospital. I would 
like to invite you participating in a research study, entitled "Prevention of irreversible left 
ventricular remodelling in patients with postpartum cardiomyopathy by addition of 
bromocriptine to standard heart failure therapy"  
 
 Before agreeing to participate, it is important that you read and understand the 
following explanation of the purpose of the study, the study procedures, benefits, 
risks, discomforts, and precautions as well as the alternative procedures that are 
available to you, and your right to withdraw from the study at any time. This 
information leaflet is to help you to decide if you would like to participate. You 
should fully understand what is involved before you agree to take part in this 
study.  
 If you have any questions, do not hesitate to ask me.  
 You should not agree to take part unless you are satisfied about all the procedures 
involved.  
 You may not participate in another medical research study, nor take any other 
investigational medicine during your participation in this study. You should not 
have participated in an investigational medicine research study within the past 30 
days.  
 Please be completely truthful with me regarding your health history, since you 
may otherwise harm yourself by participating in this study.  
 If you decide to take part in this study, you will be asked to sign this document to 
confirm that you understand the study. You will be given a copy to keep.  
 If you have a personal doctor, please discuss with or inform him/her of your 
possible participation in this study. If you wish, I can also notify your personal 
doctor in this regard. 
 
PURPOSE OF THE STUDY:  
 You have been diagnosed as suffering from peripartum cardiomyopathy and I 
would like you to consider taking part in the research of a new medicine called 
"bromocriptine".  
 The purpose of this study is to determine the improvement of your cardiac 
function.   
 This study will compare standard treatment for peripartum cardiomyopathy" plus 
placebo with standard treatment for peripartum cardiomyopathy" plus 
bromocriptine. 
A placebo is an inactive substance and it does not contain any medicine. You will be 
randomly allocated to one or other treatment (i.e. like spinning a coin). Neither you nor I 
will know which treatment you are receiving during your participation in the study. This 
procedure helps to ensure that the information gathered during the study is accurate. In 
case of an emergency, it will however be possible to determine which treatment you have 
been receiving.  
 
LENGTH OF THE STUDY AND NUMBER OF PARTICIPANTS:  
 The study will be performed at the Division of Cardiology, Chris Hani 
Baragwanath Hospital 
 20 patients will participate in this study  
 The patients will be between the ages of 18 and 50 years  
 You will be required to come for follow up to Cardiac Clinic at Chris Hani 
Baragwanath Hospital once a month for a duration of 6 months after enrolment.  
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PROCEDURES:  
If you agree to take part in this study, you will first be asked questions and examined to 
see if you qualify for this study. Before receiving your first dose of study medicine, I will 
examine you and draw several blood samples from you.  
 
Screening Visit:  
 History 
 Physical examination 
 Blood pressure measurement 
 Echocardiography 
 6 minutes walking test 
 
Baseline (enrolment) visit:  
 Informed consent 
 Physical examination 
 ECG 
 Blood pressure measurement by Dinamap 
 Echocardiography 
 MRI  
 Routine blood tests10 ml (=2 teaspoons): Full blood count, urea & creatinine, 
liver function test, thyroid function test 
 Special blood tests 15 ml (=3 teaspoons): Pro-inflammatory markers (hs-CRP), 
markers of re-modeling (MMP-2, MMP-3, MMP-9, TIMP-1, cathepsin D, PlGF 
and sFLT), cardiac function biomarkers (NT-proBNP, Fas/APO-1, oxLDL, ACE, 
angiotensin II) and hormones (Prolactin, estrogen).  
 Randomisation / Study medication: After enrolment you will be randomly 
assigned to one of two forms of treatment. Both forms of treatment will include 
the standard medication for your condition "peripartum cardiomyopathy". For a 
period of 8 weeks, you will, in addition to standard medication, either receive the 
study drug bromocriptine or an inactive substance (placebo).  
 
Follow-up visits 1, 2, 3, 4 and 5:  
After enrolment, monthly visits will be scheduled for clinical assessments, 
echocardiography (if clinically indicated) and evaluation of medication compliance. 
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Final visit after 6 months of treatment: 
 Physical examination 
 ECG 
 Blood pressure measurement by Dinamap 
 Echocardiography 
 MRI  
 Routine blood tests10 ml (=2 teaspoons): Full blood count, urea & creatinine, 
liver function test, thyroid function test 
 Special blood tests 15 ml (=3 teaspoons): Pro-inflammatory markers (hs-CRP), 
markers of re-modeling (MMP-2, MMP-3, MMP-9, TIMP-1, cathepsin D, PlGF 
and sFLT), cardiac function biomarkers (NT-proBNP, Fas/APO-1, oxLDL, ACE, 
angiotensin II) and hormones (Prolactin, estrogen).  
 
Echocardiography will be taped on video and stored at the Soweto Cardiovascular 
Research Unit, Division of Cardiology at Chris Hani Baragwanath Hospital for further 
reference and audit purposes.  
 
The blood samples will be analysed to determine the effect of the treatment you received 
on your peripartum cardiomyopathy and will help to find out the cause of peripartum 
cardiomyopathy. Echocardiography will be done to determine the effect of the treatment 
you received on the performance of your heart muscle.  
 
WILL ANY OF THESE STUDY PROCEDURES RESULT IN DISCOMFORT OR 
INCONVENIENCE?  
 Venipunctures (i.e. drawing of blood) are normally done as part of routine 
medica1 care and present a slight risk of discomfort. Drawing blood may result in 
faintness, inflammation of the vein, pain, bruising or bleeding at the puncture site. 
There is also a slight possibility of infection. Your protection is that experienced 
personnel perform the procedures under sterile conditions. A total of 50 ml of 
blood (i.e. 15 teaspoons) will be collected over the total period of 6 months.  
 Echocardiography and cardiac MRI are diagnostic procedures in cardiology that 
allows the examiner to assess the function of your heart muscle. It does not pose 
any harm to the patient  
ECG (Electrocardiogram): This examination allows the doctor to determine the 
rhythm of your heart. It is a commonly used diagnostic procedure and does not 
pose any harm to the patient.  
 
RISKS OF THE STUDY MEDICINE:  
Bromocriptine is a drug that is registered and used in South Africa to suppress lactation 
after stillbirth or when breastfeeding is contra-indicated. Adverse effects of bromocriptine 
are nausea, postural hypotension and dizziness. Serious events, including hypertension, 
myocardial infarction, seizures and stroke may occur. Dyskinesia, hallucinations, 
confusion and behavioural disturbances are more common in patients receiving high doses 
for prolonged periods. Less frequent - urticaria and skin rashes, peptic ulceration, nasal 
stuffiness, visual disturbance, impotence and urinary retention may occur. Rare adverse 
effects include retroperitoneal fibrosis, pleural thickening and effusions and digital 
vasospasm.  
 
 
UNFORSEEN RISKS:  
The study medicine is investigational in the treatment of peripartum cardiomyopathy and 
there may be other risks or side effects which are unforeseen or unknown. You should 
immediately contact me if any side effects occur throughout your participation in this 
study.  
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BENEFITS:  
The potential benefit from your participation in this study may be control of your 
peripartum cardiomyopathy. However, you may not benefit from this study. Your 
participation in this study will contribute to medical knowledge that may help other 
patients that, that like you, have "Peripartum Cardiomyopathy"  
 
ALTERNATIVE TREATMENT:  
 Alternative treatment in the form of standard treatment is used to treat peripartum 
cardiomyopathy. 
 If you decide not to take part in this study you will still receive the best current 
care, from your usual doctor; this may or may not include the study medicine.  
 
BENEFITS AND RISKS OF STANDARD ALTERNATIVE TREATMENT:  
Participating in the study you will always receive standard treatment. Some patients will 
additionally receive the new treatment "bromocriptine", some will receive a placebo.  
 
ARE THERE ANY WARNINGS OR RESTRICTIONS CONCERNING MY 
PARTICIPATION IN THIS STUDY?  
You should not participate in the study if you have any of the following: 
 Allergy to ergot alkaloids 
 Uncontrolled hypertension or severe cardiovascular disease 
 Psychotic disorders 
 Parkinsonism with dementia 
 Compromised cerebral circulation 
 Ischaemic heart disease 
 Liver disease 
 History of peptic ulcers.  
 
Due to your diagnosis "Peripartum Cardiomyopathy" you should not fall pregnant again. 
Therefore effective contraception is strongly recommended.  
 
INTERACTIONS:  
It is important that you let me know of any medicines (both prescriptions and over-the-
counter medicines), alcohol or other substances that you are currently taking.  
 
RIGHTS AS A PARTICIPANT IN THIS STUDY: 
 Voluntary: Your participation in this study is entirely voluntary and you can 
decline to participate, or stop at any time, without stating any reason. Your 
withdrawal will not affect your access to medical care at our Clinic. In fact you 
will receive standard medical therapy as clinically indicated. 
 Discontinuation of study treatment: You must inform me if you wish to stop 
taking your study medicine. I will supervise any discontinuation with your health 
as the first priority.  
 New findings: I will provide you with any additional information that becomes 
available during the study, which may affect your willingness to continue on the 
study  
 
WITHDRAWAL FROM THIS STUDY:  
 Your withdrawal will not affect your access to medical care at our Clinic. In fact 
you will receive standard medical therapy as clinically indicated.  
 I retain the right to withdraw you from the study if it is considered to be in your 
best interest. If your participation is ended early, you may be asked to return for 
study-ending tests and procedures for your safety. 
 Protocol ABCDEF, English Informed Consent, Version 1 dated ab.rt.2006  
Prof. Karen Sliwa-Hähnle / Dr. Olaf Forster  
Approved by Wits HREC ad.vv.2006 
 
Patient Initials Patient Number RB 
6 
 If you did not give an accurate history or did not follow the guidelines of the study 
and the regulations of the study facility, you may be withdrawn from the study at 
any time.  
 Pregnancy: Peripartum cardiomyopathy is defined as a cardiomyopathy without 
any other attributable cause in the period of one month antepartum to 5 months 
postpartum. Pregnancy is therefore no defined reason for withdrawal from the 
study.  
 
EMERGENCY CARE AND HOSPITALISATION:  
If you seek emergency care or if hospitalisation is required at any time during the study, 
please inform the treating doctor that you are/were enrolled in this research study and that 
you are diagnosed with "Peripartum Cardiomyopathy". Please ask the treating doctor to 
inform me about your condition.  
 
FINANCIAL ARRANGEMENTS:  
 The Soweto Cardiovascular Research Unit, Division of Cardiology, Chris Hani 
Baragwanath Hospital will provide payment for all study procedures and 
reasonable medical expenses that you may incur as a direct result of this study as 
determined by the Soweto Cardiovascular Research Unit, Division of Cardiology, 
Chris Hani Baragwanath Hospital.  
 Neither you nor your medical scheme will be expected to pay for any study 
medication, study related visit or study procedures.  
 
REIMBURSEMENT FOR STUDY PARTICIPATION:  
You will not be paid to participate in this study but your transport costs will be reimbursed 
adequately.  
 
ABPI STATEMENT ON COMPENSATION: 
All patients enrolled in this study are public hospital patients at Chris Hani Baragwanath 
Hospital. No specific sponsor exists for this study. It is an investigator driven study. 
 
ETHICAL APPROVAL:  
 This clinical study protocol has been submitted to the University of the 
Witwatersrand, Human Research Ethics Committee (HREC) and written approval 
has been granted by that committee.  
 The study has been structured in accordance with the Declaration of Helsinki (last 
updated: October 2000), which deals with the recommendations guiding doctors 
in biomedical research involving human subjects. A copy may be obtained from 
me should you wish to review it.  
 
SOURCE OF ADDITIONAL INFORMATION:  
 For the duration of the study, you will be under the care of Dr. Olaf Forster. If at 
any time between your visits, you feel that any of your symptoms are causing you 
any problems, or you have any questions during the study, please do not hesitate 
to contact me.  
Doctors from the Soweto Cardiovascular Research Unit, Division of Cardiology 
who are working on this study are:  
Professor Karen Sliwa-Hähnle 083-457-4823 
Dr. Olaf Förster  082-555-9859 
Dr. Kemi Tibazarwa  011 9338197 
Dr. Lerato Motsekuoa  011 9338197 
They can be contacted at the above 24 hour telephone numbers. 
 If you want any information regarding your rights as a research participant, or 
complaints regarding this research study, you may contact Prof. Cleaton-Jones, 
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Chairperson of the University of the Witwatersrand, Human Research Ethics 
Committee (HREC), which is an independent committee established to help 
protect the rights of research participants at the following number: 011-717-2229  
 For research information you can contact Prof Huddle, Head of Department of  
Medicine, Chris Hani Baragwanath Hospital on 011-933-8940  
 South African Medicines Control Council: If you have questions about this trial 
you should first discuss them with your doctor or the ethics committee (contact 
details as provided on this form). After you have consulted your doctor or the 
ethics committee and if they have not provided you with answers to your 
satisfaction, you should write to the South African Medicines Control Council 
(MCC) at:  
 
The Registrar  
SA Medicines Control Council  
Department of Health  
Private Bag X828  
Pretoria 0001  
Fax: 012-323-4474  
e-mail: labusa@health.gov.za  
 
CONFIDENTIALITY:  
 All information obtained during the course of this study, including hospital 
records, personal data and research data will be kept strictly confidential. Data 
that may be reported in scientific journals will not include any information that 
identifies you as a participant in this study. 
 This information will be reviewed by authorised representatives of the Soweto 
Cardiovascular Research Unit, Division of Cardiology, Chris Hani Baragwanath 
Hospital.  
The information might also be inspected by the University of the Witwatersrand. Human 
Research Ethics Committee (HREC), the South African Medicines Control Council 
(MCC), as well as your personal doctor. Therefore, you hereby authorise me to release 
your medical records to the Department of Cardiology, Chris Hani Baragwanath Hospital, 
its employees or agents, domestic and foreign regulatory health authorities, the South 
African Medicines Control Council and the University of the Witwatersrand, Human 
Research Ethics Committee (HREC). These records will be utilised by them only in 
connection with carrying out their obligations relating to this clinical study.  
Any information uncovered regarding your test results or state of health as a result of your 
participation in this study will be held in strict confidence. You will be informed of any 
finding of importance to your health or continued participation in this study but this 
information will not be disclosed to any third party in addition to the ones mentioned 
above without your written permission. The only exception to this rule will be cases of 
communicable diseases where a legal duty of notification of the Department of Health 
exists. In this case, you will be informed of my intent to disclose such information to the 
authorised state agency.  
 
PERSONAL DOCTOR / SPECIALIST NOTIFICATION OPTION:  
Please indicate below, whether you want me to notify your personal doctor or your 
specialist of your participation in this study:  
 
(   ) Yes, I want you to inform my personal doctor / specialist of my participation in this 
study. 
(   ) No, I do not want you to inform my personal doctor / specialist of my participation in 
this study  
(   ) I do not have a personal doctor / specialist  
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INFORMED CONSENT:  
I hereby confirm that I have been informed by the study doctor, Dr. Olaf Forster / Prof 
Karen Sliwa-Hähnle/Dr. Kemi Tibazarwa/Dr. Lerato Motsekuoa, about the nature, 
conduct, benefits and risks of the clinical study "Prevention of irreversible left ventricular 
remodelling in patients with postpartum cardiomyopathy by addition of bromocriptine to 
standard heart failure therapy", protocol number 123456. 
 I have also received, read and understood the above written information (Patient 
Information leaflet and Informed Consent) regarding this clinical study.  
 I am aware that the results of the study, including personal details regarding my 
sex, age, date of birth, and diagnosis will be anonymously processed into a study 
report.  
 In view of the requirements of research, I agree that the data collected during this 
study can be processed in a computerised system by the Soweto Cardiovascular 
Research Unit, Division of Cardiology, Chris Hani Baragwanath Hospital or on its 
behalf.  
 I may, at any stage, without prejudice, withdraw my consent and participation in 
the study.  
 I have had sufficient opportunity to ask questions and of my own free will declare 
myself prepared to participate in the study.  
 
 
 
Patient: ________________________________________________________________ 
Printed Name  Signature/Mark/Thumbprint Date and Time 
 
I, Prof. Karen Sliwa-Hähnle / Dr. Olaf Forster/Dr. Kemi Tibazarwa/Dr. Lerato 
Motsekuoa, herewith confirm that the above patient has been fully informed about the 
nature, conduct and risks of the above study. 
 
Study Doctor: ___________________________________________________________ 
Printed Name  Signature   Date and Time 
 
Study nurse/translator/other person explaining Informed Consent (Designation): 
 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
 
Witness (if applicable): 
 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
 114 
 
Appendix  2. Genetics Consent Forms 
 
 
Consent for PPCM Genetic Study – Form 2a English 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 REQUEST FOR MOLECULAR STUDIES (DNA) 
 
Molecular Laboratory  
Division of Human Genetics Blood should be drawn in 2 plastic EDTA Tubes 
1st Floor, Anatomy Building (Purple top) +/- 10ml each using a yellow barrel. 
UCT Medical School, Observatory 7925 Each tube should be inverted to mix and should be  
 clearly labelled with the patient's name and DOB 
Tel: (021) 406 6425        Fax: (021) 448-0906 Keep blood in fridge at 4°C until able to send to laboratory 
  
 Please DO NOT send specimens on ice or frozen. 
Please fill in all the information requested:  
 
Surname:____________________________________________First Name(s):_________________________________________ 
 
New Family:  Yes    No    (If no, please fill in family name)  Family name: ________________________________________ 
 
Medical Aid: ________________________________________________Medical Aid No: ________________________________ 
 
Sex:     M        F    Date of Birth:  Year:_____________  Month:_____________________  Day: ______________________ 
 
Number  of children: ______________________________________ 
 
Ethnic Origin : ( please indicate ancestry of both your mother and father )_______________________________________________ 
        Fax: 
Contact Address:  ____________________________________ Town: _______________________ Tel: ___________________ 
 
        Fax: 
Referring Doctor/Sister: ______________________________ Town:  ______________________ Tel: ___________________ 
 
        Fax: 
Hospital or Address:  _________________________________ Town:  ______________________ Tel: ___________________ 
 
 
Reason for Referral  (Clinical diagnosis): 
 
Affected                At Risk                 Carrier                 Spouse                 Query                 Unaffected   
 
ARVC  Hypertrophic Cardiomyopathy   Other Cardiomyopathy   
Dilated Cardiomyopathy  HIV Cardiomyopathy  Duchenne Muscular Dystrophy  
Peripartum Cardiomyopathy  Restrictive Cardiomyopathy   Hypertension   
 
Additional disorders (apparent or previously treated):  ______________________________________________________________ 
 
Additional family history                               _______________________________________________________________ 
 
Clinical Details: 
 
Physical disability           Mental retardation             Deafness             Impaired vision            Night blindness       
 
Other:  _________________________________________________________________________________________________ 
 
Have samples from this patient been sent to a DNA lab before? (DELETE WHERE NOT APPLICABLE)  YES / NO / Don't Know 
 
If Yes, where: ___________________________________________________________________________________________ 
 
For Laboratory use only: 
 
DNA number: _____________________________________  Vol.Blood: ________________(ml)     Other: _________________ 
 
Date Received:   Year: ________  Month:  ____________  Day:  _____________        Computer Index No:__________________ 
 
 
CONSENT FOR DNA ANALYSIS AND STORAGE 
 
1. 
 
I, ____________________________________________________________________  , request that an 
attempt be made using genetic material to assess the probability that:  I /  my child  /  my  unborn child  
(DELETE WHERE NOT APPLICABLE) might have inherited a disease-causing mutation in the gene 
for:______________________________________________________________________________________ 
  
2. I understand that the genetic material for analysis is to be obtained from:  blood cells/skin sample/other (specify) 
(DELETE WHERE NOT APPLICABLE) :     
  
3. I request that no portion of the sample be stored for later use.   (MARK IF APPLICABLE ) 
  Or 
I request that a portion of the sample be stored indefinitely for (DELETE WHERE NOT APPLICABLE): 
 ( a )  possible re-analysis 
 ( b )  analysis for the benefit of members of my immediate family 
 ( c )  research purposes,  subject to the approval of the University of Cape Town Research Ethics 
         Committee, provided that any information from such research will remain confidential. 
  
4. The results of the analysis carried out on this sample of stored biological material will be made known to me,  
via my doctor, in accordance with the relevant protocol,  if and when  available.  
In addition, I authorise that they may be made known to:  (DELETE WHERE NOT APPLICABLE) : 
 other doctors involved in my care 
 the following family members:   ___________________________________________________________ 
 other: _______________________________________________________________________________ 
  
5. I authorise / do not authorise my doctor(s) (DELETE WHERE NOT APPLICABLE) to provide relevant clinical 
details to the Division of Human Genetics, UCT. 
  
6. I have been informed that:  
( a ) there are risks and benefits associated with genetic analysis and storage of biological material and 
these have been explained to me.  
( b ) the analysis procedure is specific to the genetic condition mentioned above and cannot determine 
the complete genetic makeup of an individual. 
( c ) the genetics laboratory is under an obligation to respect medical confidentiality . 
( d ) genetic analysis may not be informative for some families or family members. 
( e ) even under the best conditions, current technology of this type is not perfect and could lead to 
incorrect results. 
( f ) where biological material is used for research purposes, there may be no direct benefit to me. 
  
7. I understand that I may withdraw my consent for any aspect of the above at any time without this affecting my 
future medical care. 
  
8. ALL OF THE ABOVE HAS BEEN EXPLAINED TO ME IN A LANGUAGE THAT I UNDERSTAND 
AND MY QUESTIONS ANSWERED BY: 
  
    ____________________________    DATE:     __________________                               
 
 
 
 
Patient signature _____________________   Witnessed consent    ___________________________ 
 
 
 
NOTE - PLEASE INSERT A FAMILY PEDIGREE DRAWING ON THE REVERSE OF THIS FORM 
 115 
 
 
 
 
Consent for PPCM Genetic Study – Form 2b isiZulu 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 REQUEST FOR MOLECULAR STUDIES (DNA) 
 
Molecular Laboratory  
Division of Human Genetics Blood should be drawn in 2 plastic EDTA Tubes 
1st Floor, Anatomy Building (Purple top) +/- 10ml each using a yellow barrel. 
UCT Medical School, Observatory 7925 Each tube should be inverted to mix and should be  
 clearly labelled with the patient's name and DOB 
Tel: (021) 406 6425        Fax: (021) 448-0906 Keep blood in fridge at 4°C until able to send to laboratory 
  
 Please DO NOT send specimens on ice or frozen. 
Please fill in all the information requested:  
 
Surname:____________________________________________First Name(s):_________________________________________ 
 
New Family:  Yes    No    (If no, please fill in family name)  Family name: ________________________________________ 
 
Medical Aid: ________________________________________________Medical Aid No: ________________________________ 
 
Sex:     M        F    Date of Birth:  Year:_____________  Month:_____________________  Day: ______________________ 
 
Number  of children: ______________________________________ 
 
Ethnic Origin : ( please indicate ancestry of both your mother and father )_______________________________________________ 
        Fax: 
Contact Address:  ____________________________________ Town: _______________________ Tel: ___________________ 
 
        Fax: 
Referring Doctor/Sister: ______________________________ Town:  ______________________ Tel: ___________________ 
 
        Fax: 
Hospital or Address:  _________________________________ Town:  ______________________ Tel: ___________________ 
 
 
Reason for Referral  (Clinical diagnosis): 
 
Affected                At Risk                 Carrier                 Spouse                 Query                 Unaffected   
 
ARVC  Hypertrophic Cardiomyopathy   Other Cardiomyopathy   
Dilated Cardiomyopathy  HIV Cardiomyopathy  Duchenne Muscular Dystrophy  
Peripartum Cardiomyopathy  Restrictive Cardiomyopathy   Hypertension   
 
Additional disorders (apparent or previously treated):  ______________________________________________________________ 
 
Additional family history                               _______________________________________________________________ 
 
Clinical Details: 
 
Physical disability           Mental retardation             Deafness             Impaired vision            Night blindness       
 
Other:  _________________________________________________________________________________________________ 
 
Have samples from this patient been sent to a DNA lab before? (DELETE WHERE NOT APPLICABLE)  YES / NO / Don't Know 
 
If Yes, where: ___________________________________________________________________________________________ 
 
For Laboratory use only: 
 
DNA number: _____________________________________  Vol.Blood: ________________(ml)     Other: _________________ 
 
Date Received:   Year: ________  Month:  ____________  Day:  _____________        Computer Index No:__________________ 
 
 
CONSENT FOR DNA ANALYSIS AND STORAGE 
IMVUMO YE DNA ANALYSIS NOKUGCINWA KWAYO 
  
 
1. Mina …………………………,ngicela kuzanywe ukuthi kusetshenziswe lokhu okuphathelene neDNA, 
kubhekisiswe ukuthi kungenzeka ukuthi mina / ingane yami / ingane yami engakabelethwa (susa 
okungaqondene) kungahle kwenzeke ukuthi kutholwe isifo esitholakala ngofuzo, esibanga uguquko kholokhu 
okuqala ofuzo kwisifo se :………………. 
 
2. Ngiyaqonda ukuthi lokhu okuzohlolwa kuzotholakala: kwigazi / isampuli yesi khumba / nokunye (ohaza) 
(susa okungaqondene) : 
 
3. Ngicela kungabikho ucezu lwe sampule elizogcinwa ukuze lusetshenziswe esikhathini esizayo.  (cikica 
ngokufanele) 
 
                      Noma 
 
4. Ngicela ucezu lwesampule luqcinnwe isikhashana noma singaphi ukuze lusetshenziswe (SUSA 
OKUNGAQONDENE ) 
(a) uma kungenzeka lihlaziwe 
(b) kuhlaziyo oluzoba uncedo kumndeni wami 
(c) kucwaningo (Research) ngemvume ye University of Cape Town Research Ethics Committee 
(ikomiti emele ucwaningo ngokomthetho, uma nje umbiko uzokubayimifihlo. 
 
5. Umbiko wohlaziyo olwenziwe ngamasampule ngizokwaziswa ngawo ngudokotela wami, ngendlela efanelekile 
yomgimo, uma noma usukhona. Futhi, nginikenza imvume ukuthikutshelwe: 
(SUSA OKUNGAQONDENE): 
udokotela ongilaphayo 
umndeni wami : _____________________________________ 
abanye :___________________________________________  
   
6. Nginikeza imvume\ anginikezi imvume udokotela noma odokotela (SUSA OKUNGAQONDENE) ukuthi 
kunikezwe ngemininingwane ephathelene nempilo yami kwi Division of Human Gentics, UCT. 
Ngitsheliwe ukuthi : 
(a) kungaba nengozi futhi kungaba noncedo oluhambisana naloluhlahlubo nokugcinwa kwalokhu 
okuphathelene nako ngachazelwa futhi. 
(b) Indlela okuqhutshwa ngayo kuloluhlahlubo oluqondene nofuzo osluchaziwe ngenhla, ngeke lukhombe 
ufuzo lonke lwendalo yomuntu. 
(c) I Genetics Laboratory ingaphansi kwesibopho sokuhlonipha imfihlo yokwelapha. 
(d) loluhlahlubo kungenzeka lungachazi lutho kweminye imindeni nezihlobo. 
(e)  noma ngabe ubuchwephesha kwesanyensi yaluphi uhlobo , kungenzeka imiphumela ingabi yiqiniso. 
(f) Angizukuba namvuzo kukho konke okuphathelene nesayensi yaloluhlahlubo 
a)  
 
Ngiyaqonda ukuthi ngingayihlehlisa imvume emayelana naluphi uhlobo olungenhla noma inini, ngaphandle 
kokuthinteka kokulashwa kwami esikhathini esizayo 
 
Konke okungenhla ngichazelwe ngakho ngolwimi engilizwayo futhi ngiphenduliwe imibuzo, ngu: 
__________________________________________ DATE___________ 
 
Igama lomguli (sayina  ___________________ Igama lofakazi ____________________ 
NOTE PLEASE INSERT A FAMILY PEDIGREE DRAWING ON THE REVERSE OF THIS FORM. 
 
 
Patient signature _____________________   Witnessed consent    ___________________________ 
 
 
 NOTE - PLEASE INSERT A FAMILY PEDIGREE DRAWING ON THE REVERSE OF THIS FORM 
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Appendix  3. Data Collection Tools 
 
 
Form 3a Proposed Cardiomyopathy Registry of Africa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
         Cardiomyopathy Questionnaire 
 
 
 
 
(DCM Study) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2   
- Patient Information 
 
1. Last Name_______________________________________ 
2. First Name_______________________________________ 
3. Date of Birth (dd/mm/yr)________________________________ 
4. Sex 1) Male  2) Female 
5. Education (1) No Schooling  (2) Primary (3) Secondary (4)Post Secondary  
6. Occupation  
     (1) Formal Employment: a.Skilled (Professional) b.Skilled (otherwise) c.Unskilled 
     (2) Informal Employment : a.Skilled  b.Unskilled [specify___________________] 
     (3) Unemployed  
7. Marital status (1) Married (2) Single (3)Divorced/Separated (4)Co-habiting 
8. National ID Number_______________________________ 
9. Nationality__________________________________ 
10. Home language____ 1=English 2=Afrikaans 3=Xhosa 4=Zulu 5=Sutu 6=Tshangani 7=Other 
11. Hospital number__________________________ 
12. Date of enrollment_ (dd/mm/yyyy)________________________________ 
13. Address – a) home ______________________ - b) postal___________________ 
14. Address- work___________________________________________ 
15. Telephone number – a) home _______________  – b) work_________________ 
16. Cell phone number________________________________________ 
17. Email address__________________________________________ 
18. Height (metres)____________________  
19. Weight (kg)________________________  
20. BMI (kg/m2)______________________  
3   
 – Referring Physician Information 
 
Last Name_________________________________ 
 
First Name_________________________________ 
 
Name of Hospital/ Health facility________________________ 
 
Address____________________________________________ 
 
City_______________________________________________ 
 
Province/State________________________________________ 
 
Phone – work_________________________________________ 
 
Cellular phone number___________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4   
 - HISTORY        
Date of first diagnosis of cardiomyopathy (dd/mm/yy) 
Date of earliest symptoms (dd/mm/yy) 
Presenting complaints 
 Present NYHA  Functional Class: (1) I (2) II (3) III  (4) IV 
 Palpitations                                                                 (0) No (1) Yes 
 Dizziness 
 Syncope 
 Chest pain 
 Leg swelling 
 Cardiac arrest 
 Other complaints _______________________ 
Date of first hospitalization for treatment or diagnosis of cardiomyopathy (dd/mm/yyyy) 
 
Past medical history 
       Specify  (0) No (1) Yes 
 Blood transfusion   __________________________________ 
 Cardiovascular __________________________________ 
 Pulmonary  ___________________________________ 
 Gastrointestinal ____________________________________ 
 Renal   ____________________________________ 
 Endocrine  ____________________________________ 
 Dermatological ____________________________________ 
 Haematological ____________________________________ 
 Neuromuscular/skeletal____________________________________ 
 Gynaecological ____________________________________ 
 Liver   ____________________________________ 
 Ophthalmic                 ____________________________________ 
 ENT              ____________________________________ 
 Repeated infections ____________________________________ 
 Flu-like illness ____________________________________ 
Obstetrics & Gynaecological history 
 Last menstrual period (dd/mm/yyyy)_____________________________ 
 Date of last delivery (dd/mm/yyyy)______________________________ 
 Any suggestion of amniotic fluid embolism in any pregnancy?       (0) No (1) Yes 
Family history 
 Family history of heart disease (0) No (1) Yes 
 Type of heart disease  _______________________ 
 Family history of sudden death (0) No (1) Yes 
 Number of sudden deaths in family members <35yrs old __________________ 
  Name  Relationship   Arrhythmic Events   Cardiomyopathy Diagnosed 
            
1.________ ___________  ________________   ____________________ 
2.________ ___________  ________________   ____________________ 
3. .________ ___________  ________________   ____________________ 
5   
Social history 
 Smoking  (0) No (1) Yes 
o pack years _________ 
 Alcohol intake (0) No (1) Yes 
o Quantity______________ 
o Quantity/week_____________ 
 
Medications  Dose (mg) Date started (dd/mm/yr) 
______________ ______ ___________ 
______________  _____  ____________ 
______________ ____  __________ 
______________ _______ ____________ 
_______________ _______ ______________ 
_____________ ________ ______________ 
____________ _______ ______________ 
___________  ________ ________________ 
 
Sports participation 
Prior level of participation in sports before diagnosis of Cardiomyopathy 
(1) Inactive (2) Recreational (3) Competitive/Professional (4) Unknown 
 
Prior level of participation in sports after diagnosis of Cardiomyopathy 
(1) Inactive (2) Recreational (3) Competitive/Professional (4) Unknown 
 
Sports practiced most often     (0) No (1) Yes 
 Rugby 
 Soccer 
 Baseball 
 Basketball 
 Hockey 
 Cricket 
 Tennis 
 Running 
 Biking 
 Swimming 
 Surfing 
 Other _______________________ 
 
 
 
 
 
 
 
 
 
6   
Family Tree 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7   
Physical examination and signs  
(0) Absent (1) Present 
 Pitting oedema of the legs 
 Blood pressure (mmHg) ____________ 
 Raised JVP  
 Pulse  
                        Rate _____________________ 
                        Character__________________ 
 Heart sounds 
o S3 
o S4 
o Gallop rhythm 
 Murmur 
o Systolic 
o Diastolic 
o Location _________________ 
o Grade __________________ 
o Timing __________________ 
o Character ________________ 
 Basal crepitations 
 Tender hepatomegaly 
 Ascites 
 Proximal muscle weakness 
 Deep tendon reflexes (1=normal or 2=abnormal) 
 Gait disturbance  
 
Chest X Ray 
Cardiothoracic ratio_______________________ 
Lung fields (0) Normal (2) Congested 
Left atrial enlargement (0) No (1) Yes 
Right ventricular enlargement (0) No (1) Yes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8   
 - ECG  
Standard measurements (25mm/sec) 
      (0) Done  (1) Not done 
Date (dd/mm/yyyy) 
 Ventricular rate (beats/min) _____________ 
  Baseline rhythm 
(1) Sinus rhythm 
(2) Junctional 
(3) Sinus arrhythmia 
(4) Sinus pause > 1.2sec (abrupt pause) 
(5) Pacemaker (mode) ________________ 
(6) Other ______________________ 
 PR interval (ms) ________________ 
 QRS axis ______________________ 
 ST depression(leads) ______________ 
 ST elevation (leads) __________________ 
 T wave inversion (depth in mm) _________________ 
 Abnormal Q waves (0) No (1) Yes 
 QT Interval(ms) __________________ 
 QTc (ms) ________________ 
 QT dispersion  _________________ 
 Left atrial enlargement (0) No (1) Yes 
 Right atrial enlargement(0) No (1) Yes 
 QRS morphology (0) Normal (1) Delta wave (2) RBBB 
      (3) LBBB) (4) LAH (5) LPH (6) RBBB + LAH or LPH 
 Arrhythmias 
(1) None 
(2) Atrial flutter  
(3) Atrial fibrillation  
(4) Supraventricular tachycardia  
(5) Ventricular ectopy 
(6) Non-sustained ventricular tachycardia (3-10 consecutive beats) 
(7)  Sustained ventricular tachycardia (> 10 consecutive beats)  
(8) Torsade de Pointes 
(6) Ventricular fibrillation 
2. PVC morphology 
(0) No PVC  (1) RBBB 
(2) LBBB  (4)Both RBBB and LBBB (5) Indeterminate 
 Others _____________________ 
 Heart block 
(0)None 
(1)1
st
 degree 
(2)2
nd
 degree________________________ 
(3)3
rd
 degree block 
 Presence of epsilon wave 0) No (1) Yes 
9   
 LVH 
 Sokolow-Lyon 0) No (1) Yes 
 Cornell voltage 0) No (1) Yes 
 
 
 
- ECHOCARDIOGRAPHY 
      (0) Done  (1) Not done 
Date (dd/mm/yy) ____________________ 
Heart rate (b/min) ______________________ 
Left atrial diameter (cm) ________________ 
Aortic root diameter (cm)  
Left ventricle 
IVSTd (cm)  
PTWd (cm) 
IVSTd/ PTWd ratio 
LVEDD (cm)  
LVESD (cm)  
FS (%)  
EF (%)  
EPSS (cm)  
SAM at rest: (0) No (1) Yes 
 
Short axis view 
Prominent LV trabeculation and deep intratrabecular recesses-Apical level (0) No (1) Yes 
Colour flow in recesses (0) No (1) Yes 
Ratio of noncompacted/compacted >2 (0) No (1) Yes 
LV wall motion (Global) (1) Normal (2) Mildly reduced (3) Severely reduced 
 
Regional LV Wall Motion 
(0) Normal (1) diastolic bulge (2) Mild hypokinesia (3) Severe hypokinesia (4)Akinesia 
(5) Dyskinesia (aneurysms)    (6) LV thinning 
 Septal ____ 
 Anterior________ 
 Posterolateral________ 
 Inferior_____________ 
 Apical____________ 
Mitral Valve Prolapse (1) None (2) Mild (3) Moderate (4) Severe 
 
Right ventricle 
Right ventricular outflow tract (RVOT) (cm) _______ 
Ratio of RVOT/Aortic valve ____________ 
 
Dilated RA (0) No (1) Yes 
Valve lesions (0) No (1) Yes 
Specify valve________________________options 1=tricuspid 2=pulmonary 
10   
Doppler studies 
Left ventricular outflow tract (LVOT) Velocity (m/s)  
LVOT pressure gradient at rest (continous wave)  
Aortic velocity 
Right ventricular pressure in systole (RVPs) (mmHg):  
 
Colour flow 
Presence of regurgitation (0) No (1) Yes 
   (Grade1-4, use 0 if not present)Mitral regurgitation grade _______ 
Aortic  regurgitation grade _________ 
Tricuspid regurgitation grade ________ 
Pulmonary regurgitation grade ________  
 
Diastolic function 
 
1. Using pulsed wave Doppler  
Mitral E wave (m/s) ______         
Mitral A wave (m/s) _____           
Mitral E/A Ratio ___________     
Deceleration time (ms) ___________ 
 
Tricuspid E wave (m/s) __________  
Tricuspid A wave (m/s) __________ 
Tricuspid E/A Ratio ___________      
Deceleration time (ms) __________  
 
2. Using tissue Doppler imaging 
LV (lateral annulus)  
Systolic myocardial velocity (Sm) (m/s) ___  
E wave (m/s) _______________                               
A wave (m/s) ____________                                                                    
E/A ratio ____________                                                                              
LV (medial annulus) 
Systolic myocardial velocity (Sm) (m/s) ___  
E wave (m/s) ______________                      
A wave (m/s) _______________                   
E/A ratio ______________                            
 
Presence of pericardial effusion (0) no (1) Yes 
Presence of mural thrombus (0) none (1) Yes 
RA ________ 
RV________ 
LA ___________ 
LV ___________ 
 
 
11   
- Cardiac catheterization  
    (0) Done  (1) Not done 
Date (dd/mm/yy) 
 
Left Ventricle 
Dilated LV (0) No (1) Yes 
LV global function (1) Normal (2) Mildly reduced (3) Severely reduced 
 
LV regional wall motion abnormalities 
  (1) Normal (2) Diastolic bulge (3) Mild hypokinesia (4) Severe hypokinesia  
  (5) Akinesia (6) Dyskinesia (aneurysms)  (7) Unknown 
 Septal 
 Anterior 
 Posterior Submitral 
 Inferior 
Apical 
Mitral regurgitation grade (1-4, use 0 if not present)  (5) Prolapse 
 
LV Measurements 
LVEDV (ml) 
LVESV (ml) 
LVEF (%) 
LV systolic pressure (mmHg) 
LV diastolic pressure (mmHg) 
LVEDP (mmHg) 
Aortic pressure (mmHg) 
LV systolic gradient  
 
Right Ventricle 
Dilated RV (0) No (1) Yes 
RV global function (1) Normal (2) Mildly reduced (3) Severely reduced 
 
RV Abnormalities- Morphology 
(0) Normal (1) Scalloped contours (series of sacs or pouches)  (2) Trabecular 
traverse deep fissure  (3) Trabecular hypertrophy (>4mm) (4) Aneurysm (5) Unknown 
 RVOT 
 Anteroseptal free wall 
 Subtricuspid posterobasal 
 Apical 
RV regional wall motion abnormalities 
  (1) Normal (2) Diastolic bulge (3) Mild hypokinesia (4) Severe hypokinesia  
  (5) Akinesia (6) Dyskinesia (aneurysms)  (7) Unknown 
 RVOT 
 Anteroseptal free wall 
 Subtricuspid posterobasal 
 Apical 
12   
RV Measurements 
RVEDV (ml) 
RVESV (ml) 
RVEF (%) 
Pulmonary artery pressure mean (mmHg) 
RA pressure (mmHg) 
RVEDP (mmHg) 
Pulmonary capillary wedge pressure (mmHg) 
Tricuspid regurgitation grade (1-4, use 0 if not present)   
Tricuspid valve prolapse 
 
Coronary angiography 
Dominance (1) Right (2) Left  (3) Balanced 
Presence of coronary artery obstruction (0) No (1) Yes 
Percentage of obstruction __________ 
Location of Stenosis (1) LMCA (2) LAD  (3) LCx (4) RCA 
 
BLOOD TEST RESULTS 
             (0) Done  (1) Not done                                   (0) Done  (1) Not done          
Haemoglobin (g/dl)        
White cell count                    
MCV (fl)                     
Platelet count                     
Random blood sugar (mmol)                  
Serum sodium (mmol/l)        
Potassium (mmol/l)         
Chloride (mmol/l)        
Urea (mmol/l)_______________                                          
Creatinine (µmol/l)                                          
Bilirubin (µmol/l)   
Alanine transferase (ALT) (U/l) 
Aspartate transferase(AST) (U/l) 
Albumin (g/dl) 
Total protein (g/dL)____________                                          
GGT  
ESR in 1 Hr 
C-reactive protein (mg/dl) 
Pro-BNP  
Total Cholesterol (mmol/l)  
HDL (mmol/l)  
TG (mmol/l)  
LDL (mmol/l)  
TSH (mIU/l) 
fT3 (pmol/l) 
fT4 (pmol/l)  
HIV screening _________      HIV confirmatory test _____________  
13   
GENETIC TESTING 
                                                                       (0) Done  (1) Not done 
Chromosomal location 
Genes identified  
Other ________________ 
 
 – Diagnosis 
 
Suspected diagnosis 
Final diagnosis 
Other____________________________ 
 
 
 - FOLLOW – UP  
Follow –up number _____________ 
Date of follow –up ________________(dd/mm/yyyy) 
Type of follow –up (1) Regularly scheduled follow up (2) unscheduled (3) lost to follow 
up 
 
Presenting complaints __________________ 
_____________________________________ 
Events since last follow up (1) No (2) Yes 
Details of Event ________________________ 
 
Current Medications 
 Drug name  Total daily Dose (mg) 
 _________  __________________ 
 ________  __________________ 
 __________  __________________ 
 __________  __________________ 
 ___________  ____________________ 
___________________ __________________ 
 ___________  ____________________ 
 
Surgery (1) No (2) Yes 
Type of surgery______________ 
Pacemaker insertion (1) No (2) Yes 
Date of Insertion (dd/mm/yr) 
Type of pacemaker ________________ 
ICD implantation (1) No (2) Yes 
Date of Insertion (dd/mm/yr) 
Catheter ablation (1) No (2) Yes 
Date performed dd/mm/yr 
Indication __________________ 
 
 
14   
TERMINAL EVENTS 
Cardiac death (1) No (2) Yes (3) Unknown 
Sudden death (1) No (2) Yes (3) Unknown 
Heart failure (1) No (2) Yes (3) Unknown 
Non cardiac death (1) No (2) Yes (3) Unknown 
Details ____________________________________ 
_______________________________________________ 
 
 
AUTOPSY (1) No (2) Yes (3) Unknown 
Results _________________________________________________ 
________________________________________________________ 
 
_____________________________________________________ 
___________________________________________________ 
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 Form 3b Echocardiography Form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                         Echocardiography Report Form (Courtesy of Groote Schuur Hospital) 
 
PD390                                        ECHOCARDIOGRAPHY REPORT 
 
  DD  / MM /   YYYY 
DATE:     WARD/DEPT: 
NAME:  DIAGNOSIS: 
I.D.:  
DOB: Sex :  RECORDING NO: 
HEIGHT________(cm)   WEIGHT________(Kg)   BSA_______(m
2
) 
 
LEFT VENTRICULAR STUDY AORTIC VALVE STUDY 
 DIASTOLIC SYSTOLIC 
RVW  cm (-)  cm AORTA (2-3.8)  cm 
RVID  cm (2.8)  cm L.A. (2-4)  cm 
IVS  cm (0.5-1.3)  cm PEAK GRADIENT  mmHg 
LVID  cm (3-5.3)  cm MEAN GRADIENT  mmHg 
LVPW  cm (0.8-1.2)  cm PEAK VELOCITY  m/Sec 
 PRESSURE HALFTIME  m/Sec 
SHORTENING FRACTION  % (24 - 41)  
EJECTION FRACTION  % 
 
MITRAL VALVE STUDY TRICUSPID VALVE STUDY 
D.E.  cm REGURG. VELOCITY  m/Sec 
E-F  cm/Sec RV SYSTEM PRESS.  mmHg + JVP 
MITRAL VALVE AREA  cm²  
PEAK E. VELOCITY  m/Sec 
PEAK A. VELOCITY  m/Sec PULMONARY VALVE STUDY 
E:A RATIO   PEAK VELOCITY  m/Sec 
MEAN GRADIENT  mmHg PEAK GRADIENT  mmHg 
PRESSURE HALFTIME  m/Sec  
MV DECT  m/Sec 
TDI   
LATERAL Ea VELOCITY  cm/Sec 
LATERAL Sa VELOCITY  cm/Sec 
PW/TDI E/Ea RATIO   
 
REPORT 
 
OPERATOR: CONSULTANT: 
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 Form 3c The Minnesota Code 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Minnesota Code Classification System= for
 Electrocardiographic Findings
Q and QS Patterns
(Do not code in the presence of WPW code 6-4-1.)  To qualify as a Q- or QS-wave, the deflection should be at least 0.1
mV (1 mm in amplitude).
Anterolateral site (leads I, aVL, V6)
1-1-1 Q/R amplitude ratio ≥ 1/3, plus Q duration ≥ 0.03 sec in lead I or V6.
1-1-2 Q duration ≥ 0.04 sec in lead I or V6.
1-1-3 Q duration ≥ 0.04 sec, plus R amplitude ≥ 3 mm in lead aVL.
1-2-1 Q/R amplitude ratio ≥ 1/3, plus Q duration ≥ 0.02 sec and < 0.03 sec in lead I or V6.
1-2-2 Q duration ≥ 0.03 sec and < 0.04 sec in lead I or V6.
1-2-3 QS pattern in lead I.  Do not code in the presence of 7-1-1.
1-2-8 Initial R amplitude decreasing to 2 mm or less in every beat (and absence of codes 3-2, 7-1-1, 7-2-1, or 7-3
between V5 and V6.  (All beats in lead V5 must have an initial R > 2 mm.)
1-3-1 Q/R amplitude ratio ≥ 1/5 and < 1/3, plus Q duration ≥ 0.02 sec and < 0.03 sec in lead I or V6.
1-3-3 Q duration ≥ 0.03 sec and < 0.04 sec, plus R amplitude ≥ 3 mm in lead aVL.
Posterior (inferior) site (leads II, III, aVF)
1-1-1 Q/R amplitude ratio ≥ 1/3, plus Q duration ≥ 0.03 sec in lead II.
1-1-2 Q duration ≥ 0.04 sec in lead II.
1-1-4 Q duration ≥ 0.05 sec in lead III, plus a Q-wave amplitude ≥ 1.0 mm in the majority of beats in lead aVF.
1-1-5 Q duration ≥ 0.05 sec in lead aVF.
1-2-1 Q/R amplitude ratio ≥ 1/3, plus Q duration ≥ 0.02 sec and < 0.03 sec in lead II.
1-2-2 Q duration ≥ 0.03 sec and < 0.04 sec in lead II.
1-2-3 QS pattern in lead II. Do not code in the presence of 7-1-1.
1-2-4 Q duration ≥ 0.04 sec and < 0.05 sec in lead III, plus a Q-wave ≥ 1.0 mm amplitude in the majority of beats in
aVF.
1-2-5 Q duration ≥ 0.04 sec and < 0.05 sec in lead aVF.
1-2-6 Q amplitude ≥ 5.0 mm in leads III or aVF.
1-3-1 Q/R amplitude ratio ≥ 1/5 and < 1/3, plus Q duration ≥ 0.02 sec and < 0.03 sec in lead II.
1-3-4 Q duration ≥ 0.03 sec and < 0.04 sec in lead III, plus a Q-wave ≥ 1.0 mm amplitude in the majority of beats in
lead aVF.
1-3-5 Q duration ≥ 0.03 sec and < 0.04 sec in lead aVF.
1-3-6 QS pattern in each of leads III and aVF.  (Do not code in the presence of 7-1-1.)
Anterior site (leads V1, V2, V3, V4, V5)
1-1-1 Q/R amplitude ratio ≥ 1/3 plus Q duration ≥ 0.03 sec in any of leads V2, V3, V4, V5.
1-1-2 Q duration ≥ 0.04 sec in any of leads V1, V2, V3, V4, V5.
1-1-6 QS pattern when initial R-wave is present in adjacent lead to the right on the chest, in any of leads V2, V3,
V4,V5, V6.
1-1-7 QS pattern in all of leads V1-V4 or V1-V5.
1-2-1 Q/R amplitude ratio ≥ 1/3, plus Q duration ≥ 0.02 sec and < 0.03 sec, in any of leads V2, V3, V4, V5.
1-2-2 Q duration ≥ 0.03 sec and < 0.04 sec in any of leads V2, V3, V4, V5.
1-2-7 QS pattern in all of leads V1, V2, and V3.  (Do not code in the presence of 7-1-1).
1-2-8 Initial R amplitude decreasing to 2.0 mm or less in every beat (and absence of codes 3-2, 7-1-1, 7-2-1, or 7-3)
between any of leads V2 and V3, V3 and V4, or V4 and V5.  (All beats in the lead immediately to the right on the
chest must have an initial R > 2 mm.)
1-3-1 Q/R amplitude ratio ≥ 1/5 and < 1/3 plus Q duration ≥ 0.02 and < 0.03 sec in any of leads V2, V3, V4, V5.
1-3-2 QS pattern in lead V1 and V2.  (Do not code in the presence of 3-1 or 7-1-1.)
QRS Axis Deviation
(Do not code in presence of low-voltage QRS, code 9-1, WPW 6-4-1, ventricular conduction defects, or 7-1-1, 7-2-1, and
7-4.)
2-1 Left.  QRS axis from -300 through -900 in leads I, II, III.  (The algebraic sum of major positive and major
negative QRS waves must be zero or positive in I, negative in III, and zero or negative in II.)
2-2 Right.  QRS axis from +1200 through -1500 in leads I, II, III. (The algebraic sum of major positive and major
negative QRS waves must be negative in I, and zero or positive in III, and in I must be one-half or more of that in
III.)
2-3 Right (optional code when 2-2 is not present).  QRS axis from +900 through +1190 in leads I, II, III.  (The
algebraic sum of major positive and major negative QRS waves must be zero or negative in I and positive in II
and III.)
2-4 Extreme axis deviation (usually S1, S2, S3 pattern).  QRS axis from -900 through -1490 in leads I, II, and III
(The algebraic sum of major positive and major negative QRS waves must be negative in each of leads I, II, and
III.)
2-5 Indeterminate axis QRS axis approximately 900 from the frontal plane.  (The algebraic sum of major positive and
major negative QRS waves is zero in each of leads I, II and III, or the information from these three leads is
incongruous.)
High Amplitude R Waves
3-1 Left:  R amplitude > 26 mm in either V5 or V6, or R amplitude > 20.0 mm in any of leads I, II, III, aVF, or R
amplitude > 12.0 mm in lead aVL. (All criteria measured only on second to last complete normal beat.)
3-2 Right: R amplitude ≥ 5.0 mm and R amplitude ≥ S amplitude in the majority of beats in lead V1, when S
amplitude is > R amplitude somewhere to the left on the chest of V1 (codes 7-3 and 3-2, if criteria for both are
present).
3-3 Left (optional code when 3-1 is not present):  R amplitude > 15.0 mm but ≤ 20.0 mm in lead I, or R amplitude in
V5 or V6, plus S amplitude in V1 > 35.0 mm. (Measured only on second to last complete normal beat.)
3-4 Criteria for 3-1 and 3-2 both present.
ST Junction (J) and Segment Depression
(Do not code in the presence of codes 6-4-1, 7-1-1, 7-2-1 or 7-4.  When 4-1, 4-2, or 4-3 is coded, then a 5-code must
also be assigned except in lead V1.)
Anterolateral site (leads I, aVL, V6)
4-1-1 STJ depression ≥ 2.0 mm and ST segment horizontal or downward sloping in any of leads I, aVL, or  V6.
4-1-2 STJ depression ≥ 1.0 mm but < 2.0 mm, and ST segment horizontal or downward sloping in any of leads I,
aVL, or V6.
4-2 STJ depression ≥ 0.5 mm and < 1.0 mm and ST segment horizontal or downward sloping in any of leads I,
aVL, or V6.
4-3 No STJ depression as much as 0.5 mm but ST segment downward sloping and segment or T-wave nadir ≥ 0.5
mm below P-R baseline, in any of leads I, aVL, or V6.
4-4 STJ depression ≥ 1.0 mm and ST segment upward sloping or U-shaped, in any of leads I, aVL, or V6.
Posterior (inferior) site (leads II, III, aVF)
4-1-1 STJ depression ≥ 2.0 mm and ST segment horizontal or downward sloping in lead II or aVF.
4-1-2 STJ depression ≥ 1.0 mm but < 2.0 mm and ST segment horizontal or downward sloping in lead II or aVF.
4-2 STJ depression ≥ 0.5 mm and < 1.0 mm and ST segment horizontal or downward sloping in lead II or aVF.
4-3 No STJ depression as much as 0.5 mm, but ST segment downward sloping and segment or T-wave nadir ≥
0.5 mm below P-R baseline in lead II.
4-4 STJ depression ≥ 1.0 mm and ST segment upward sloping, or U-shaped, in lead II.
ST Junction (J) and Segment Depression (continued)
Anterior site (leads V1, V2, V3, V4, V5)
4-1-1 STJ depression ≥ 2.0 and ST segment horizontal or downward sloping in any of leads V1, V2, V3, V4, V5.
4-1-2 STJ depression ≥ 1.0 mm but < 2.0 mm and ST segment horizontal or downward sloping in any of leads V1,
V2, V3, V4, V5
4-2 STJ depression ≥ 0.5 mm and < 1.0 mm and ST segment horizontal or downward sloping in any of leads V1,
V2, V3, V4, V5.
4-2 No STJ depression as much as 0.5 mm, but ST segment downward sloping and segment or
T-wave nadir ≥ 0.5 mm below P-R baseline in any of leads V2, V3, V4, V5.
4-4 STJ depression ≥ 1.0 mm and ST segment upward sloping or U-shaped in any of leads V1, V2, V3, V4, V5.
T-Wave Items
(Do not code in the presence of code 6-4-1, 7-1-1, 7-2-1 or 7-4.)
Anterolateral site (leads I, aVL, V6)
5-1 T amplitude negative 5.0 mm or more in either of leads I, V6, or in lead aVL when R amplitude is ≥ 5.0 mm.
5-2 T amplitude negative or diphasic (positive-negative or negative-positive type) with negative phase at least 1.0
mm but not as deep as 5.0 mm in lead I or V6, or in lead aVL when R amplitude is ≥ 5.0 mm.
5-3 T amplitude zero (flat), or negative, or diphasic (negative-positive type only) with less than 1.0 mm negative
phase in lead I or V6, or in lead aVL when R amplitude is ≥ 5.0 mm.
5-4 T amplitude positive and T/R amplitude ratio < 1/20 in any of leads I, aVL, V6;  R wave amplitude must be ≥
10.0 mm.
Posterior (inferior) site (leads II, III, aVF)
5-1 T amplitude negative 5.0 mm or more in lead II, or in lead aVF when QRS is mainly upright.
5-2 T amplitude negative or diphasic with negative phase (negative-positive or positive-negative type) at least 1.0
mm but not as deep as 5.0 mm in lead II, or in lead aVF when QRS is mainly upright.
5-3 T amplitude zero (flat), or negative, or diphasic (negative-positive type only) with less than 1.0 mm negative
phase in lead II; not coded in lead aVF.
5-4 T amplitude positive and T/R amplitude ratio < 1/20 in lead II; R wave amplitude must be ≥ 10.0 mm.
Anterior site (leads V2, V3, V4, V5)
5-1 T amplitude negative 5.0 mm or more in any of leads V2, V3, V4, V5.
5-2 T amplitude negative (flat), or diphasic (negative-positive or positive-negative type) with negative phase at least
1.0 mm but not as deep as 5.0 mm, in any of leads V2, V3, V4, V5.
5-3 T amplitude zero (flat), or negative, or diphasic (negative-positive type only) with less than 1.0 mm negative
phase, in any of leads V3, V4, V5.
5-4 T amplitude positive and T/R amplitude ratio < 1/20 in any of leads V3, V4, V5;  R wave amplitude must be ≥
10.0 mm.
A-V Conduction Defect
6-1 Complete (third degree) A-V block (permanent or intermittent) in any lead.  Atrial and ventricular complexes
independent, and atrial rate faster than ventricular rate, with ventricular rate < 60.
6-2-1 Mobitz Type II (occurrence of P-wave on time with dropped QRS and T).
6-2-2 Partial (second degree) A-V block in any lead (2:1 or 3:1 block).
6-2-3 Wenckebach's Phenomenon (P-R interval increasing from beat to beat until QRS and T dropped).
6-3  P-R (P-Q) interval ≥ 0.22 sec in the majority of beats in any of leads I, II, III, aVL, aVF.
6-4-1 Wolff-Parkinson-White Pattern (WPW), persistent.  Sinus P-wave.  P-R interval < 0.12 sec, plus QRS duration ≥
0.12 sec, plus R peak duration ≥ 0.06 sec, coexisting in the same beat and present in the majority of beats in any
of leads I, II, aVL, V4, V5, V6.  (6-4-1 suppresses 1-2-3, 1-2-7, 1-2-8, 1-3-2, 1-3-6, all 3, 4, 5, 9-2, 9-4, 9-5
codes.)
6-4-2 WPW Pattern, intermittent.  WPW pattern in ≤ 50% of beats in appropriate leads.
6-5 Short P-R interval.  P-R interval < 0.12 sec in all beats of any two of leads I, II, III, aVL, aVF.
6-6 Intermittent aberrant atrioventricular conduction.  P-R > 0.12 sec (except in presence of 6-5 or heart rate greater
than 100);  wide QRS complex > 0.12 sec; normal P-wave when most beats are sinus rhythm.  (Do not code in
the presence of 6-4-2.)
6-8 Artificial pacemaker.
Ventricular Conduction Defect
7-1-1 Complete left bundle branch block (LBBB).  (Do not code in presence of 6-1, 6-4-1, 6-8, 8-2-1 or 8-2-2.)  QRS
duration ≥ 0.12 sec in a majority of beats in any of leads I, II, III, aVL, aVF, plus R peak duration ≥ 0.06 sec in a
majority of beats (of the same QRS pattern) in any of leads I, II, aVL, V5, V6.  (7-1-1 suppresses 1-2-3, 1-2-7, 1-
2-8, 1-3-2, 1-3-6, all 2, 3, 4, 5, 9-2, 9-4, 9-5 codes.  If any other codable Q-wave coexists with the LBBB pattern,
code the Q and diminish the 7-1-1 code to a 7-4 code.)
7-1-2 Intermittent left bundle branch block.  Same as 7-1-1 but with presence of normally conducted
QRS complexes of different shape than the LBBB pattern.
7-2-1 Complete right bundle branch block (RBBB).  (Do not code in the presence of 6-1, 6-4-1, 6-8, 8-2-1 or 8-2-2.)
QRS duration ≥ 0.12 sec in a majority of beats in any of leads I, II, III, aVL, aVF, plus: R' > R in V1 or V2; or
QRS mainly upright, with R peak duration ≥ 0.06 sec in V1 or V2; or S duration >R duration in all beats in lead I
or II.  (7-1 suppresses 1-2-3, 1-2-7, 1-2-8, 1-3-2, 1-3-6, all 2, 3, 4, 5, 9-2, 9-4, 9-5 codes.
7-2-2 Intermittent right bundle branch block. Same as 7-2-1 but with presence of normally conducted QRS complexes
of different shape than the RBBB pattern.
7-3 Incomplete right bundle branch block.  QRS duration < 0.12 sec in each of leads I, II, III, aVL, aVF, and R' > R in
either of leads V1, V2 .(Code as 3-2 in addition if those criteria are met.  7-3 suppresses code 1-2-8.)
7-4 Intraventricular block.  QRS duration ≥ 0.12 sec in a majority of beats in any of leads I, II, III, aVL, aVF.  (7-4
suppresses all 2, 3, 4, 5, 9-2, 9-4, 9-5 codes.)
7-5 R-R' pattern in either of leads V1, V2 with R' amplitude ≥ R.
7-6 Incomplete left bundle branch block.  (Do not code in the presence of any codable Q- or QS-wave.)  QRS duration
≥ 0.10 sec and < 0.12 in the majority of beats of each of leads I, aVL, and V5 or V6.
7-7 Left anterior hemiblock (LAH).  QRS duration < 0.12 sec in the majority of beats in leads I, II, III, aVL, aVF, plus
Q-wave amplitude ≥ 0.25 mm and < 0.03 sec duration in lead I, plus left axis deviation of -450 or more negative.
(In presence of 7-2, code 7-8 if axis is < -450 and the Q-wave in lead I meets the above criteria.)
7-8 Combination of 7-7 and 7-2.
Arrhythmias
8-1-1 Presence of frequent atrial or junctional premature beats (10% or more of recorded complexes).
8-1-2 Presence of frequent ventricular premature beats (10% or more of record complexes).
8-1-3 Presence of both atrial and/or junctional premature beats and ventricular premature beats (so that individual
frequencies are < 10% but  combined premature beats are ≥ 10% of complexes).
8-1-4 Wandering atrial pacemaker.
8-1-5 Presence of 8-1-2 and 8-1-4.
8-2-1 Ventricular fibrillation or ventricular asystole.
8-2-2 Persistent ventricular (idioventricular) rhythm.
8-2-3 Intermittent ventricular tachycardia.  Three or more consecutive ventricular premature beats occurring at a rate
≥100.  This includes more persistent ventricular tachycardia.
8-2-4 Ventricular parasystole (should not be coded in presence of 8-3-1).
8-3-1 Atrial fibrillation (persistent).
8-3-2 Atrial flutter (persistent).
8-3-3 Intermittent atrial fibrillation (code if 3 or more clear-cut, consecutive sinus beats are present in any lead).
8-3-4 Intermittent atrial flutter (code of 3 or more clear-cut, consecutive sinus beats are present in any lead).
8-4-1 Supraventricular rhythm persistent.  QRS duration < 0.12 sec; and absent P-waves or presence of abnormal P-
waves (inverted or flat in aVF); and regular rhythm.
8-4-2 Supraventricular tachycardia intermittent.  Three consecutive atrial or junctional premature beats occurring at a
rate ≥ 100.
8-5-1 Sinoatrial arrest.  Unexpected absence of P, QRS and T, plus a R-R interval at a fixed multiple of he normal
interval, + 10%.
8-5-2 Sinoatrial block.  Unexpected absence of P, QRS and T, preceded by progressive shortening of P-P intervals.  (R-
R interval at a fixed multiple of the normal interval, + 10%.
8-6-1 A-V dissociation with ventricular pacemaker (without capture).  Requires: P-P and R-R occur at variable rates
with ventricular rate as fast as or faster than the atrial rate, plus variable P-R intervals, plus no capture beats.
8-6-2 A-V dissociation with ventricular pacemaker (with capture).
8-6-3 A-V dissociation with atrial pacemaker (without capture).
8-6-4 A-V dissociation with atrial pacemaker (with capture).
8-7 Sinus tachycardia (over 100/min).
8-8 Sinus bradycardia (under 50/min).
8-9 Other arrhythmias.  Heart rate may be recorded as a continuous variable.
ST Segment Elevation
Anterolateral site (leads I, aVL, V6)
9-2 ST segment elevation ≥ 1.0 mm in any of leads I, aVL, V6.
Posterior (inferior) site (leads II, III, aVF)
9-2 ST segment elevation ≥ 1.0 mm in any of leads II, III, aVF.
Anterior site (leads V1, V2, V3, V4,V5)
9-2 ST segment elevation ≥ 1.0 mm in lead V5 or ST segment elevation ≥ 2.0 mm in any of leads V1, V2, V3, V4.
Miscellaneous Items
9-1 Low QRS amplitude.  QRS peak-to-peak amplitude < 5 mm in all beats in each of leads I, II, III, or < 10 mm in all
beats in each of leads V1, V2, V3, V4, V5, V6.  (Check calibration before coding.)
9-3 P-wave amplitude ≥ 2.5 mm in any of leads II, III, aVF, in a majority of beats.
9-4-1 QRS transition zone at V3 or to the right of V3 on the chest.  (Do not code in the presence of 6-4-1, 7-1-1, 7-2-1
or 7-4.)
9-4-2 QRS transition zone at V4 or to the left of V4 on the chest. (Do not code in the presence of 6-4-1, 7-1-1, 7-2-1 or
7-4.)
9-5 T-wave amplitude > 12 mm in any of leads I, II, III, aVL, aVF, V1, V2, V3, V4, V5, V6.  (Do not code in the
presence of 6-4-1, 7-1-1, 7-2-1 or 7-4.)
9-8-1 Technical problems which interfere with coding.
9-8-2 Technical problems which do not interfere with coding.
Incompatible Codes
The codes in the left column suppress codes in the right column.
Code                           Suppress this code(s)
All Q-, QS-codes 7-6
Q > 0.03 in lead I 7-7
3-1 1-3-2
3-2 1-2-8, 7-3
6-1 All other codes except 8-2
6-4-1 All other codes
6-8 All other codes
7-1-1 1-2-3, 1-2-7, 1-2-8, 1-3-2, 1-3-6, all 2-, 3-, 4-, and 5- codes, 7-7, 9-2, 9-4, 9-5
7-2-1 1-2-8, all 2-, 3-, 4-, and 5-codes, 9-2, 9-4, 9-5
7-3 1-2-8
7-4 All 2-, 3-, 4-, and 5-codes, 9-2, 9-4, 9-5
8-1-2 8-2-4
8-1-4 8-1-1, 9-3
8-2-1 All other codes
8-2-2 All other codes
8-2-3 8-1-2
8-3-1 8-1-1, 8-1-2
8-3-2 6-2-2, 8-1-1, 8-1-2
8-3-3 8-1-1, 8-1-2
8-3-4 6-2-2
8-4-1 6-5
8-4-1 + heart rate ≥ 140 All other codes except 7-4 or 6-2
Heart rate > 100 6-5
8-4-2 8-1-1
9-1 All 2-codes
Categories of Minnesota ECG Abnormalities
Diagnostic ECG:
(any ECG may be used for this classification)
D1. An ECG record with any Diagnostic Q-code (Minn. code 1-1-1 through 1-2-5 plus 1-2-7).
D2. An ECG record with ST-segment elevation code 9-2 PLUS (T-wave inversion code 5-1 or
5-2 in the absence of 7-2-1 or 7-4).
Equivocal ECG:
(any ECG may be used for this classification)
E1. An ECG record with an Equivocal Q-code [(Minn. code 1-2-8 in the absence of a 7-1-1 or
7-3 or (any 1-3-code)].
E2. An ECG record with ST-segment depression (code 4-1-x or 4-2 or 4-3 in the absence of 7-
2-1 or 7-4), or 1-3-x.
E3. An ECG record with T-wave inversion (code 5-1 or 5-2 or 5-3 in the absence of 7-2-1 or 7-
4).
E4. An ECG record with ST-segment elevation code 9-2.
Other ECG:
01. Reference ECG coded 7-1-1.
02. Any ECG coded 7-1-1.
03. Normal ECG(s), defined as 1 in “clear” field of all ECGs.
04. Other findings including 1-2-6.
Uncodable ECG:
U1.  Technical errors coded 9-8-1 by Minnesota Code.
Absent ECG:
A1.  No ECG available for coding.
= Prineas R, Crow R, Blackburn H.  The Minnesota Code Manual of Electrocardiographic
Findings. John Wright-PSG, Inc. Littleton, MA, June 1982.
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Appendix 5. Documents advertising for PPCM patient recruitment 
 
 
5a  Poster (Johannesburg) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WHO AND WHAT ARE WE STUDYING?
We would like to examine the women with PPCM, and her adult close family 
members, as we suspect family members may be at risk of developing 
similar problems with their heart. We will perform all necessary tests and 
provide follow up care for these women and their adult family members.
Calling the Heart Failure 
clinic on (011) 933 8879 
and speaking to: 
Sr. Bridget Phooke (Research Nurse)
Louis Kunika (Also : 933 8000 #6501)
Dr. Tibazarwa
Prof. Sliwa (933 8000 #6513)
Coming straight to the “Heart of Soweto” 
Cardiac Research Unit at the Cardiology 
department, Chris Hani Baragwannath 
Hospital, on any working day of the week.
WHAT IS PERIPARTUM CARDIOMYOPATHY?
Peripartum cardiomyopathy (PPCM) is one of several types of heart diseases 
where the main heart chamber is enlarged and so the heart does not pump 
properly (Dilated Cardiomyopathy).
OR
THE SOWETO CARDIAC RESEARCH UNIT (CRU) 
is launching a new study 
on familial 
and would like to invite you and your 
family to participate in the study!
 PERIPARTUM CARDIOMYOPATHY
Division of Cardiology
Chris Hani Baragwanath Hospital
P O Bertsham 
Johannesburg 2013
 
 
WARD 18 
 
WARD 20 
COLLEGE
 
ENTRANCE
 
 
SOWET0  
TAXI
 
RANK
 
 
MORTUARY
 
 
WARD 31
 
M
 
BRIDGE
 
MAIN GATE
 
GYNAE STREET
 
METABOLLIC STREET 
MEDICAL STREET 
 
CONSTRUCTION 
SITE
 
 
 
 
 e  
CARDIOLOGY
HEART OF SOWETO
Unusual shortness
 of breath Feeling of 
heart racing
Chest pain
Fainting
Recent new diagnosis
 of heart failure
 associated with pregnancy OR
Swelling of the legs 
combined with any
 one of the above
If you or any woman that you know fit this profile, please contact us by either :
We are seeking women in late pregnancy or within their first 6 
months after delivery who experience  the following :
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 5b Brochure (Johannesburg) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PERIPARTUM CARDIOMYOPATHY 
 
A NEW STUDY 
Peripartum cardiomyopathy (PCM) is an acute form of heart failure whereby 
the left ventricle is enlarged and systolic function is reduced.  
 
We are seeking women in late pregnancy or within their first 5 months after 
delivery who present with symptoms or signs of: 
 
Recent or new diagnosis of acute heart failure unexplained 
by any known prior/concurrent condition 
 
And who fit with the following inclusion and exclusion criteria: 
 
 
 
 
 
 
 
 
 
 
___________________________________________________________ 
We would greatly appreciate you would ask these patients to visit our  
Tuesday morning clinic at the Cardiac Clinic, New Groote Schuur Hospital,  
to be seen at our clinic as soon as possible when they have stabilised from  
initial hospital discharge. We will see the patient for 2 visits, after which we  
will refer them back to their original clinics for follow-up. 
                                                                                OR 
Please contact either of the following: 
• Dr. Tibazarwa (Bleep XXXX) 
• Dr. Ntusi (Bleep 2345) 
• Sister Tshifularo (UCT – 021 406 6361) 
 
 
 
INCLUSION CRITERIA 
 
• Unexplained acute left sided 
failure with LV dilatation; 
REGARDLESS of HIV status 
 
• On full  treatment and 
ambulant 
EXCLUSION CRITERIA 
 
1. Hypertension or hypertensive heart 
disease (alone or in pregnancy; 
current or in prior pregnancies) 
 
2. Valvular heart disease 
 
3. Structural heart disease of any 
kind 
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 5c  Poster (Cape Town) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WE NEED YOUR HELP TO 
HELP THESE WOMEN AND 
THEIR FAMILIES
Chris Hani 
Baragwanath Hospital
P.O Bertsham, 
Johannesburg 2013
If you know of any woman 
who fits this profile, and who 
would like to join in our 
study, please ask them to 
contact us by either:
Calling the Heart Failure 
Clinic on (011) 933 8879 
and speaking to: 
Sr. Bridget Phooke
Louis Kunika (933 8000 #6501)
Dr. Tibazarwa
Prof. Sliwa (933 8000 #6513)
Coming straight to the “Heart 
of Soweto” Cardiac Research 
Unit at the Cardiology 
Department, Chris Hani 
Baragwanath Hospital, on 
any working day of the week.
OR
SOWETO 
DIVISION OF
 CARDIOLOGY
 
 
WARD 18
 
 
WARD 20
 
COLLEGE
 
ENTRANCE
 
 
SOWET0  
TAXI  
RANK
 
 
MORTUARY
 
 WARD 31
 
M  
BRIDGE  
MAIN GATE
 
GYNAE STREET 
METABOLLIC STREET
 
MEDICAL STREET
 
 
CONSTRUCTION 
SITE 
 
 
 
  
CARDIOLOGY
HEART OF SOWETO
What Is Peripartum 
Cardiomyopathy?
Peripartum 
Cardiomyopathy, or 
PPCM, is one of several 
types of heart diseases 
where the main heart 
chamber is enlarged and 
the heart does not pump 
properly (Dilated 
Cardiomyopathy).
Who Can Get PPCM?
PPCM is a rare illness that 
occurs in women any time 
between their last month 
of pregnancy and within 
the first 5 months of 
delivery. 
A woman in her last month 
of pregnancy or in the first 
5months after delivery may 
have PPCM if she feels any 
of the following:
Ø Unusual shortness of 
breath
Ø Feeling of heart racing
Ø Chest pain
Ø Fainting
Ø Recent diagnosis of heart 
failure associated with 
pregnancy
Ø Swelling of the legs 
combined with any of the 
above
OR
Not everybody who feels 
this has PPCM! 
BUT!!!!
If you or any woman you 
know has experienced 
the symptoms listed on 
t h e  p r e v i o u s  p a g e  
between her last month of 
pregnancy and the first 5 
months after pregnancy, 
we would like to see her, 
and later also her close 
family members.
Ø To be able to help 
more women with 
PPCM, we want to 
better understand 
this rare disease.
Ø We strongly suspect 
family members may 
be at risk of 
developing similar 
problems with their 
heart.
WHY???
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Appendix 6. Cardiomyopathy Registry (electronic database) 
 
 
6a  One-page summary/guide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cardiomyopathy Database 
 
How to open the Cardiomyopathy database 
Open it with Access database and enter research when asked for a password. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How to enter new record 
When the database is first opened, the screen is ready to accept new record. If it currently 
displays a certain record, just click on the ’Add Record’ button (circled in blue) found on the 
upper right corner of the screen. To go from one field to another, simply click the tab key. 
When the end of the field on a page is reached, it will automatically go to the next 
window/page. 
 
How to save record 
Each time a data is entered in a field, the data is automatically saved. But for your ease of 
mind, simply click the ‘Save Record’ button (circled in purple) to save a record or updated 
data. 
 
How to display an existing record 
Click on the drop down button (shown below in red circle) and a list of existing record will be 
displayed. Select the record you want to display and it will show up on your form. 
 
How to display a list of all the patients recorded on the database 
A list of all the patients with their date of birth and gender will be displayed when the ‘Display 
All Patients’ (circled in green) button is clicked. 
 
How to print a list of all the patients recorded on the database 
Click the ‘Print List’ button (circled in yellow) and a list of patients recorded in the database 
will be printed in the default printer. Note: Make sure that the computer is connected to a printer.   
 
How to exit from the database 
Click the ‘Exit database’ button (circled in orange).   
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6b Index of Data/Terminology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CC&Blood/Genetic test results Data Type Description 
 
ID Long Automated Primary ID 
 
Cardiac_cath Integer Cardiac catherization (0:Done; 1:Not done) 
 
Date_Cardiac_Cath Date Date of cardiac catherization 
 
Dilated_LV Integer Left ventricle- Dilated LVt (0:No; 1:Yes) 
 
LVfunc Integer LV Global Function (1:Normal; 2:Mildly reduced; 3:Severely reduced) 
 
LVab_septal_wall Integer LV septal wall motion abnormalitites (1:Normal; 2:Diastolic bulge; 3:Mild Hypokinesia; 4:Severe Hypokinesia; 5:Akinesia; 6:Dyskinesia-aneurysms; 7:Unknown) 
 
LVab_ant_wall Integer LV anterior wall motion abnormalitites (1:Normal; 2:Diastolic bulge; 3:Mild Hypokinesia; 4:Severe Hypokinesia; 5:Akinesia; 6:Dyskinesia-aneurysms; 7:Unknown) 
 
LVab_post_wall Integer LV posterior submitral wall motion abnormalitites (1:Normal; 2:Diastolic bulge; 3:Mild Hypokinesia; 4:Severe Hypokinesia; 5:Akinesia; 6:Dyskinesia-aneurysms; 7:Unknown) 
 
LVab_inf_wall Integer LV inferior wall motion abnormalitites (1:Normal; 2:Diastolic bulge; 3:Mild Hypokinesia; 4:Severe Hypokinesia; 5:Akinesia; 6:Dyskinesia-aneurysms; 7:Unknown) 
 
LVab_apical_wall Integer LV apical wall motion abnormalitites (1:Normal; 2:Diastolic bulge; 3:Mild Hypokinesia; 4:Severe Hypokinesia; 5:Akinesia; 6:Dyskinesia-aneurysms; 7:Unknown) 
 
Regurg_mitral_mode Integer Mitrarl regurgitation mode (1-4,0 if not present, 5 if Prolapse) 
 
LVEDV Integer LVEDV (ml) 
 
LVESV Integer LVESV (ml) 
 
LVEF Integer LVEF (%) 
 
LV_sys Integer LV systolic pressure (mmHg) 
 
LV_dia Integer LV diastolic pressure (mmHg) 
 
LVEDP Integer LVEDP (mmHg) 
 
AortPress Integer Aortic Pressure (mmHg) 
 
LV_sys_grad Integer LV systolic gradient 
 
RV_dilated Integer Dilated right ventricle (0:No; 1:Yes) 
 
RVfunc Integer Right ventricle global function (1:Normal; 2:Mildly reduced; 3:Severely reduced) 
 
RVOT_Morph Integer RV Abnormalities - Morphology: RVOT (0:Normal; 1:Scalloped Contours; 2:Trabecular traverse deep fissure; 3:Trabecular hypertrophy>4mm; 4:Aneurysm; 5:Unknown) - abnormalities 
 
Anteroseptal_Morph Integer RV Abnormalities - Morphology: Anteroseptal free wall (0:Normal; 1:Scalloped Contours; 2:Trabecular traverse deep fissure; 3:Trabecular hypertrophy>4mm; 4:Aneurysm; 5:Unknown) - abnormalities 
 
Subtri_Morph Integer RV Abnormalities - Morphology: Subtricuspid posterobasal (0:Normal; 1:Scalloped Contours; 2:Trabecular traverse deep fissure; 3:Trabecular hypertrophy>4mm; 4:Aneurysm; 5:Unknown) - abnormalities 
 
Apical_Morph Integer RV Abnormalities - Morphology: Apical (0:Normal; 1:Scalloped Contours; 2:Trabecular traverse deep fissure; 3:Trabecular hypertrophy>4mm; 4:Aneurysm; 5:Unknown) - abnormalities 
 
RVOT_reg_wall Integer RV regional wall motion abnormalities: RVOT (0:Normal; 1:Scalloped Contours; 2:Trabecular traverse deep fissure; 3:Trabecular hypertrophy>4mm; 4:Aneurysm; 5:Unknown) 
 
Anteroseptal_reg_wall Integer RV regional wall motion abnormalities: Anteroseptal free wall (0:Normal; 1:Scalloped Contours; 2:Trabecular traverse deep fissure; 3:Trabecular hypertrophy>4mm; 4:Aneurysm; 5:Unknown) 
 
Subtri_reg_wall Integer RV regional wall motion abnormalities: Subtricuspid posterobasal (0:Normal; 1:Scalloped Contours; 2:Trabecular traverse deep fissure; 3:Trabecular hypertrophy>4mm; 4:Aneurysm; 5:Unknown) 
 
Apical_reg_wall Integer RV regional wall motion abnormalities: Apical (0:Normal; 1:Scalloped Contours; 2:Trabecular traverse deep fissure; 3:Trabecular hypertrophy>4mm; 4:Aneurysm; 5:Unknown) 
 
RVEDV Integer RVEDV (ml) 
 
RVESV Integer RVESV (ml) 
 
RVEF Integer RVEF (%) 
 
PAP Integer Pulmonary artery pressure mean (mmHg) 
 
RA_press Integer RA pressure (mmHg) 
 
RVEDP Integer RVEDP (mmHg) 
 
Pulm_capwedge_press Integer Pulmonary capillary wedge pressure (mmHg) 
 
Regurg_tri_grade Integer Tricuspid regurgitation grade (1-4, 0 if not present) 
 
Tri_prolapse Integer Tricupsid valve prolapse 
 
Dominance Integer Dominance (1:Right; 2:Left; 3:Balanced) 
 
CA_obstruct Integer Presence of Coronary artery obstruction (0:No; 1:Yes) 
 
CA_obstruct_percent Integer Percentage of obstruction 
 
Stenosis Integer Location of stenosis (1:LMCA; 2:LAD; 3:LCx; 4:RCA) 
 
Blood_test Integer Blood test (0:Done; 1:Not done) 
 
Hb Integer Haemoglobin (g/dl) 
 
WCC Integer White cell count 
 
MCV Integer MCV (fl) 
 
Plt Integer Platelet count 
 
BSL Integer Random blood sugar (mmol) 
 
Na Integer Serum sodium (mmol/l) 
 
K Integer Potassium (mmol/l) 
 
Cl Integer Chloride (mmol/l) 
 
Urea Integer Urea (mmol/l) 
 
Cr Integer Creatinine (umol/l) 
 
Bilirubin Integer Bilirubin (umol/l) 
 
ALT Integer Alanine transferase (U/l) 
 
AST Integer Aspartate transferase (U/l) 
 
Alb Integer Albumin (g/dL) 
 
Protein Integer Total protein (g/dL) 
 
GGT Integer gamma GT 
 
ESR Integer ESR in one hour 
 
CRP Integer C-reactive protein (mg/dl) 
 
Pro_BNP Integer Pro-BNP 
 
TC Double Total cholesterol (mmol/l) 
 
HDL Double High Density Lipoprotein (mmol/l) 
 
TG Double TG (mmol/l) 
 
LDL Double Low Density Lipoprotein (mmol/l) 
 
TSH Integer Thyroid Stimulating Hormone (mIU/l) 
 
fT3 Integer fT3 (pmol/l) 
 
fT4 Integer fT4 (pmol/l) 
 
HIV_screen Integer HIV screening 
 
HIV_confirm Integer HIV confirmatory test 
 
GeneTest Integer Genetic testing (0:Done; 1:Not done) 
 
Chrom_loc Text Chromosomal location test 
 
GeneID Text Genes identified 
 
Genes_other Text Other 
 
Diag_Suspect Text Suspected Diagnosis 
 
Diag_Final Text Final Diagnosis 
 
Diag_Other Text Other 
 
FUpNo Long Follow-up Number 
 
Date_FUp Date Date of follow-up 
 
Type_FUp Integer Type of follow-up (1:Regularly scheduled follow up; 2:Unscheduled follow up; 3:Lost to follow up) 
 
Complaints Text Presenting complaints 
 
Events_FUp Integer Events since last follow up (0:No; 1:Yes) 
 
Events_details Text Details of events 
 
Med1 Text Current medications (drug name) 
 
Dose1 Integer Total daily dose (mg) 
 
Med2 Text Current medications (drug name) 
 
Dose2 Integer Total daily dose (mg) 
 
Med3 Text Current medications (drug name) 
 
Dose3 Integer Total daily dose (mg) 
 
Med4 Text Current medications (drug name) 
 
Dose4 Integer Total daily dose (mg) 
 
Med5 Text Current medications (drug name) 
 
Dose5 Integer Total daily dose (mg) 
 
Med6 Text Current medications (drug name) 
 
Dose6 Integer Total daily dose (mg) 
 
Med7 Text Current medications (drug name) 
 
Dose7 Integer Total daily dose (mg) 
 
Surgery Integer Surgery (0:No; 1:Yes) 
 
SurgType Text Type of surgery 
 
Pacemaker Integer Pacemaker insertion (0:No; 1:Yes) 
 
Date_pacemaker Date Date of insertion of pacemaker 
 
Type_pacemaker Text Type of pacemaker 
 
ICD Integer ICD implantation (0:No; 1:Yes) 
 
Date_ICD Date Date of insertion 
 
Cath_abl Integer Catheter ablation (0:No; 1:Yes) 
 
Date_Cath_abl Date Date performed 
 
Indication Text Indication 
 
Cardiac_terminal Integer Terminal Events: Cardiac death (0:No; 1:Yes; 2:Unknown) 
 
Sudden_terminal Integer Terminal Events: Sudden death (0:No; 1:Yes; 2:Unknown) 
 
HF_terminal Integer Terminal Events: Heart failure (0:No; 1:Yes; 2:Unknown) 
 
NonCardiac_terminal Integer Terminal Events: Non-Cardiac death (0:No; 1:Yes; 2:Unknown) 
 
Detail_terminal Text Details of terminal event 
 
Autopsy Integer Autopsy (0:No; 1:Yes; 2:Unknown) 
 
Autopsy_Results Text Autopsy results 
    
    Patient/Physician Information Data Type Description 
 
ID Long 
 
 
LastName Text Last Name 
 
FirstName Text First Name 
 
DOB Date Date of Birth (dd/mm/yyyy) 
 
Sex Integer Sex (1:Male; 2:Female) 
 
Education Integer Education (1:No schooling; 2:Primary; 3:Secondary; 4:Post Secondary) 
 
Employment Integer Employment (1:Formal; 2:Informal; 3:Unemployed) 
 
FormalEmp_type Integer Formal employment (1:Skilled professional; 2:Skilled otherwise; 3:Unskilled) 
 
InformalEmp_type Integer Informal specified (1:Skilled; 2:Unskilled) 
 
UnskilledEmp_type Text Informal Unskilled Employment specified 
 
Housewife Integer Housewife (0:No; 1:Yes) 
 
Unemployed Integer Unemployed (0:No; 1:Yes) 
 
Student Integer Student (0:No; 1:Yes) 
 
Marital_Status Integer Marital status (1:Married; 2:Single; 3:Divorced/Separated; 4:Co-habiting;4:Widowed) 
 
National_ID Long National ID Number 
 
Nationality Text Nationality 
 
Home_Lang Integer Home Language (1:English; 2:Afrikaans; 3:Xhosa; 4:Zulu; 5:Sutu; 6:Tshangani; 7:Other) 
 
HospNo Long Hospital Number 
 
DOE Date Date of enrollment 
 
Add_Home Text Home Address 
 
Add_Post Text Postal Address 
 
Add_Work Text Work Address 
 
PhHome Text Home Telephone Number 
 
PhWk Text Work Telephone Number 
 
CellNo Text Cell Phone Number 
 
Email Text Email Address 
 
Height Double Height(metres) 
 
Weight Double Weight (kg) 
 
BMI Double BMI(kg/m2) 
 
PhysLastName Text Physicians Last Name 
 
PhysFirstName Text Physicians First Name 
 
Hosp_FacName Text Name of Hospital/Health Facility 
 
PhysAdd Text Physicians Address 
 
PhysCity Text Physicians City of Location 
 
Phys_Prov_State Text Physcians Province/State 
 
Phys_PhWk Text Physicians Work Telephone Number 
 
Phys_CellNo Text Physicians Cell Phone Number 
    Physical examination and 
signs Data Type Description 
 
ID Long 
 
 
Date_diag_CM Date Date of first diagnosis of cardiomyopathy 
 
Date_symp_CM Date Date of earliest symptoms 
 
NYHA Integer Present NYHA (0:No; 1:Yes) 
 
NYHA_Class Integer Present NYHA Functional Class (1:I; 2:II, 3:III; 4:IV) 
 
Palpitations Integer Palpitations (0:No; 1:Yes) 
 
Dizziness Integer Dizziness (0:No; 1:Yes) 
 
Syncope Integer Syncope (0:No; 1:Yes) 
 
Chest_Pain Integer Chest Pain (0:No; 1:Yes) 
 
Leg_Swelling Integer Leg Swelling (0:No; 1:Yes) 
 
Cardiac_arrest Integer Cardiac Arrest (0:No; 1:Yes) 
 
Other_ complaints Text Other complaints 
 
Date_FirstHosp_CM Date Date of first hospitalization for treatment/diagnosis of cardiomyopathy 
 
Blood_Trans Integer Blood Transfusion (0:No; 1:Yes) 
 
Blood_Trans_Sp Text Blood Transfusion - Specified 
 
Cardiovascular Integer Cardiovascular (0:No; 1:Yes) 
 
Cardiovascular_Sp Text Cardiovascular - Specified 
 
Pulmonary Integer Pulmonary (0:No; 1:Yes) 
 
Pulmonary_Sp Text Pulmonary - Specified 
 
GI Integer Gastrointestinal (0:No; 1:Yes) 
 
GI_Sp Text Gastrointestinal - Specified 
 
Renal Integer Renal (0:No; 1:Yes) 
 
Renal_Sp Text Renal - Specified 
 
Endocrine Integer Endocrine (0:No; 1:Yes) 
 
Endocrine_Sp Text Endocrine - Specified 
 
Dermatological Integer Dermatological (0:No; 1:Yes) 
 
Dermatological_Sp Text Dermatological - Specified 
 
Haematological Integer Haematological (0:No; 1:Yes) 
 
Haematological_Sp Text Haematological - Specified 
 
Neuromuscular Integer Neuromuscular/Skeletal (0:No; 1:Yes) 
 
Neuromuscular_Sp Text Neuromuscular/Skeletal - Specified 
 
Gynaecological Integer Gynaecological (0:No; 1:Yes) 
 
Gynaecological_Sp Text Gynaecological - Specified 
 
Liver Integer Liver (0:No; 1:Yes) 
 
Liver_Sp Text Liver - Specified 
 
Ophthalmic Integer Opthalmic (0:No; 1:Yes) 
 
Opthalmic_Sp Text Opthalmic - Specified 
 
ENT Integer ENT (0:No; 1:Yes) 
 
ENT_Sp Text ENT - Specified 
 
Repeat_Infec Integer Repeated Infections (0:No; 1:Yes) 
 
Repeat_Infec_Sp Text Repeated Infections - Specified 
 
Flu_illness Integer Flu-like illness (0:No; 1:Yes) 
 
Flu_ illness_Sp Text Flu-like illness - Specified 
 
Date_Menstrual Date Last Menstrual Period 
 
Date_Delivery Date Date of last delivery 
 
Amniotic_Fluid Integer Any suggestion of amniotic fluid in any pregnancy (0:No; 1:Yes) 
 
FamHxHD Integer Family History of Heart Disease (0:No; 1:Yes) 
 
HD_type Text Type of Heart Disease 
 
FamHxSuddenDeath Integer Family History of sudden death (0:No; 1:Yes) 
 
SuddenDeath_no Integer Number of sudden deaths in family members <35 years old 
 
SuddenDeath_name1 Text Name of family member suffering sudden death 
 
SuddenDeath_relation1 Text Relationship to family member suffering death 
 
SuddenDeath_arrhy_events1 Text Arrythmic events suffered during sudden death 
 
SuddenDeath_CM1 Text Cardiomyopathy diagnosis of family member suffering sudden death 
 
SuddenDeath_name2 Text Name of family member suffering sudden death 
 
SuddenDeath_relation2 Text Relationship to family member suffering death 
 
SuddenDeath_arrhy_events2 Text Arrythmic events suffered during sudden death 
 
SuddenDeath_CM2 Text Cardiomyopathy diagnosis of family member suffering sudden death 
 
SuddenDeath_name3 Text Name of family member suffering sudden death 
 
SuddenDeath_relation3 Text Relationship to family member suffering death 
 
SuddenDeath_arrhy_events3 Text Arrythmic events suffered during sudden death 
 
SuddenDeath_CM3 Text Cardiomyopathy diagnosis of family member suffering sudden death 
 
HxSmoking Integer Smoking History (0:No; 1:Yes) 
 
Pack_yrs Integer Pack years 
 
Alcohol Integer Alcohol Intake (0:No; 1:Yes) 
 
Alcohol_qty Integer Alcohol Quantity 
 
Alcohol_qty_week Integer Alcohol Quantity per Week 
 
Medications Integer Medication (0:No; 1:Yes) 
 
Meds1 Text Medicine 
 
Dose1 Integer Dose (mg) 
 
Date_start1 Date Date Started Medication 
 
Meds2 Text Medicine 
 
Dose2 Integer Dose (mg) 
 
Date_start2 Date Date Started Medication 
 
Meds3 Text Medicine 
 
Dose3 Integer Dose (mg) 
 
Date_start3 Date Date Started Medication 
 
Meds4 Text Medicine 
 
Dose4 Integer Dose (mg) 
 
Date_start4 Date Date Started Medication 
 
Meds5 Text Medicine 
 
Dose5 Integer Dose (mg) 
 
Date_start5 Date Date Started Medication 
 
Meds6 Text Medicine 
 
Dose6 Integer Dose (mg) 
 
Date_start6 Date Date Started Medication 
 
Meds7 Text Medicine 
 
Dose7 Integer Dose (mg) 
 
Date_start7 Date Date Started Medication 
 
Meds8 Text Medicine 
 
Dose8 Integer Dose (mg) 
 
Date_Start8 Date Date Started Medication 
 
Sport_prior Integer Sport Participation prior to myopathy diagnosis (1:Inactive; 2:Recreational; 3:Competitive/Professional; 4:Unknown) 
 
Esthr_prior Integer Estimated hours of activity per week prior to diagnosis 
 
Sport_after Integer Sport Participation following myopathy diagnosis (1:Inactive; 2:Recreational; 3:Competitive/Professional; 4:Unknown) 
 
Esthr_after Integer Estimated hours of activity per week after diagnosis 
 
Rugby Integer Rugby (0:No; 1:Yes) 
 
Soccer Integer Soccer (0:No; 1:Yes) 
 
Baseball Integer Baseball (0:No; 1:Yes) 
 
Basketball Integer Basketball (0:No; 1:Yes) 
 
Hockey Integer Hockey (0:No; 1:Yes) 
 
Cricket Integer Cricket (0:No; 1:Yes) 
 
Tennis Integer Tennis (0:No; 1:Yes) 
 
Running Integer Running (0:No; 1:Yes) 
 
Biking Integer Biking (0:No; 1:Yes) 
 
Swimming Integer Swimming (0:No; 1:Yes) 
 
Surfing Integer Surfing (0:No; 1:Yes) 
 
Sport_Other Text Other sport practiced most often 
 
Oedema Integer Pitting oedema of the legs (0:Absent; 1:Present) 
 
BP Text Blood Pressure (mmHg) 
 
JVP Integer Raised JVP (0:Absent; 1:Present) 
 
PulseRate Integer Pulse Rate 
 
Pulse_Character Integer Pulse Character 
 
HeartSounds Integer Heart Sounds (0:No; 1:Yes) 
 
Heart Sounds_sp Integer Heart Sounds Specified (1:S3; 2:S4; 3:Gallop Rhythm) 
 
Systolic Integer Systolic (0:No; 1:Yes) 
 
Diastolic Integer Diastolic (0:No; 1:Yes) 
 
Location Integer Location (0:No; 1:Yes) 
 
Location_sp Text Location specified 
 
Grade Integer Grade (0:No; 1:Yes) 
 
Grade_sp Text Grade specified 
 
Timing Integer Timing (0:No; 1:Yes) 
 
Timing_sp Text Tminig specified 
 
Character Integer Character (0:No; 1:Yes) 
 
Character_sp Text Characer specified 
 
Crepitations Integer Basal crepitations (0:Absent; 1:Present) 
 
hepatomegaly Integer Tender hepatomegaly (0:Absent; 1:Present) 
 
Ascites Integer Ascites (0:Absent; 1:Present) 
 
muscle_weak Integer Proximal muscle weakness (0:Absent; 1:Present) 
 
Tendon_Reflexes Integer Deep tendon reflexes (0:Absent; 1:Present) 
 
TendonReflexes_sp Integer Deep tendon reflexes specified (1:Normal; 2:Abnormal) 
 
Gait_disturb Integer Gait disturbance (0:Absent; 1:Present) 
 
Cardiothor_ratio Double Cardiothoracic ratio 
 
Lung_fields Integer Lung fields (0:Normal; 2:Congested) 
 
LAenlarge Integer Left atrial enlargement (0:No; 1:Yes) 
 
RVenlarge Integer Right ventricular enlargement (0:No; 1:Yes) 
 
ECG Integer ECG (0:Done; 1:Not done) 
 
ECG_Date Date Date of ECG 
 
Ventricular_rate Integer Ventricular rate 
 
Baseline_rhythm Integer Baseline rhythm (1:Sinus rhythm; 2:Junctional; 3:Sinus arrythmia; 4:Sinus pause>1.2sec-abrubt pause; 5:Pacemaker; 6:Other) 
 
Pacemaker_mode Text Pacemaker mode 
 
Pacemaker_other Text Other 
 
PRint Integer PR interval (ms) 
 
QRSaxis Integer QRS axis 
 
STd Integer ST depression (leads) 
 
STd_sp Text ST depression  (leads) specified 
 
STe Integer ST elevation (leads) 
 
STe_sp Text ST elevation  (leads) specified 
 
Twave Integer T wave inversions (depth in mm) 
 
AbnormalQ Integer Abnormal Q waves  (0:No; 1:Yes) 
 
QTint Integer QT interval (ms) 
 
QTc Integer QTc (ms) 
 
QTdisp Integer QT dispersion 
 
LA_enlargement Integer Left atrial enlargement (0:No; 1:Yes) 
 
RA_enlargement Integer Right atrial enlargement (0:No; 1:Yes) 
 
QRS_morph Integer QRS morphology (0:Normal; 1:Delta wave; 2:RBBB; 3:LBBB; 4:LAH; 5:LPH; 6:RBBB+LAH or LPH) 
 
Arrhythmia Integer Arrhythmias (1:None; 2:Atrial flutter; 3:Atrial fibrillation; 4:Supraventric tachy; 5:Ventricular ectopy; 6:Non-sustained ventric tachy=3-10 consecut beats; 7:Sustained ventricr tachy=>10 consecut beats; 8:Torsade de Pointes; 9:Ventricular fibrillation) 
 
PVC Integer PVC morphology (0:No PVC; 1:RBBB; 2:LBBB; 3:Both RBBB and LBBB; 4:Indeterminate) 
 
Others Text Others 
 
Hrt_Blk Integer Heart Block  (0:None; 1:1st degree; 2:2nd degree; 3:3rd degree block) 
 
Epsilon Integer Presence of Epsilon wave  (0:No; 1:Yes) 
 
Sokolow_Lyon Integer Sokolow-Lyon  (0:No; 1:Yes) 
 
Cornell_voltage Integer Cornell voltage (0:No; 1:Yes) 
 
Echo Integer Echocardiography (0:Done; 1:Not done) 
 
Date_echo Date Date of Echocardiography 
 
HR Integer Heart rate  (b/min) 
 
LA_diameter Integer Left atrial diameter (cm) 
 
Aortic_root_diameter Integer Aortic root diameter (cm) 
 
IVSTd Single IVSTd (cm) 
 
PTWd Single PTWd (cm) 
 
IVSTd/PTWd ratio Single IVSTd/PTWd ratio 
 
LVEDD Integer LVEDD (cm) 
 
LVESD Integer LVESD (cm) 
 
FS Integer FS (%) 
 
EF Integer EF (%) 
 
EPSS Integer EPSS (cm) 
 
SAM Integer SAM at rest (0:No; 1:Yes) 
 
LV_level Integer Prominent LV trabeculation and deep intrabecular recesses-Apical level (0:No; 1:Yes) 
 
Colour_flow Integer Colour flow in recesses (0:No; 1:Yes) 
 
Ratio_compact Integer Ratio of noncompacted/compacted >2  (0:No; 1:Yes) 
 
LV_WallMotion Integer Global LV wall motion (1:Normal; 2:Mildly reduced; 3:Severely reduced) 
 
Septal_WallMotion Integer Regional LV wall motion - septal (0:Normal; 1:Diastolic bulge; 2:Mild hypokinesia; 3:Severe hypokinesia; 4:Akinesia; 5:Dyskinesia(aneurysms); 6:LV thinning) 
 
Anterior_WallMotion Integer Regional LV wall motion - anterior (0:Normal; 1:Diastolic bulge; 2:Mild hypokinesia; 3:Severe hypokinesia; 4:Akinesia; 5:Dyskinesia(aneurysms); 6:LV thinning) 
 
Posterolateral_WallMotion Integer Regional LV wall motion - posterolateral (0:Normal; 1:Diastolic bulge; 2:Mild hypokinesia; 3:Severe hypokinesia; 4:Akinesia; 5:Dyskinesia(aneurysms); 6:LV thinning) 
 
Inferior_InferiorWotion Integer Regional LV wall motion - Inferior (0:Normal; 1:Diastolic bulge; 2:Mild hypokinesia; 3:Severe hypokinesia; 4:Akinesia; 5:Dyskinesia(aneurysms); 6:LV thinning) 
 
Apica_WallMotion Integer Regional LV wall motion - apical (0:Normal; 1:Diastolic bulge; 2:Mild hypokinesia; 3:Severe hypokinesia; 4:Akinesia; 5:Dyskinesia(aneurysms); 6:LV thinning) 
 
Mitral_ prolapse Integer Mitral Valve Prolapse (1:None; 2:Mild; 3:Moderate; 4: Severe) 
 
RVOT Integer Right ventricular outflow tract (cm) 
 
Ratio_RVOT_Aortic Single Ratio of right ventricular outflow tract/aortic valve 
 
Dilated_RA Integer Dilated RA (0:No; 1:Yes) 
 
Valve_lesions Integer Valve lesions (0:No; 1:Yes) 
 
Valve_sp Integer Valve specifed (1:tricuspid; 2:pulmonary) 
 
LVOT_Velocity Integer Left ventricular outflow tract velocity (m/s) 
 
LVOT_PressGrad Integer Left ventricular outflow tract pressure gradient at rest (continous wave) 
 
Aortic_Velocity Integer Aortic velocity 
 
RVP_sys Integer Right ventricular pressure in systole (mmHg) 
 
Regurg Integer Presence of regurgitation (0:No; 1:Yes) 
 
Regurg_Mitral Integer Mitral  regurgitation grade 
 
Regurg_Aortic Integer Aortic  regurgitation grade 
 
Regurg_Tri Integer Tricuspid  regurgitation grade 
 
Regurg_Pulm Integer Pulmonary  regurgitation grade 
 
E_Mitral_wave Integer Mitral E wave (m/s) 
 
A_Mitral_wave Integer Mitral A wave (m/s) 
 
EA_Mitral_ratio Single Mitral E/A ratio 
 
Decel_time1 Integer Deceleration time (ms) 
 
E_tri_wave Integer Tricuspd E wave (m/s) 
 
A_tri_wave Integer Tricuspid A wave (m/s) 
 
EA_tri_ratio Single Tricuspid E/A ratio 
 
Decel_time2 Double Deceleration time (ms) 
 
SMV_lat_ann Integer Systolic myocardial velocity (m/s)_lateral annulus 
 
Ewave_lat_ann Integer E wave (m/s)_lateral annulus 
 
Awave_lat_ann Integer A wave (m/s)_lateral annulus 
 
EAratio_lat_ann Integer E/A ratio_lateral annulus 
 
SMV_med_ann Integer Systolic myocardial velocity (m/s)_medial annulus 
 
Ewave_med_ann Integer E wave (m/s)_medial annulus 
 
Awave_med_ann Integer A wave (m/s)_medial annulus 
 
EAratio_med_ann Integer E/A ratio_medial annulus 
 
Pericardial_effusion Integer Presence of pericardial effusion (0:No; 1:Yes) 
 
Mural_thrombus Integer Presence of mural thrombus(0:No; 1:Yes) 
 
RA Integer RA 
 
RV Integer RV 
 
LA Integer LA 
 
LV Integer LV 
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Appendix 7. For Section 3.2.2 – Pedigrees of All Families Included in Final Analysis (N= 27) 
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